













This thesis has been submitted in fulfilment of the requirements for a postgraduate degree 
(e.g. PhD, MPhil, DClinPsychol) at the University of Edinburgh. Please note the following 
terms and conditions of use: 
 
This work is protected by copyright and other intellectual property rights, which are 
retained by the thesis author, unless otherwise stated. 
A copy can be downloaded for personal non-commercial research or study, without 
prior permission or charge. 
This thesis cannot be reproduced or quoted extensively from without first obtaining 
permission in writing from the author. 
The content must not be changed in any way or sold commercially in any format or 
medium without the formal permission of the author. 
When referring to this work, full bibliographic details including the author, title, 






Natriuretic Peptides in Valvular Heart Disease 
 
Thesis submitted in accordance with the requirements of the University of 
Edinburgh for the degree of Doctor of Medicine 
 
by 









This thesis represents research undertaken at Middlemore Hospital and Green Lane 
Cardiovascular Unit, Auckland, New Zealand and supervised by Professor Newby at 
the Centre for Cardiovascular Science, University of Edinburgh, United Kingdom. I 
certify that this thesis has been composed by me and that I have made a substantial 
contribution to this research as part of a research group. I am grateful for the 
assistance of colleagues and their contribution has been formally acknowledged. 
Much of this work has been published in peer-reviewed journals as outlined in the 
bibliography. The material contained in the thesis has not been presented, nor is 


















I am extremely grateful for the advice and support of my local supervisors Dr 
Andrew Kerr and Dr Raph Stewart who provided me with support and guidance 
during my time in New Zealand. They provided invaluable advice in study design 
and assistance with the interpretation of difficult studies. I would also like to 
acknowledge the role of Professor Newby who has provided immense support 
throughout my period of research. In particular his support whilst drafting this thesis, 
which coincided with a period of significant illness of my mother has been sincerely 
appreciated.  
 
I would also like to acknowledge fellow members of our research group Dr Niels 
Van Pelt, Dr Ruvin Gabriel and Dr Chris Raffel. In particular the study of natriuretic 
peptides in mitral regurgitation (chapter 5) was led primarily by Dr Raffel. However 
my contribution to this study remained substantial including the recruitment, 
performance of baseline assessment, exercise echocardiography, collection of blood 
samples for natriuretic peptides and echocardiographic analysis in one third of 
subjects. In addition I performed the right ventricular analysis of the whole cohort of 
patients with mitral regurgitation. Although I was not directly involved in the 
drafting of the manuscript as it occurred during a period that I had returned to the 
UK, given my contribution to this study it has been included in this thesis.     
 
I would also like to acknowledge the assistance from Prof Mark Richards and Prof 
Tim Yandle at the Christchurch Cardioendocrine Research Group, Christchurch, 
Otago, New Zealand who performed the analysis of the blood samples for natriuretic 
peptide concentrations.  
 
I would also like to thank the New Zealand Heart Foundation, the Middlemore 
Hospital Cardiac Trust and Green Lane Research and Education Fund for supporting 
this research through the award of project grants. 
 
 4 
 I am also extremely grateful for the help and support of our research nurses Mrs 
Jenny White and Mrs Penny Eadie who helped coordinate the various studies and 
assisted with subject recruitment and initial processing of blood samples.  
 
I am also grateful for the expertise of our cardiac sonographer, Margaret Oldfield 
who helped with the exercise echocardiography studies and to Gillian Whalley who 
performed the left ventricular volume analysis. I am also grateful to Jean 
Cunningham for her secretarial support and patience during the drafting of this 
thesis.  
 
Finally, I would like to thank my wife Helen and my children Matthew and Luke for 
their patience and understanding during this research. This necessitated the family 
relocating between the UK and New Zealand on several occasions for long periods 





Plasma natriuretic peptide concentrations rise in response to either atrial or 
ventricular wall stretch and have been found to be useful in the diagnosis and 
assessment of patients with congestive cardiac failure. Although previous studies 
have suggested that plasma natriuretic peptides may offer some prognostic 
information in patients with valvular heart disease, it is unclear whether 
concentrations reflect disease severity and how plasma concentrations vary across 
different valve lesions. The aim of this research was to identify the factors that affect 
natriuretic peptide releases in valvular heart disease (VHD) and to investigate 
whether natriuretic peptides can be used in clinical practice to identify those patients 
who may benefit from early intervention.  
 
Plasma brain natriuretic peptide (BNP) and atrial natriuretic peptide (ANP) 
concentrations were measured in patients with normal left ventricular (LV) systolic 
function and isolated VHD (mitral regurgitation, MR, n=33; aortic regurgitation, AR, 
n=39; aortic stenosis, AS, n=34; mitral stenosis, MS, n=30), and age and sex 
matched controls (n=39) immediately prior to exercise stress echocardiography. 
Peptide levels were compared against age and sex matched controls and against 
markers of severity for each valve lesions and across different valve lesions.  
 
Compared to controls, patients with all types of VHD had elevated plasma BNP 
concentrations [(MR median 35(inter quartile range 23-52), AR 34(22-45), AS 
31(22-60), MS 58(34-90); controls 24(16-33) pg/mL; p<0.01 for all]. LV end 
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diastolic volume index varied by valve lesion; [MR (mean ± standard deviation 
77±14), AR (91±28), AS (50±17), MS (43±11), controls (52±13) mL/m2; p<0.0001].  
There were no associations between LV volume and BNP.  Left atrial (LA) area 
index varied  [MR (18±4cm2/m2), AR (12±2), AS (11±3), MS (19±6), controls 
(11±2); p<0.0001], but correlated with plasma BNP concentrations: MR 
(r=0.42,p=0.02), MS (r=0.86,p<0.0001), AR (r=0.53,p=0.001), AS (r=0.52, 
p=0.002). Higher plasma BNP concentrations were associated with increased 
pulmonary artery pressure and reduced exercise capacity. Despite adverse cardiac 
remodelling, 81(60%) patients had a BNP concentration within the normal range. In 
patients with MS BNP was strongly associated with left atrial area index (r=0.86; 
p<0.0001) and a BNP level of greater than 2 times the upper limit of normal 
identified patients who fulfilled guideline criteria for intervention (Area under the 
curve (AUC) 0.87 [0.74,0.99], p =0.006) and lower exercise capacity (AUC 0.82 
[0.67,0.97]; p=0.004). In AR patients significant remodelling could occur whilst 
BNP remained within the normal range and in general BNP appeared less useful in 
assessing disease severity. However raised levels of BNP was associated with more 
severe AR as assessed by left ventricular outflow tract:AR Jet area ratio (r=0.43 
p=0.0007). AR patients with an abnormal BNP had signs of early LV dysfunction on 
exercise with a lower LV longitudinal strain rate post exercise compared to AR 
patients with a normal BNP (0.68±0.31 vs. 1.06±0.45 1/sec; p=0.02).  In MR 
patients, higher plasma BNP concentrations were associated with larger left atrial 
area index (r=0.42, p=0.02), higher pulmonary artery pressure (r=0.53, p=0.002) and 
a lower exercise time (r=-0.60, p=0.0002). BNP was not associated with any marker 
of left ventricular size or function in MR.  
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These findings suggest that despite significant LV remodelling, plasma BNP 
concentrations are often normal in patients with VHD. Consequently, plasma BNP 
concentrations should be interpreted with caution when assessing patients with VHD. 
However natriuretic peptide levels offer complementary information to the standard 
assessment of patients with VHD and an unexplained finding of an elevated BNP in 
an otherwise asymptomatic patient should prompt further investigation. 
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1.1 VALVULAR HEART DISEASE 
 
Valvular heart disease remains a common cause of cardiovascular mortality and 
morbidity worldwide. The development of acute valvular lesions such as acute mitral 
regurgitation secondary to a ruptured chordae or acute aortic regurgitation secondary 
to aortic dissection are usually poorly tolerated and present with signs of severe acute 
heart failure. Patients presenting with acute valvular lesions often need to be 
managed by relatively urgent or even emergency cardiac surgery to prevent death.  
 
In contrast however, patients with chronic valve disease often remain asymptomatic 
for many years. Valvular heart disease (VHD) results in abnormal pressure and/or 
volume load on the heart and a number of compensatory changes may occur in 
response to this. Previous studies have identified that once patients become 
symptomatic, their survival without surgery to repair the valve defect is poor 
[Delahaye et al 1991, Horstkotte and Loogen 1988, Klodas et al 1997, Ross and 
Braunwald 1968, Wood 1954]. Consequently the presence of symptoms is a key 
feature in the assessment of patients with VHD and their presence is a strong factor 
when considering intervention or valve surgery in the current guidelines for the 
management of patients with VHD [Bonow et al 2006, Nishimura et al 2014].    
 
However due to the often slowly progressive nature of VHD, defining the exact onset 
of symptoms in patients with VHD can be difficult. In addition many patients who 
remain asymptomatic can develop significant dilatation of cardiac chambers and 
occasionally impairment of ventricular function or pulmonary hypertension prior to 
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the development of overt symptoms. These patients are at increased risk of 
perioperative complications at the time of surgery and in some cases the heart size 
and function may not return to normal levels of function post-operatively. 
Conversely operating on patients too early (unless the valve is repairable) has the 
consequence of patients having an artificial heart valve in situ for a longer period. In 
the case of mechanical heart valves this is associated with a 1-2% risk per annum of 
complications and in the case of a biological valve increases the likelihood that 
further valve replacement will be necessary assuming the patient has a reasonable 
life expectancy. Consequently early diagnosis, regular follow- up and careful timing 
or referral for cardiac surgery is essential to optimally manage patients with valve 
disease.   
 
1.1.1 DIAGNOSIS AND ASSESSMENT OF VALVULAR HEART DISEASE 
In the normal heart, blood flow through the heart valves is relatively laminar and 
consequently relatively silent on auscultation except in haemodynamically active 
states. However valve abnormalities such as stenotic or regurgitant jets result in 
turbulent high velocity flow.  This results in audible murmurs that have typical 
characteristics depending on the underlying heart lesion. Consequently cardiac 
auscultation remains an important part of cardiac screening and assessment for heart 
valve disease and in many parts of the world it still remains the only readily available 
screening method. However with the increasing availability of echocardiography 
including the advent of hand-held devices, echocardiography is now a routine 
investigation for patients with suspected cardiac disease even in the developing 
world. Indeed a significant number of patients are diagnosed with VHD incidentally 
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on trans-thoracic echocardiography performed for other reasons. In addition 
transthoracic echocardiography is an extremely valuable tool in the assessment of the 
severity of VHD.  In the majority of patients, no other investigations are required but 
in selected cases other modalities such as trans-oesophageal echocardiography, 
cardiac magnetic resonance imaging and very occasionally cardiac catheterisation 
may be necessary to accurately assess severity.  
 
1.2 SPECIFIC VALVE LESIONS 
 
Different valvular lesions result in different pressure and volume loads within the 
heart and although ultimately if untreated they can all result in signs of cardiac 
failure, the pathophysiology of each valve lesion need to be considered carefully 
during the assessment. In addition the parameters measured on echocardiography and 
the guidelines for intervention vary considerably between lesions. A standardised 
approach to their assessment is therefore extremely important.  
 
1.3 MITRAL STENOSIS 
 
Mitral Stenosis (MS) remains a common valve lesion worldwide particularly in the 
developing countries. It remains a common problem in Auckland, New Zealand with 
the high immigrant population from the Pacific Islands. MS is almost always due to 
previous rheumatic fever but in a minority of cases can be congenital or due to very 
severe degenerative calcification of the mitral valve annulus that extends into the 
leaflets. Rheumatic MS results in thickening of the leaflets particularly at the tips 
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with fusion of the commissures. In addition there is thickening and shortening of the 
chordae. In more advanced cases there can be significant calcification. This results in 
decreased mobility of the leaflets both in systole and diastole with reduced valve 
opening. In addition the restriction of the leaflets can result in concomitant mitral 
regurgitation. 
 
MS results in increased pressure loads within the left atrium, as blood needs to be 
forced through the reduced valve orifice. This results in left atrial dilatation, an 
increased pressure gradient across the mitral valve and the backpressure transmitted 
into the pulmonary circulation can lead to pulmonary congestion. In severe cases this 
can result in pulmonary hypertension and right ventricular failure. In contrast the left 
ventricle is not exposed to this increased pressure load and often LV-end diastolic 
pressures remain normal or even low.  
 
1.3.1 CLINICAL ASSESSMENT 
As above the presence or absence of symptoms is a vital part of the assessment of 
patients with MS. However it may be decades between the onset of rheumatic fever 
to the point at which symptoms develop. During this time many patients become 
more sedentary, often without realising it or attribute reduced exercise capacity down 
to the physiological effects of ageing so that the assessment to symptomatic status is 
not entirely straightforward.  In addition careful assessment for signs of heart failure 
is important as well as determining the presence of atrial fibrillation (AF), which is a 
common finding in these patients. The combination of AF and MS is important to 
 21 
recognise as they are at a much higher risk of thromboembolic complications that 
patients with non-valvular AF.  
 
1.3.2 ECHOCARDIOGRAPHIC ASSESSMENT IN MITRAL STENOSIS 
Rheumatic MS results in typical echocardiographic appearances on 
echocardiography (Figure 1.1). As above there is leaflet thickening, particularly at 
the tips. The restriction of motion in diastole results in a typical ‘hockey stick’ 
appearance in the parasternal long axis view. 
 
 
       
Fig 1.1 Parasternal long axis view (left) demonstrating a rheumatic mitral valve with 
typical ‘hockey stick’ appearance of the anterior mitral valve leaflet. Parasternal 
short axis view (right) shows thickening of leaflet tips with reduced valve opening. 
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The current guidelines for the assessment of the severity of mitral stenosis 
recommend the measurement of 3 key echocardiographic parameters on resting 
echocardiography [Baumgartner et al 2009]. These are the mitral valve area (MVA), 
the mean pressure gradient (MG) across the mitral valve and the pulmonary artery 
systolic pressure (PAP). This is in addition to standard echocardiography to assess 
chamber size, ventricular function and the assessment of other valves. However there 
are limitations with the assessment of all these parameters and it is not uncommon 
for different parameters to suggest different degrees of severity. There is also a 
problem of intra- and inter-observer variation and it is extremely important to 
minimise this variation when assessing severity over time.  
 
There are 4 different methods of estimating MVA on echocardiography. These 
include planimetry of the valve using 2D or increasingly commonly 3D 
echocardiography, the pressure half-time method (PHT), the volumetric method and 
the proximal iso-velocity surface area (PISA) method. The 2 most commonly used 
methods on trans-thoracic echocardiography are planimetry and PHT. 
 
The mean gradient is calculated by tracing around the velocity time integral obtained 
by tracing around the continuous wave Doppler signal through the mitral valve. The 
right ventricular systolic pressure is estimated from the maximum velocity of 
tricuspid regurgitation and added to an estimate of the right atrial pressure. In the 
absence of pulmonary stenosis this is approximately the same as the pulmonary 
artery pressure. However both of these parameters can be very heart rate dependant 
and coupled with the known difficulties in the methods of estimating mitral valve 
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area results in problems in accurately determining the overall severity of MS by 
resting echocardiography alone.  
 
1.3.3 HAEMODYNAMIC CONSEQUENCES OF MITRAL STENOSIS 
The main consequence of MS is a rise in the left atrial pressure in order to maintain 
left ventricular (LV) filling. Consequently the left ventricle is relatively protected 
against the increased pressure loads and consequently is relatively unaffected. 
However in severe cases of MS, overall LV ejection fraction may be reduced. This is 
usually as a result of increased calcification of the MV annulus resulting in decreased 
longitudinal motion and thickening and retraction of the chordal apparatus.  The 
increased left atrial (LA) pressure results in significant LA dilatation. This 
predisposes to atrial fibrillation, which can further impair LV filling and is often 
poorly tolerated in MS. The high LA pressure is transmitted to the lungs leading to 
increased pulmonary pressure predisposing to signs and symptoms of heart failure 
include pulmonary oedema. Without intervention, MS progresses to the development 
of significant pulmonary hypertension and right ventricular (RV) dilatation and/or 
impairment of RV function. Consequently the aim of clinical and echocardiographic 
assessment is to identify patients with haemodynamically significant MS prior to the 
development of pulmonary hypertension or significant adverse remodelling.  
 
1.3.4 RECOMMENDED INDICATIONS FOR VALVE INTERVENTION 
Echocardiography performed at rest and the clinical assessment patients’ symptoms 
are the cornerstones of established guidelines in determining the optimal timing of 
intervention. The American College of Cardiology/American Heart Association 
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(ACC/AHA) guidelines [Bonow et al 2006] in place during the period of this 




Figure 1.2. Criteria for intervention for Mitral Stenosis according to ACC/AHA 
criteria. [Bonow et al 2006] 
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In addition symptomatic patients with severe MS and pulmonary hypertension who 
are not suitable for percutaneous mitral balloon valvotomy (PMBV) should be 
considered for open commissurotomy or mitral valve replacement (class IIa) 
 
According to these guidelines the key parameters in determining severity of disease 
in MS are mitral valve area, mean gradient across the mitral valve and pulmonary 
artery hypertension. The grading of severity of these parameters is listed in Table 1.1 
[Baumgartner et al 2009] 
 
 
Table 1.1 Criteria for assessing MS severity [Baumgartner et al 2009] 
 
 Mild Moderate Severe 
Specific Findings    
 Mitral Valve Area (cm2) >1.5 1.0 – 1.5 <1.0 
Supportive Findings    
 Mean gradient (mmHg) <5 5 - 10 >10 
 Pulmonary Artery Pressure 
 (mmHg) 
<30 30 - 50 >50 
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1.4 MITRAL REGURGITATION 
 
Significant mitral regurgitation (MR) remains one of the commonest valve lesions 
encountered in clinical practice. Previous studies have found it to be the most 
common valve lesion in the United States of America [Nkomo et al 2006] and the 
second most common in Europe [Iung et al 2003]. Like MS it can remain 
asymptomatic for many years.  The regurgitant flow into the LA during systole 
results in an increase volume and pressure load on the left atrium. However in the 
subsequent diastole, the left ventricle needs to accommodate this extra regurgitant 
volume in addition to the normal volume of blood that has passed through the 
pulmonary circulation. Therefore in contrast to MS, the left ventricle is exposed to 
wall stretch and in severe MR, significant LV dilation can occur. If valve surgery is 
delayed, this can result in irreversible impairment of LV function. Consequently the 
optimal timing of surgery in mitral regurgitation is crucial.  
 
1.4.1 CAUSES OF MITRAL REGURGITATION 
The fundamental cause of mitral regurgitation is a reduction in the normal coaptation 
of the anterior and posterior mitral valve leaflets [Enriquez-Sarano et al 2009]. There 
are a number of underlying mechanisms that can result in this loss of coaptation. 
Describing the mechanism of this failure of coaptation led to the classification 
system devised by Carpentier which is summarised in Table 1.2 [Carpentier 1983]. 
This is based on leaflet motion with Type 1 demonstrating normal leaflet motion, 
Type II displaying excessive motion and Type III resulting in restricted motion in 
systole (IIIa) or diastole (IIIb). 
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In western countries, the commonest causes of mitral regurgitation are degenerative, 
comprising myxomatous, flail leaflets, and annular calcification. These comprise 
around 60-70% of cases [Enriquez-Sarano et al 2009]. Ischaemic mitral regurgitation 
accounts for around 20% of cases with endocarditis and rheumatic accounting for 
around 2-5% each. However in New Zealand, particularly in the North Island there is 
a much larger proportion of patients presenting with rheumatic mitral regurgitation 
due to the large immigrant population from the Pacific Islands 
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Table 1.2. Causes of mitral regurgitation [Carpentier 1983, Enriquez-Sarano et al 2009] 
 
 Organic Functional 
































PM : Papillary Muscle, LV : Left  Ventricle 
 29 
1.4.2 CLINICAL ASSESSMENT 
The clinical assessment of patients with MR revolves around an accurate 
determination of the patient’s symptomatic status and signs of heart failure or 
significant LV volume overload. However as with mitral stenosis, accurate 
determination of the point at which patients become symptomatic can be difficult and 
the physical signs of decompensation and LV volume overload occur late and should 
not be relied upon to determine the need for surgery [Bonow et al 2006]. 
Consequently echocardiographic assessment is crucial in determining the severity of 
mitral regurgitation and assessing for any significant haemodynamic consequences 
that may determine the need for surgery. The increased success of MV repair and the 
finding that patients with signs of early LV dysfunction or those with significantly 
dilated left ventricles do less favourably post MV surgery has also prompted the 
earlier referral of patients for consideration of MV repair.  
 
1.4.3 ECHOCARDIOGRAPHIC ASSESSMENT 
The key variables in assessing the severity of MR according to the European 
Association of Echocardiography/American Society of Echocardiography (EAE 
/ASE) recommendations are shown in Table 1.3. In addition assessment should be 
made of the haemodynamic consequences of MR including the measurement of 
chamber dimension or preferably chamber volumes and the estimation of pulmonary 
artery pressure.  
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Table 1.3 Guidelines for the assessment of native mitral regurgitation [Zoghbi et al 2003] 
 Mild Moderate Severe 
Specific Signs Of Severity    
 Jet Size 
Small central jet <4cm2 or  
<20% LA area 
Signs of MR>mild present  
but no criteria for severe MR 
>40% LA area or a wall impinging 
jet of any size swirling in LA 
 Vena Contracta <0.3cm  >0.7cm for large central jet 
 Flow Convergence None or minimal  Large flow convergence 
 Pulmonary Vein Flow Systolic dominant flow  Systolic flow reversal 
 Leaflets   
Prominent flail leaflet or  
ruptured papillary muscle 
Supportive Signs    
 Pulse Wave Doppler Mitral Valve A-wave dominant inflow Intermediate signs/findings E-wave dominant inflow (E>1.2m/s) 
 Continuous Wave Doppler Density Soft density, parabolic shape  Dense triangular signal 
 Left Atrial Size Normal  Enlarged 
 Left Ventricular Size Normal  Enlarged 
Quantitative Parameters    
 Regurgitant Volume (mls) <30 30 – 44 45 – 59  
 Regurgitant Fraction (%) <30 30 – 39 40 – 49 ≥60 
 Effective Regurgitant Orifice  
 Area (cm2) 
<0.20 0.20 – 0.29 0.30 – 0.39 ≥50 
 
LA : left atrial; MR: Mitral regurgitation. 
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1.4.4 RECOMMENDATIONS FOR VALVE SURGERY 
Symptomatic patients with severe MR have a class 1 indication for surgery 
regardless of LV size unless there is severe LV dysfunction. Similarly asymptomatic 
patients with Severe MR have a class 1 indication if there is very significant LV 
enlargement (end-systolic dimension >40mm) or signs of early LV dysfunction 
(LVEF <60%). The ACC/AHA recommendations for the management of chronic 
mitral regurgitation are summarised in Figure 1.3 [Bonow et al 2006] 
 
However signs of haemodynamic compromise such as pulmonary hypertension or 
new onset atrial fibrillation should also prompt consideration of MV surgery (Class 
IIa). The presence of a prosthetic heart valve is associated with a complication rate of 
approximately 1% per year [Pibarot and Dumesnil 2009]. Consequently the benefits 
of surgery must outweigh not only the upfront risks of surgery but also the yearly 
risk of complications associated with a mechanical valve. Consequently MV 
replacement is not recommended in patients with severe MR if they are truly 
asymptomatic unless there are signs of haemodynamic compromise. Mitral valve 
repair is now much more successful with conversion to a MV replacement as low as 
1% in high volume centres. Although the perioperative risks for an MV repair are 
similar and indeed often lower than that of a replacement, patients with a successful 
MV repair are not subject to the same annual rate of complications and lifelong 
anticoagulation is not required. Consequently provided local expertise in MV repair 
is available, referral for MV repair is recommended for all asymptomatic patients 




EF: Ejection Fraction, ESD: End-Systolic Diameter, MVR: Mitral Valve Replacement. MV: Mitral 









1.5 AORTIC STENOSIS 
 
Aortic stenosis (AS) is the commonest valve lesion in Europe and with an ever-
ageing population, the incidence of degenerative AS is likely to continue to rise. Of 
the different valve lesions, aortic stenosis has the most evidence to guide clinical 
practice. The recommendation to perform aortic valve replacement in symptomatic 
patients with severe AS is well established and has been shown to increase survival. 
However a number of difficulties remain, not least the management of patients with 
asymptomatic severe aortic stenosis and patients with low-flow, normal ejection 
fraction AS.  
 
1.5.1 CAUSE OF AORTIC STENOSIS 
The commonest causes of AS are calcific AS, bicuspid aortic valves, true congenital 
AS or AS secondary to rheumatic heart disease. Calcific aortic stenosis of either a 
tricuspid or bicuspid aortic valve is by far the most common. In calcific aortic 
stenosis it is believed that there is initial plaque formation in a similar manner to that 
of atherosclerosis. Indeed AS and significant atherosclerotic burden often co exist in 
the same patient. The on-going damage results in progressive calcification, which 
distorts blood flow through the valve orifice. This disruption in blood flow results in 
further areas of damage, thereby accelerating the calcific process. This disruption of 
flow is an important factor in the calcification that occurs in bicuspid valves which 




1.5.2 CLINICAL ASSESSMENT 
As with other valvular lesions, the presence of a typical murmur alerts the clinician 
to the possibility of underlying aortic stenosis and this may be found incidentally on 
physical examination. The presence of a softened second heart sound with the 
absence of an aortic component and a reduction in the upstroke of the carotid pulse is 
suggestive of severe aortic stenosis. However the presence or absence of these signs 
is an unreliable in determining the need for intervention or surgery.  In addition, the 
accurate assessment of symptomatic status is extremely important as once patients 
with severe aortic stenosis become symptomatic, the survival without surgery is 
poor. Typical symptoms include exertional breathlessness or angina and in severe 
cases, syncope and sudden cardiac death. 
 
1.5.3 ECHOCARDIOGRAPHIC ASSESSMENT 
Echocardiography is the mainstay of diagnosis and assessment of severity. 2D 
echocardiography can identify the morphology of the aortic valve and in particular 
whether it is tricuspid. Visual assessment of the degree of leaflet excursion and the 
extent of thickening and calcification can be a good guide to overall severity. In 
addition the accurate assessment of left ventricular function and stroke volume is 
important to correctly interpret the findings from quantitative assessment of severity. 
The key parameters to quantify the severity of aortic stenosis are the aortic valve area 
(AVA), the mean pressure drop across the aortic valve and the peak velocity through 
the stenotic valve. Unlike for MS, planimetry using standard 2D transthoracic 
echocardiography is not recommended to calculate the AVA due to the difficulty in 
ensuring the ultrasound beam images is positioned at the leaflet tips. Furthermore 
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artefact from heavily calcified valves often precludes assessment. Consequently 
AVA is estimated using the continuity principle and based on the flow through the 
left ventricular outflow tract (LVOT) being equal to the flow through the aortic valve 
(in the absence of a left-to- right shunt through a ventricular septal defect). The peak 
velocity and mean gradient are derived from the continuous wave Doppler profile 
through the aortic valve. However it is essential that the maximum velocity is 
obtained and hence imaging from a number of different echocardiographic windows 
is necessary.  The guidance for the assessment of AS severity is outlined in Table 
1.4.  
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Table 1.4. Echocardiographic assessment for the severity of aortic stenosis 
 
 Aortic sclerosis Mild Aortic Stenosis Moderate Aortic Stenosis Severe Aortic Stenosis 
Aortic Jet Velocity (m/s) ≤ 2.5 2.6–2.9 3.0–4.0 >4.0 
Mean Gradient (mmHg) - <20 (<30a) 20–40b (30–50a) >40b (>50a) 
AVA (cm2) - >1.5 1.0 – 1.5 <1.0 
Indexed AVA (cm2/m2)  >0.85 0.60 – 0.85 <0.6 
Velocity Ratio  >0.50 025–0.50 <0.25 
 
 
AVA : aortic valve area 
aESC guidance [Vahanian et al 2007] 
bACC/AHA guidance [Bonow et al 2006] 
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1.5.4 GUIDELINES FOR INTERVENTION 
There is clear consensus that operating on patients with symptomatic severe aortic 
stenosis is justified both to relive symptoms but to avoid the risk of sudden cardiac 
death. Severe aortic stenosis is defined as a peak velocity of >4m/s, a mean pressure 
drop of 40mm Hg and an AVA of <1.0cm2 [Bonow et al 2006, Vahanian et al 2007]. 
The ACC/AHA guidelines for aortic valve replacement are summarised in Figure 
1.4. Whilst these guidelines are universally accepted, there is a significant degree of 
variation regarding the valve area at which patients become symptomatic [Otto et al 
1997]. This may result from variations in aortic compliance, body size, differential 
stroke volumes or an inability to accurately define the symptomatic status.   
 
However the optimal management of asymptomatic patients with severe AS 
determined by resting echocardiographic parameters is uncertain. Asymptomatic 
patients with severe AS have a life expectancy similar to that of an age matched 
population without severe AS and their risk of sudden cardiac death is less than 1% 
per year [Pellikka et al 2005, Ross and Braunwald 1968]. This is lower that the 
surgical mortality of an aortic valve replacement (2-3%) and similar to the annual 
risk of complications of a prosthetic valve replacement [Pibarot and Dumesnil 2009]. 
Consequently routine aortic valve replacement (AVR) in all asymptomatic patients 







AVA: Aortic Valve Area, Vmax: Peak velocity through aortic valve, CABG: Coronary Artery Bypass 
Grafting, BP: Blood Pressure, LV: Left Ventricular  
 
 




1.6 AORTIC REGURGITATION 
 
1.6.1 CAUSES OF AORTIC REGURGITATION 
The incidence of aortic regurgitation (AR) is less well defined that that of other 
valvular lesions. Singh et al described an incidence of around 13% in men and 8.5% 
of women but when stratified by age, less than 1% of patients had greater than 
moderate AR except in those over 70 years of age [Singh et al 1999]. 
 
There are a number of causes of AR that include abnormalities of the valve or 
dilatation of the aorta. Common causes of chronic AR are listed in table 1.5. In 
developed countries, bicuspid aortic valves and abnormalities of the aortic root are 
the most common cause of AR. However worldwide and in particularly in 
developing countries, AR secondary to rheumatic fever remains common.  
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Table 1.5  Causes of Aortic Regurgitation 
 
Valve causes 
 Bicuspid aortic Valve 
 Previous endocarditis 
 Degenerative valve disease 
 Rheumatic fever 
Aortic causes 
 Dilatation of the aortic root 
 Marfan’s disease 
 Hypertension 
 Connective tissue disease 




1.6.2 CLINICAL ASSESSMENT 
Acute severe AR especially in the context of aortic dissection is a surgical 
emergency and rapid diagnosis by clinical assessment, echocardiography and if 
appropriate computed tomography is vital. In contrast however chronic AR can 
remain clinically stable for many years. Chronic AR results in an increased volume 
load on the left ventricle and consequently patients can develop significant LV 
chamber dilatation. Ultimately this progresses to LV dysfunction and the 
development of symptoms such as dyspnea, decreased exercise capacity or 
pulmonary congestion.  
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The typical clinical signs include an early diastolic murmur, systolic hypertension 
and a wide pulse pressure. In addition the increased forward flow through the aortic 
valve causes a systolic flow murmur.  The elevated systolic pressure and large stroke 
volume result in a number of eponymous clinical signs including a bounding carotid 
pulse (Corrigan’s pulse), head bobbing (de Musset’s sign), pulsation of he uvula 
(Muller’s sign), and pistol shot sounds over the femoral artery with compression 
(Traube’s sign). During compression with a glass slide, capillary pulsations 
(Quincke’s sign) can be seen on the fingernail [Bekeredjian and Grayburn 2005]. In 
addition in severe AR significant LV dilatation can result in a displaced, hyper-
dynamic apex beat.  
 
 
1.6.3 ECHOCARDIOGRAPHIC ASSESSMENT 
Echocardiography is the most important diagnostic test in AR. It allows assessment 
of valve morphology, including whether there is a bicuspid or tricuspid valve. In 
addition assessment of the aortic root size can be made and if there is significant 
dilatation of the aortic root this may prompt consideration of aortic root and valve 
replacement even if the AR is not severe. Quantitative and qualitative assessment of 
AR severity can also be performed. The key parameters to assess AR severity are 
similar to those in MR and include assessment of the vena contracta width, the 
effective orifice area calculated via the PISA method and the regurgitant volume 
calculated by the PISA method or the continuity method. In addition other 
parameters include the ratio of the LVOT to AR jet width, the AR jet area to the 
LVOT area and the pressure half time of AR. Other supporting features of moderate 
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to severe AR include flow reversal in the descending thoracic and abdominal aorta 
respectively. However many of these measurements can be more difficult to perform 
in AR than in MR. Indeed of all valve lesions, echocardiographic assessment of 
severity in AR is arguably the most difficult to perform precisely and other 
modalities such as trans-oesophageal echocardiography, cardiac magnetic resonance 
imaging and cardiac catheterisation can be helpful. The echocardiographic criteria 
for the assessment of AR are shown in Table 1.6 
 
Other key parameters to assess on echocardiography are signs of early left 
ventricular dysfunction or increasing chamber dilatation. Indeed if excessive 
chamber dilation occurs and/or LV function becomes depressed, this may not 
normalize after AVR. Furthermore patients, who are symptomatic, have decreased 
LV function (LVEF <50%) or severe LV dilatation (LV end systolic dimension: 50– 
55 mm) have a poorer outcome after AVR [Bonow et al 2006, Gabriel et al 2008, 





Table1.6. Guidelines for the assessment of severity of native aortic regurgitation [Zoghbi et al 2003] 
 
 Mild Moderate Severe 
Structural Parameters    
 Left Atrial Size Normal Normal or dilated Usually dilated 
 Aortic Leaflets Normal or abnormal Normal or abnormal 
Abnormal or flail / wide coaptation 
defect 
Doppler Variables    
 Jet Width In LVOT Small Intermediate 
Large in centre jets; variable in 
eccentric jets 
 Jet Density Incomplete or faint Dense Dense 
 Pressure Half Time (ms) Slow >500 Medium 500 – 200 Steep <200 
 Diastolic Flow Reversal In DA Brief early diastolic reversal Intermediate Prominent holodiastolic reversal 
Quantitative Variables    
 Vena Contracta Width (cm) <0.3 0.30 – 0.60 >0.6 
 Jet Width/LVOT Width (%) <25 25 – 45 46 – 64 ≥65 
 Jet Area/LVOT Area (%) <5 5 – 20 21 – 59 ≥60 
 Regurgitant Volume (mls) <30 30 – 44 45 – 59 ≥60 
 Regurgitant Fraction (%) <30 30 – 39 40 – 49 ≥50 
 Effective Regurgitant Orifice Area (cm2) <0.10 0.10 – 0.19 0.20 – 0.29 ≥0.30 
 
LVOT: Left ventricular outflow Tract; DA: Descending aorta 
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1.6.4 GUIDELINES FOR CONSIDERATION OF VALVE INTERVENTION IN AR 
The decision to intervene in chronic severe AR is based on the patient’s symptomatic 
status and the degree of LV dilatation or dysfunction if the patient remains 
asymptomatic. These guidelines are summarized in Figure 1.5. Current criteria for 
LV dilatation include an end-systolic dimension of greater than 55mm or an end 
diastolic diameter of 75mm. In addition LV dysfunction is defined as an ejection 
fraction of less than 50%.  
 
If there is difficulty determining the symptomatic status, exercise testing can be 
considered. However it remains unclear what constitutes an abnormal exercise test 
and what parameters should be assessed in AR. In addition other modalities such as 
Cardiac magnetic resonance imaging can be very helpful in assessing the severity of 
MR by calculating the regurgitant volume and assessing LV volumes. However 
again it remains unclear what cut-offs should be used to determine referral for 
cardiac surgery. As with other valve disease this is vitally important as the death rate 
for asymptomatic patients with normal LV size and function is extremely low at 





AVR: Aortic Valve Replacement, MRI: Magnetic Resonance Imaging, RVG: Radionuclide 
Ventriculography, SD: End-systolic Dimension, DD: End-diastolic Dimension, EF: ejection fraction, 
LV: Left Ventricular  
 
 
Figure 1.5 Guidelines for the management of severe Chronic AR [Bonow et al 2006] 
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1.7 THE NEED FOR ALTERNATIVE METHODS FOR THE 
ASSESSMENT OF VHD 
 
The role of echocardiography performed at rest is well established in the assessment 
of the severity of valvular heart disease. Similarly there is reasonable evidence that 
valve surgery or intervention in symptomatic patients with severe valve disease is 
appropriate to improve symptomatic status and improve prognosis. Consequently this 
is a class 1 indication for surgery in most guidelines for the management of VHD 
provided the operative risks are acceptable.  
 
However there are number of difficulties in clinical practice with this approach. 
Firstly as discussed the onset of symptoms can be extremely difficult to assess 
accurately on clinical assessment alone. This is vitally important, as longitudinal 
studies have shown that whilst the prognosis of asymptomatic patients with severe 
valve disease is good, even mild symptoms are associated with a much poorer 
prognosis [Klodas et al 1997, Ross and Braunwald 1968]. With an ageing population 
and a more sedentary lifestyle, the accurate assessment of symptomatic status is 
becoming more difficult.  
 
Secondly a number of patients may be symptomatic despite seemingly mild or 
moderate disease as assessed on echocardiography performed at rest. These patients 
may have evidence of haemodynamically significant valve disease detected on 
exercise stress echocardiography and this can be associated with a poorer prognosis 
if untreated [Magne et al 2010]. 
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Thirdly patients with severe VHD may develop significant LV dilatation and 
possibly early LV dysfunction or pulmonary hypertension without becoming 
symptomatic [Vahanian et al 2007]. These patients remain at risk of other 
cardiovascular complications such as the onset of atrial fibrillation and a small 
excess risk of sudden cardiac death. In addition their operative mortality in the 
presence of LV dysfunction of pulmonary hypertension is increased and there is a 
reduced probability of LV size and function returning to normal post surgical repair.  
 
Finally the echocardiographic assessment of valve disease severity can be difficult 
and without careful, detailed protocols and good quality assurance within 
departments, inter-observer and intra-observer variability can be a significant issue. 
In addition in more complex cases, the need for further specialist investigations 
combined with the need for regular follow-up places a large strain on 
echocardiography departments and financial resources. This is a major problem in 
developing countries where there is a high burden of VHD.  
 
To overcome these difficulties, previous research has focussed on 2 key areas to 
better risk stratify asymptomatic patients with severe VHD or those patients whose 
symptoms are out of keeping with the severity of VHD on resting echocardiography. 
These are the role of exercise stress echocardiography and the measurement of 




1.8 STRESS ECHOCARDIOGRAPHY IN VHD 
 
Stress echocardiography has a number of potential benefits in assessing patients with 
valvular heart disease. Low-dose dobutamine stress echocardiography has an 
established role in patients with severe aortic stenosis who have a reduced LV 
ejection fraction. This allow differentiation between true severe aortic stenosis and 
pseudo-aortic stenosis in which reduced valve opening is due to low stroke volumes 
in the context of LV impairment rather than valve stenosis. In addition it allows the 
assessment of contractile reserve in patients with poor LV ejection fraction to assess 
their suitability to undergo major cardiac surgery. Stress echocardiography with 
dobutamine can also be used to assess for co-existing myocardial ischaemia that may 
be contributing to the patients symptoms or look for worsening of ischaemic mitral 
regurgitation. There is also limited data in using dobutamine stress echocardiography 
in the assessment to mitral stenosis [Reis et al 2004] 
 
Physiological stress in the form of treadmill exercise or a cycle ergometer is 
generally more helpful in the assessment of valvular heart disease. The 2006 
guidelines (Bonow et al. 2006) on the management of VHD formally recommended 
exercise stress echocardiography/electrocardiography for asymptomatic patients with 
severe AS (peak velocity >4m/s or mean gradient >40mmHg) and in asymptomatic 
moderate or severe MS (MVA <1.5cm2). They also suggested exercise testing may 
be helpful in symptomatic patients with mild MS.  For patients with MS, a rise in 
PAP of >60mm Hg or a pulmonary capillary wedge pressure (PCWP) of >25mm Hg 
was considered an indication for intervention. In patients with AR and MR there was 
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no clear recommendation made about when to consider exercise testing. These 
recommendations are predominantly consensus driven and it is unclear whether this 
approach is helpful in clinical practice.  
 
However performing exercise testing on patients with VHD provides an objective 
measure of functional capacity and overcomes many of the difficulties in assessing 
this based on clinical assessment alone. Furthermore exercise stress 
echocardiography has the ability to identify haemodynamic consequences of severe 
VHD such as pulmonary hypertension with exercise, a failure to augment systolic 
blood pressure or reduced contractile reserve. Abnormalities on exercise testing may 
suggest that the underlying VHD is more severe than indicated by resting 
echocardiography alone and prompt the clinician to reassess the severity of VHD or 
consider the need for valve surgery.  
 
 
1.9 NATRIURETIC PEPTIDES IN VALVULAR HEART DISEASE 
 
1.9.1 WHAT ARE NATRIURETIC PEPTIDES 
The vasoactive properties of atrial tissue were first identified in 1981 when it was 
demonstrated that infusion of extracted atrial tissue caused significant diuresis in rats 
[Agnoletti et al 1987]. Following on from this observation a number of peptides have 
been identified with significant diuretic and natriuretic properties. These peptides 
form an important role in regulation of blood pressure and the maintenance of plasma 
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volume. There are 3 natriuretic peptides, atrial natriuretic peptide, brain natriuretic 
peptide, and C-type natriuretic peptide [Levin et al 1998].  
 
As the name suggests, atrial natriuretic peptide (ANP) is released predominantly by 
the atria. This is mainly in response to an increase in atrial wall stretch. Brain 
natriuretic peptide (BNP) was originally identified in extracts of porcine brain. 
Although it is also contained within the human brain, much higher quantities are 
found within the ventricles of the heart.  Brain natriuretic peptide release is more 
closely related to ventricular wall stretch [Qi et al 2001, Yoshimura et al 1993]. C-
type natriuretic peptide is predominantly found within the central nervous system, 
anterior pituitary and kidney. Very low levels of C-type natriuretic peptide are found 
in plasma making it of less use in clinical practice. Both ANP and BNP are derived 
from pro hormones that are cleaved into an inactive N terminal component (NT pro-
BNP, NT pro-ANP) and the active peptide. The N-terminal fragments are more 
stable in vivo and hence often used as surrogates for the active component. However 
direct measurement of the active component has theoretical advantages when looking 
to identify significant changes in natriuretic peptide concentrations over a short time 
period. 
 
1.9.2 THE CARDIOVASCULAR EFFECTS OF NATRIURETIC PEPTIDES 
The cardiovascular effects of natriuretic peptides are complex and act through a 
variety of mechanisms to reduce blood pressure and intravascular circulating volume. 
The main mechanisms of action are considered below:  
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1.9.3 NATRIURESIS  
Natriuretic peptide (NPs) acts directly on the kidney to produce both natriuresis and 
diuresis. NPs cause dilatation of the afferent renal arterioles leading to an increase in 
blood flow and greater filtration of plasma [Marin-Grez et al 1986]. They cause 
relaxation of mesangial cells, which creates a greater surface area for filtration [Fried 
et al 1986, Stockand and Sansom 1997].  In addition NPs act directly on the tubules 
to promote natriuresis [Schulz-Knappe et al 1988]. 
 
1.9.4 INHIBITION OF THE RENIN ANGIOTENSIN ALDOSTERONE SYSTEM 
Natriuretic peptides inhibit sodium and water reuptake within the proximal 
convoluted tubules [Harris et al 1987]. Within the collecting ducts they act through 
the inhibition of vasopressin and via cyclic guanosine monophosphate (cGMP) to 
further inhibit water and sodium reabsorption [Dillingham and Anderson 1986, Light 
et al 1989, Sonnenberg et al 1986, Zeidel 1995, Zeidel et al 1988].     
 
1.9.5 EXTRAVASCULAR FLUID SHIFT  
Natriuretic peptides reduce the circulating volume by causing a shift of fluid from the 
intravascular to the extravascular space. This is through an increase in permeability 
of vascular endothelial cells and an increase in hydrostatic pressure within the 
capillary bed [Levin et al 1998]. 
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1.9.6 EFFECTS ON THE SYMPATHETIC NERVOUS SYSTEM 
Natriuretic peptides reduce sympathetic tone predominantly by suppression of the 
sympathetic outflow from the central nervous system (Figure 1.6). In addition they 
inhibit the vagal activation in response to a lowering of circulating volume thereby 





Figure 1.6 Physiological effects of natriuretic peptides [Levin et al 1998]
 53 
1.9.7 PATHOPHYSIOLOGY OF NATRIURETIC PEPTIDES 
As outlined above the release of natriuretic peptides is closely linked to atrial 
(predominantly ANP) and ventricular (predominantly BNP) wall stretch. 
Consequently conditions that result in an increasing wall stretch of the cardiac 
chambers result in increased circulating levels of natriuretic peptides. In particular 
congestive cardiac failure results in very high plasma concentrations of natriuretic 
peptides and consequently BNP in particular has been studied extensively in heart 
failure. Indeed measurement of BNP or NT-Pro BNP is recommended in 
contemporary guidelines for the investigation of patients with dyspnoea [Dickstein et 
al 2008]. These guidelines suggest that low plasma concentrations of BNP in a 
patient presenting with dyspnoea make it extremely unlikely that heart failure is the 
cause of their symptoms. Plasma BNP concentrations have also been used to monitor 
response to heart failure treatment with a failure of BNP levels to fall with treatment 
associated with an adverse prognosis. It has also been suggested that plasma 
concentrations of natriuretic peptides may become elevated before the onset of 
symptoms in patients with left ventricular systolic dysfunction and that they increase 
progressively with the severity of left ventricular impairment [McDonagh et al 1998, 
Qi et al 2001].
 
 
Brain natriuretic peptide concentrations measured early after myocardial infarction 
are a strong predictor of mortality, even after adjusting for left ventricular ejection 
fraction [de Lemos et al 2001, Omland et al 1996, Richards et al 1999]. 
Experimental animal models suggest that increased BNP may be a marker of the 




published data on changes in natriuretic peptides in valvular heart disease are more 
limited [Gerber et al 2003, Gerber et al 2003, Prasad et al 1997, Qi et al 2001].
 
 
1.9.8 THE POTENTIAL ROLE OF NATRIURETIC PEPTIDES IN VALVULAR 
HEART DISEASE 
Natriuretic peptides have the potential to be extremely useful in the assessment of 
patients with VHD who do not have an established indication for surgery. They are 
easily measurably with a number of well-established assays [Yandle et al 1993]. Due 
to their pathophysiology, plasma levels are increased with left ventricular wall 
stretch and consequently they may offer complementary information to that of 
echocardiography in VHD. Elevation of plasma natriuretic peptides concentrations 
may predate the onset of symptoms in patients with cardiac failure and given the 
known difficulty in symptomatic assessment, measurement of natriuretic peptide 
concentrations may be extremely helpful in VHD. Like in congestive cardiac failure, 
VHD results in increased volume and pressure loads on the cardiac chambers. 
However in VHD the cardiac chambers that are exposed to these increased 
haemodynamic loads vary significantly depending on the type of valve lesion. For 
example in mitral stenosis, the left atrium is exposed to significant pressure overload 
and ultimately high degrees of wall stretch as the chamber dilates. However the left 
ventricle in this setting is not exposed to increased pressure or volume overload and 
is in fact often relatively small and under-filled. Conversely in aortic regurgitation, 
the left ventricle is exposed to a large volume and dilates with consequently 
increasing wall stretch but the left atrium is relatively protected from increased 
pressure or volume overload until left ventricular dysfunction develops. 
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Understanding the response to natriuretic peptides in different valve lesions is 
therefore essential in determining whether they can be useful in the management of 
patients with heart valve disease.    
 
Furthermore defining the exact onset of symptoms can be challenging and accurate 
assessment is vital to ensure that patients are not exposed to risks of sudden cardiac 
death and cardiac failure if not appropriately referred for surgery. It has been shown 
that natriuretic peptide levels in symptomatic patients are higher in than 
asymptomatic patients [Gerber et al 2003] and again this may provide further 
information regarding the haemodynamic consequences of the underlying valve 
lesion. However it remains unclear whether NPs can accurately identify patients with 
severe VHD and what degree of elevation of plasma concentration should prompt 
further assessment.  
 
In addition although exercise stress echocardiography (SE) has an important role in 
assessing symptomatic status and the haemodynamic response to exercise in VHD, 
SE does not feature prominently in clinical guidelines and when it is recommended it 
is done so predominantly on the basis of expert opinion. It remains unclear which 






1.9.8 GENERAL HYPOTHESIS  
1.  Given that VHD results in wall stretch of either the atria or the ventricles, it is 
hypothesised that either atrial natriuretic peptide and/or brain type natriuretic 
peptides may be useful in detecting patients with haemodynamically significant 
valve disease or those with an adverse prognosis. 
2. That stress echocardiography may perform better in identifying patients with 
haemodynamically significant VHD or those with an adverse prognosis than clinical 
assessment and resting echocardiography alone.   
 
 
1.10 AIMS OF THIS STUDY 
 
The aims of thesis were to  
 
In VHD patients without an indication for valve surgery (Chapter 3) 
 Assess the role of exercise stress echocardiography in VHD 
 Determine whether exercise stress echocardiography can identify patients at 
high risk of adverse events 
In patients with mitral stenosis (Chapter 4) 
 Compare and contrast the ability of BNP and ANP to identify patients with 
haemodynamically significant VHD. 
In patients with mitral regurgitation (Chapter 5) 
 57 
 To determine whether BNP can identify patients with signs of early LV 
dysfunction either at rest or with exercise 
 
In patients with aortic regurgitation (Chapter 6) 
 To determine whether BNP can identify patients with signs of early LV 
dysfunction either at rest or with exercise 
In patients with VHD (Chapter 7) 
 To compare and contrast the level of BNP across different valvular lesions  
 To determine whether BNP can identify patients with more severe valve 












Valvular heart lesions lead to abnormal cardiovascular physiology and an increase in 
either intra-cardiac pressure or an increased volume load within the heart. Moreover 
different valvular lesions result in different degrees of pressure and volume overload. 
Due to the fact that in chronic valve disease these pressure and volume loads increase 
gradually over time, it can be difficult to define the when intervention should be 
considered. The point at which to intervene depends on a number of different factors. 
This includes the extent to which the underlying valve lesion is impacting the 
patient’s lifestyle and indeed the patient’s symptomatic status features heavily in 
established guidelines for the management of VHD [Bonow et al 2006]. Other 
factors to consider are the underlying severity of valve disease as assessed by 
echocardiography, the reparability of the valve defect and the risk of future 
complications. However as discussed there are a number of difficulties with this 
approach in clinical practice and stress echocardiography and/or measurement of 
natriuretic peptides may help to identify patients who would benefit from 
intervention at an early stage.  
 
2.1.1 STRESS ECHOCARDIOGRAPHY 
Exercise stress echocardiography has been used for the assessment of possible 
underlying ischaemic heart disease for many years. However it is gaining an 
increasing role in the assessment of valvular heat disease and its use does feature in 
established guidelines for VHD [Bonow et al 2006].  However it remains unclear 
what variables to measure and whether the use of exercise stress echocardiography 
 60 
alters clinical outcome. In addition newer echocardiographic techniques such as the 
assessment of contractile reserve, tissue Doppler imaging and either Doppler or 
speckle-tracking derived strain and strain rate measurements may better identify 
patients with haemodynamically significant valve disease compared to standard 
assessment alone.  
 
2.1.2  NATRIURETIC PEPTIDES 
Natriuretic peptides are known to increase in conditions that result in increased wall 
stretch within the heart. They have an established use in the assessment of patients 
with suspected cardiac failure. They have been shown to exclude heart failure in 
patients with dyspnoea if concentrations remain within the normal range [Dickstein 
et al 2008]. In addition elevated plasma concentrations have been associated with 
adverse prognosis in a number of conditions such as myocardial infarction [Omland 
et al 1996], heart failure [Anand et al 2003] and pulmonary embolism [Coutance et 
al 2008]. However little is known about their ability to identify patients with 
significant valve disease.  
 
2.2  GENERAL METHODOLOGY 
 
2.2.1  STUDY DESIGN 
We undertook a case-control study comparing patients with different valvular lesions 
and age and sex matched controls. All patients underwent comprehensive clinical 
assessment; resting echocardiography and sampling of plasma natriuretic peptides 
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immediately prior to exercise stress echocardiography. Natriuretic peptides were also 
measured immediately post exercise. Patients underwent follow up for a period of 2 
years after enrollment.  
 
2.2.2 STUDY POPULATION  
Patients with isolated valve lesions of at least moderate severity were identified from 
the outpatient clinics or echocardiograms reports conducted at Middlemore hospital, 
Otahuhu, New Zealand or Green Lane Cardiovascular Unit, Auckland City Hospital, 
New Zealand. Age and sex matched controls were recruited by advertisement.  
 
2.2.3 INCLUSION CRITERIA 
1. At least moderate valve disease defined as follows: 
a. Moderate to severe aortic stenosis (peak velocity >3m/s) 
b. Moderate to severe aortic regurgitation (AR:LVOT ratio >0.3) 
c. Moderate to severe mitral stenosis (MVA<1.5cm2) 
d. Moderate-severe or severe mitral regurgitation (EROA>0.3cm2) 
2. Normal LV systolic function (aortic stenosis EF>50%, aortic regurgitation 
EF>50%, mitral regurgitation EF>60% and mitral stenosis EF>50%).  
3. Aged 18 and able to give informed consent 
 
2.2.4  EXCLUSION CRITERIA 
The exclusion criteria included known ischaemic heart disease, significant renal 
impairment (creatinine >160 µmol/L, respiratory disease, and an inability to walk on 
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a treadmill or a contraindication to exercise testing. Patients with any other valvular 
lesion other than the inclusion valve lesion graded more than mild in severity were 
excluded from the study.  
 
2.2.5 ETHICAL APPROVAL 
The study was approved by the Auckland Regional Ethics Committee. All patients 
gave informed written consent prior to inclusion in the study.  
 
2.3 CLINICAL ASSESSMENT 
 
All patients underwent comprehensive assessment by an experienced cardiologist at 
the time of enrollment. This included documentation of any co-existing medical 
conditions, relevant cardiovascular medications and assessment for any pre specified 
exclusion criteria. The case report form is attached in Appendix 1. The patients 
symptomatic status was assessed according to the New York Heart Association 
(NYHA) criteria by the cardiologist blinded to the result of the echocardiographic, 




2.4.1 STANDARD ECHOCARDIOGRAPHY 
All echocardiograms were performed by experienced sonographers on modern 
commercially available echo machines (Vivid 7, General Electric Vingmed 
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Ultrasound, Norway). All patients underwent comprehensive examination including 
M-mode, 2D, Doppler and tissue Doppler echocardiography modified according to 
their underlying valvular lesions consistent with current guidelines [Baumgartner et 
al 2009, Zoghbi et al 2003]. Sample study protocols are shown in Appendix 2 and 3.  
   
2.4.2 ANALYSIS OF CHAMBER VOLUMES  
The LV end-systolic and end-diastolic volumes and LV ejection fraction were 
measured from the apical four-chamber view using the modified Simpson’s single-
plane method [Leung et al 1996]. This method was chosen to allow comparison with 
the post-exercise volumes. The left atrial area was measured in the apical four-
chamber view [Lester et al 1999]. The right ventricular dimension and fractional area 
change were measure in the apical 4-chamber view. LV mass was calculated from 
linear dimensions using the American Society of Echocardiography recommended 
formula [Lang et al 2005].   
 
2.4.3 ASSESSMENT OF AORTIC STENOSIS SEVERITY 
Quantitative and qualitative measures of aortic stenosis severity were made 
according to American Society of Echocardiography guidelines [Baumgartner et al 
2009]. Quantitative measures of AS severity included peak velocity, mean pressure 
drop and aortic valve area.  
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Measurement Of Aortic Peak Velocity And Mean Gradient  
The view with the highest recorded velocity was used to obtain the maximum aortic 
velocity. The mean gradient was obtained from tracing around this Doppler profile. 
All measurements were averaged over 3-5 beats. 
 
Calculation Of Aortic Valve Area 
The continuity principle was utilised to estimate the aortic valve area. The flow of 
blood through the LVOT was calculated by placing a pulse wave Doppler (PW) 
sample in the LVOT in the apical 5 chamber view and tracing around the signal to 
calculate the velocity time integral (VTI) and multiplying by the LVOT area. The 
LVOT was assumed to be circular and hence the LVOT area was calculated by the 
formula:  
 
LVOT area  = π *(LVOT diameter/2)2 
 
The VTI through the aortic valve was calculated by tracing around a continuous 
wave Doppler (CW) signal through the aortic valve in the apical 5-chamber view. In 
the absence of a left to right shunt, the flow through the LVOT and through the aortic 
valve is equal. 
 
VTILVOT * AreaLVOT = VTIAV * AVA 
Therefore we calculated the AVA according to the formula 
 
AVA  = (VTILVOT * AreaLVOT)  / VTIAV 
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2.4.4  ASSESSMENT OF AR SEVERITY  
Quantitative and qualitative measures of aortic regurgitation severity were made 
according to American Society of Echocardiography guidelines [Zoghbi et al 2003]. 
Quantitative measures included AR jet:LVOT width ratio, vena contracta, effective 
regurgitant orifice area, regurgitant volume, AR pressure half time and peak diastolic 
and end-diastolic flow velocities in the descending thoracic and abdominal aorta.  
Regurgitant volume was calculated via the continuity and PISA methods. 
 
Measurement Of LVOT:AR Jet Width Ratio And Vena Contracta 
This was obtained from a zoomed image of the LVOT. The jet width was measured 
at the same place as the LVOT dimension.  The vena contracta was measured just 
distal to the area of flow convergence at the narrowest point. (Figure 2.1) 
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Figure 2 .1 Measurement of LVOT: AR jet ratio and Vena Contracta 
 
LVOT: Left Ventricular Outflow Tract, AR: Aortic Regurgitation, VC : Vena Contracta 
 
 
Quantification Of AR 
The effective orifice area was calculated using the proximal isovelocity surface area 
(PISA) as described above.  The AR radius was measured in either a zoomed 
parasternal long axis (PLAX) view or the apical 5-chamber view. The Nyquist limit 
was reduced to allow better delineation of the area of flow convergence. The peak 
AR velocity was measured from a CW Doppler profile measured from the apical 5-
chamber view. The VTI signal was traced from the apical 5-chamber view to allow 
calculation of the regurgitant volume.  
 
In addition the regurgitant volume was calculated using the volumetric method. The 
mitral valve inflow was calculated by multiplying the mitral annular cross sectional 
area by the VTI obtained from a PW sample placed at the level of the mitral valve 
annulus. The mitral annular area was estimated from the mitral annular diameter and 
vc 
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assuming a circular orifice. The LVOT flow was calculated as previously described 
by obtaining the VTI from a PW sample placed in the LVOT and multiplying by the 
cross sectional area of the LVOT. The regurgitant volume was obtained by 
subtracting the MV inflow form the LVOT forward flow.  
 
The peak and end diastolic velocities from the diastolic flow reversal within the 
descending aorta were obtained from a PW sample placed in the proximal 
descending aorta.  
 
2.4.5  ASSESSMENT OF MR SEVERITY  
The severity of MR was assessed according to established guidelines [Zoghbi et al 
2003]. MR severity was assessed semi-quantitatively using the vena contracta and 
measurement of the jet area. 
 
The effective orifice area was calculated using the PISA and continuity methods 
[Enriquez-Sarano et al 1995]. The radius of flow convergence was measured in the 
apical 4-chamber view. The Nyquist limit was reduced to approximately 40cm/s to 
facilitate clearer definition of the area of flow convergence. The peak velocity of the 
MR jet was obtained from a CW signal in the apical 4-chamber view. The regurgitant 
volume was calculated by tracing around the MR VTI signal.  
 
For the volumetric method the LVOT flow was calculated from the PW VTI signal 
and LVOT area as described above. The mitral valve inflow was calculated from the 
PW VTI signal obtained from the MV annulus and multiplied by the area of the MV 
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annulus. The regurgitant volume was calculated by subtracting the LVOT outflow 
from the MV inflow. 
 
The stroke volumes obtained from the two methods were averaged to give a mean 
regurgitant volume. [Detaint et al 2005] 
 
2.4.6  ASSESSMENT OF MS SEVERITY  
The mitral valve area (MVA) was obtained using direct planimetry, pressure half 
time, proximal isovelocity area and continuity methods as described below [Hatle et 
al 1978, Martin et al 1979, Nakatani et al 1988]. The median MVA from these four 
methods was used for analysis.  
 
Planimetry Assessment Of MV Area 
This was performed in the parasternal short axis view. The ultrasound beam was 
scanned through the valve until it imaged the tips of the valve. The image was frozen 
the area of valve opening estimated by tracing around it in mid diastole. The main 
limitation of this method is that due to the conical shape of the mitral valve opening, 
positioning of the beam only a few millimetres towards the LA side of the valve can 
result in significant overestimation of the MVA.  
 
Pressure Half Time Method 
This method of calculating mitral valve area was first described in 1978 [Hatle et al 
1979]. It is based on the concept that the rate of decline of a pressure gradient across 
the mitral valve orifice is determined partly by the size of the orifice, although other 
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factors such as the degree of left atrial and left ventricular compliance and the LV 
end diastolic pressure also affect this. The early (E) trans-mitral Doppler signal 
typically has triangular shape with a steady rate of decline from the maximum to the 
baseline. The PHT is defined as the time in milliseconds for the trans-mitral diastolic 
pressure gradient to fall from any value to half that value but in clinical practice it is 
the time from the maximum velocity to half the maximum value (Figure 2.2) 
A CW sample was placed through the MV in the apical 4-chamber view. The sweep 
speed and scale were optimised to maximise the size of the CW profile on the screen. 
A line was drawn from the maximum velocity along the profile of the CW jet to 
calculate the pressure half time, The mitral valve area was estimated from the 
formula :  
Mitral valve orifice area = 220/PHT 
 
 
Figure 2.2 Calculation of Mitral valve are using the Pressure half time method 
 
Continuity Method 
This is a common method utilised across different valve lesions to assess the 
severity. In the case of MS it is based that in the absence of a shunt or coexisting 
regurgitant lesions, the flow through the mitral valve orifice in diastole should be the 
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same as the flow through the LVOT in systole. The flow of blood through the LVOT 
was calculated as described above by placing a PW sample in the LVOT and tracing 
around the signal to calculate the velocity time integral (VTI) and multiplying by the 
LVOT area. The LVOT was assumed to be circular and hence the LVOT area was 
calculated by the formula:  
 
LVOT area  = π *(LVOT diameter/2)2 
 
In the absence of any significant shunts or regurgitation, the outflow though the 
LVOT should be equal to the inflow through the mitral valve.  
 
VTILVOT * AreaLVOT = VTIMV * MVA 
 
Therefore the MVA was calculated according to the formula:  
 
MVA =  (VTILVOT * AreaLVOT) / VTIMV 
 
Proximal Iso-velocity Area Method 
This is also based on the continuity principle and assumes that the flow through the 
MW on the LA side must be equal to the flow through the valve emerging on the LV 
side. It does not require the assessment of flow through the aortic valve. As blood 
converges from the LA towards a narrowed mitral valve orifice, the velocity must 
increase to allow the blood to flow through the valve orifice. At any given distance 
from the orifice, the velocity of blood will be equal, resulting in a series of 
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hemispherical arcs radiating out from the orifice. By using the concept of aliasing, 
the velocity at which the Doppler colour scale changes from positive to negative, the 
Nyquist limit (NL) the velocity at one of these arcs can be determined. Consequently 
by using the surface area of a hemisphere (2πr2) and the velocity of blood flow, the 
flow through the mitral valve can be calculated using the following formula 
Flow through MV  = 2πr2 * NL 
 
                
 
Figure 2.3.  Flow convergence on the LA side of the mitral valve.  The PISA radius 
is measured from the point of aliasing to the mitral valve orifice. Due to the area of 
flow convergence becoming constrained due to the mitral valve leaflets, only a 
portion of a hemisphere of flow convergence is present. It is therefore necessary to 
modify the calculation by multiplying by the angle α/180. 
 
 
The Nyquist Limit (NL) was set at approximately 40cm/s to minimise measurement 
error of the PISA radius. However unlike in MR, whereby the regurgitant orifice, is 
relatively perpendicular to the velocity of blood allowing the formation of a complete 
hemisphere (except in eccentric jets), in MS the hemisphere is constrained by the 
angle (α) of the valve leaflets (Figure 2.3). Consequently significantly less than a full 
α 
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hemisphere is obtained and hence an angle correction must be performed to use this 
in MS. 
 
Flow through MV in MS = 2πr2 * NL * (α/180) 
 
(α/180) * 2πr2 * NL = MVA * MVvmax 
 
Consequently MVA = (2πr2 * α/180* NL) / MVvmax. 
 
Mitral Valve Area Used For Calculation 
The median MVA obtained from these methods was used for analysis.  
 
Mean Trans-mitral Pressure Gradient 
Mean trans-mitral pressure gradients were obtained by tracing the continuous wave 
Doppler signal across the mitral valve [Quinones et al 2002].  
 
2.4.7  MEASUREMENT OF PULMONARY ARTERIAL PRESSURE   
To facilitate estimation of right ventricular (RV) systolic pressure, agitated saline 
was injected to enhance the tricuspid regurgitation profile [Himelman et al 1989]. 
The peak pulmonary artery systolic pressure (PAP) was derived using the simplified 
Bernouilli equation from the peak tricuspid regurgitant jet and added to an estimate 
of right atrial pressure obtained from imaging of the inferior vena cava [Otto 2000]. 
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2.4.8 INDEXING TO BODY SURFACE AREA  
 Left atrial area, left ventricular volumes, valve areas and effective regurgitant orifice 
areas were indexed to body surface area [DuBois and DuBois 1916] 
 
2.4.9  ASSESSMENT OF DIASTOLIC FUNCTION 
Diastolic function was assessed using measurements of trans-mitral early (E) and late 
(A) inflow velocities at the mitral valve leaflet tips using a 5 mm sample volume in 
the apical four- chamber window. Pulsed wave tissue Doppler imaging of the mitral 
annulus was taken by placing a 5 mm sample volume at the junction of the LV wall 
and the septal and lateral mitral valve annulus. Care was taken to ensure the smallest 
possible angle between the ultrasound beam and longitudinal myocardial motion. 
The septal E/E’ ratio was used to give an estimate of LV filling pressure.  
 
2.4.10 ECHOCARDIOGRAPHY POST EXERCISE  
 Echocardiographic images were obtained immediately following peak exercise. 
Apical four-chamber views were obtained first for LV volumes and then after 
injection of agitated saline for the TR profile to estimate pulmonary artery pressure. 
In most patients images were obtained in less than 1-minute post exercise.  
 
2.4.11  SPECKLE TRACKING DERIVED STRAIN 
In the aortic regurgitation cohort, additional images were obtained pre and post 
exercise for 2D speckle tracking based LV longitudinal strain, strain rate and torsion 




2.4.12  ECHOCARDIOGRAPHIC ANALYSIS 
Images were stored digitally and analysis was performed offline (Echopac PC 
version 4.0.0 GE Healthcare, Milwaukee, WI, USA) by an experienced cardiologist 
blinded to the results of the patient characteristics and peptide data. All 
measurements were averaged from averaged from three to five cardiac cycles.  
 
2.4.13  QUALITY ASSURANCE 
All echocardiograms were performed and interpreted by experienced operators in a 
nationally recognised echocardiography department. Formal quality assurance 
programmes where in place and reviewed regularly within the department. A limited 
number of observers performed the echocardiograms or performed the analysis. The 
main criteria used for the assessment of valve severity have been shown to be highly 
reproducible. In aortic stenosis, Doppler estimates of aortic valve area, and mean 
gradient in aortic stenosis have been shown to have the intra-observer variability and 
reproducibility coefficients have been previously shown to be 1.88% and 0.16 m/s 
for Vmax, 2.05% and 0.18 cm
2 for aortic valve area and 7.87% and 6.30 mmHg for 
mean gradient.  For inter-observer variability, the variation and reproducibility 
coefficients were 2.00% and 0.14 m/s for Vmax, 7.67% and 0.16 cm
2 for AVA and 
8.53% and 7.06 mmHg for mean gradient respectively.  Both intra- and inter-
observer studies showed excellent intraclass correlation coefficients (ICC) for all 
echocardiographic parameters (ICC ranged from 0.943 to 0.992) [Moura et al 2011].  
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In mitral stenosis both inter and observer agreement for the assessment of MVA non 
invasively found it to be highly reproducible with good inter-observer agreement 
(ICC was 0.95 and 0.90 for PHT) and intra-observer agreement (ICC was 0.92 and 
0.96) [Zamorano et al 2004]     
 
In this study, the measurement of LV volumes, which have a greater degree of 
variation than other measures, were performed by a single operator.  
 
2.5 EXERCISE TESTING 
 
2.5.1 PROTOCOL 
All patients underwent symptom-limited exercise testing on a motorized treadmill 
(GE/Marquette T2000, GE Healthcare, Milwaukee, WI, USA). A standard Bruce 
protocol was used for patients with mitral regurgitation. However it was noted that 
there was significant clustering of exercise times at the end of each stage and this 
was felt to adversely affect the objectivity of the determination of exercise capacity. 
Consequently for subsequent patients, the protocol was adjusted so that the speed 
and/or incline of the treadmill were increased at 1-minute intervals. The maximum 
workload at the end of each 3-minute stage remained equivalent to that of the 
standard Bruce protocol. The exercise protocol is attached in appendix 6.  
 
2.5.2 PATIENT MONITORING 
All patients underwent continuous ECG monitoring throughout the test. Blood 
pressure (BP) was recorded by an automated blood pressure cuff (SunTech Tango+, 
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SunTech Medical, Morrisville, NC, USA) placed on the left arm.  BP was recorded 
at 1 minute then 2 minute intervals.  
 
2.5.3 TERMINATION CRITERIA 
Exercise was stopped for significant dyspnoea, chest discomfort, presyncope, fatigue 
or at patient request. 
 
2.6 MEASUREMENT OF NATRIURETIC PEPTIDES 
 
Blood samples were obtained from an indwelling intravenous catheter after 15 min 
lying supine, immediately prior to the baseline echocardiogram and immediately post 
exercise. Patients fasted for 2 hours prior to the investigations. Blood samples were 
collected in ethylene diamine tetraacetic acid tubes (7.5 mg/5 mL; Vacutainer, 
Becton Dickinson, Rutherford, NI). They were centrifuged for 10 minutes at 4C and 
plasma stored at –80 C. The samples were sent to the Department of Endocrinology 
at the Christchurch Heart Institute for measurement of natriuretic peptides at the 
completion of the study.  
 
2.6.1 EXTRACTION OF ANP AND BNP FROM PLASMA 
BNP and ANP were extracted from human plasma on reverse phase cartridges and 
the extract subjected to established radioimmunoassays [Yandle et al 1993]. For 
measurement of BNP concentrations, plasma was extracted on 500 mg SepPak vac 
C18 reverse phase cartridges, washed and eluted with 80% isopropanol in 0.1% 
Trifluroacetic acid (TFA). The extract is dried under air and reconstituted in assay 
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buffer. The antiserum used was hBNP-32 antiserum (Cat # RAS9086, Peninsula 
Laboratories, USA), raised in rabbit. [125I]BNP-32 prepared by ChloramineT 
iodination and purified by high performance liquid chromatography (HPLC) was 
used as a tracer.  
 
For measurement of ANP concentrations, 3mL of plasma was extracted on 500 mg 
SepPak vac C18 reverse phase cartridges, washed and eluted with 80% isopropanol 
in 0.1% TFA. The extract is dried under air and reconstituted in assay buffer. Locally 
raised hANP (99-126) (R31) raised in a rabbit was used as antiserum. [125I]hANP 
(99-126) prepared by Chloramine T iodination and purified by HPLC. 
 
2.6.2 ASSAY CHARACTERISTICS 
The upper limit of the normal reference range for BNP is 42 pg/mL. The intra-assay 
coefficients of variation were 10.11 % at 25.7 pg/mL and 6.79% at 52.5 pg/mL and 
13.76% at 82.4 pg/mL.  The inter-assay coefficients of variation were 15.02% at 25.7 
pg/mL and 15.74% at 52.5 pg/mL and 14.88% at 82.4 pg/mL. 
  
The upper limit of the normal reference range for ANP is 83pg/mL. The intra-assay 
coefficients of variation were 5.82% at 50.8 pg/mL and 5.66% at 80.2 pg/mL and 
5.68% at 247.2 pg/mL.  The inter-assay coefficients of variation were 8.47% at 50.8 
pg/mL and 13.05% at 80.2 pg/mL and 5.1% at 247.2 pg/mL 
 
To convert BNP levels expressed in pg/mL to pmol/L, divide by 3.47 ad for ANP 
divide by 3.08 [Van Pelt et al 2007, Yandle et al 1993].   
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2.7  STATISTICAL ANALYSIS 
 
Categorical data were presented as frequency and percentage, and continuous data 
were presented as mean  standard deviation (SD), or median and inter-quartile 
range (IQR).  BNP underwent natural log transformation in analyses due to its right 
skewed distributions unless specified, and was reported as median and inter-quartile 
range.  Two sample student t-tests or Mann Whitney U test (for non-normally 
distributed data) were used for comparing continuous variables between patient 
groups. Comparison of all valves versus the control group, and comparison of valve 
subgroups was performed using the Chi-square or Fisher’s exact tests for categorical 
data where appropriate. For comparison between subgroup of valves, one-way 
analysis of variance (ANOVA) was performed followed by the Dunnett’s test, was 
used to compare each valve with control subjects. The Kruskal-Wallis test was used 
when the continuous data was not normally distributed. Pearson correlation 
coefficients or Spearman correlation coefficients were reported for linear 
associations. SAS released 8.0 software (SAS Institute Inc., Cary, NL, USA) and R 
2.1.1(The R Foundation for Statistical Computing) was used for analysis. All tests 
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Exercise echocardiography in patients with valvular heart disease  






Stress echocardiography is recommended for the assessment of asymptomatic 
patients with severe valvular heart disease (VHD) when there is discrepancy between 
symptoms and resting markers of severity. The aim of this study was to determine 
the prognostic value of exercise stress echocardiography in patients with common 
valve lesions.  
 
One hundred and fifteen patients with VHD (AS n=28; AR n=35; MR n=26; MS 
n=26), and age- and sex-matched controls (n=39) with normal ejection fraction 
underwent exercise stress echocardiography. The primary end point was a composite 
of death or hospitalisation for heart failure.  
 
Asymptomatic VHD patients had lower exercise capacity than controls and 37% of 
patients achieved less than 85% of their predicted metabolic equivalents (METs). 
There were 3 deaths, 4 hospital admissions and 24 patients underwent surgery during 
follow-up. An abnormal stress echocardiogram (METs <5, blood pressure rise <20 
mm Hg, or PAP post exercise >60 mmHg) was associated with an increased risk of 
death or hospital admission (12% vs 2%, p=0.03). The assessment of contractile 
reserve did not offer additional predictive value.  
 
An abnormal stress echocardiogram is associated with an increased rate of death and 
hospitalisation with heart failure at 2 years. Stress echocardiography should be 





Valvular heart disease (VHD) remains a common cause of cardiovascular morbidity 
and mortality worldwide. Acute valvular lesions such as acute aortic or mitral 
regurgitation often present with signs of acute severe heart failure and the prognosis 
without urgent cardiac surgery is poor. In contrast patients with chronic valve disease 
may remain asymptomatic for many years. Previous studies have demonstrated that 
during this asymptomatic phase, the prognosis remains relatively favourable but once 
symptoms develop, the prognosis without valve surgery becomes poor [Delahaye et 
al 1991, Horstkotte and Loogen 1988, Klodas et al 1997, Ross and Braunwald 1968, 
Wood 1954]. Consequently the assessment of symptomatic status in patients with 
VHD forms a key factor in current guidelines on the management of VHD [Bonow et 
al 2006, Nishimura et al 2014]. However due to the often slowly progressive nature 
of VHD, defining the exact onset of symptoms in patients with VHD can be difficult. 
In addition many patients who remain asymptomatic can develop significant 
dilatation of cardiac chambers and impairment of ventricular function or pulmonary 
hypertension prior to developing overt symptoms. In many patients, the assessment 
of the severity of the underlying valve disease can be problematic with discordant 
markers of severity on resting echocardiography. Furthermore a number of patients 
complain of symptoms despite objectively mild or moderate valve disease at rest.   
 
3.2.1 RECOMMENDATIONS FOR STRESS ECHOCARDIOGRAPHY IN VHD 
To overcome these difficulties current guidelines [Bonow et al 2006, Nishimura et al 
2014] recommend the use of exercise testing in patients with valve disease.  
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However this is mainly consensus driven and it is unclear whether performing 
exercise echocardiography in VHD patients leads to a clinical for these patients.  
 
3.2.2 STUDY AIMS 
The aim of this study was to determine the value of performing exercise 
echocardiography in patients with common valvular heart lesions without an 
established indication for surgery according to current guidelines. We aim to 
determine whether patients who demonstrate adverse features on stress 
echocardiography have a worse outcome during follow up than those with normal 
exercise stress echocardiograms. A secondary aim was to compare the value of 





3.3.1 PATIENT SELECTION 
Asymptomatic patients with severe valve disease, patients with a discrepancy 
between symptoms and Doppler echocardiography performed at rest or those with 
equivocal symptoms were identified from echocardiogram reports and outpatient 
clinics in the Auckland region. These comprised patients with isolated aortic 
stenosis, aortic regurgitation, mitral regurgitation and mitral stenosis. All patients had 
normal left ventricular ejection fraction (AS ≥ 50%, AR >50%, MR ≥ 60%, MS≥ 50) 
[Baumgartner et al 2009, Bonow et al 2006, Zoghbi et al 2003]. Exclusion criteria 
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included ischaemic heart disease, significant renal impairment (creatinine >160 
µmol/L), respiratory disease, a contraindication to exercise testing, additional 
valvular lesions graded greater than mild or an established indication for valve 
surgery according to the ACC/AHA guideline criteria [Bonow et al 2006, Nishimura 
et al 2008].  All patients eligible for inclusion were invited to participate.  The 
patients’ symptomatic status was assessed according to the NYHA criteria by an 
experienced cardiologist blinded to echocardiographic data. Control subjects were 
volunteers from the local community who were age and sex matched. They were 
recruited by advertisement and had no clinical evidence of cardiovascular or 
respiratory disease. The study was approved by the Northern X Ethics Committee, 
Auckland. All patients gave written consent after a full explanation of the purpose 




All patients underwent comprehensive echocardiography at rest as outlined in section 
2. All analysis was performed offline by an experienced cardiologist blinded to the 
results of the patients’ clinical assessment. All measurements were averaged from at 
least 3, or in cases of AF, 5 cardiac cycles.  
 
Quantitative and qualitative measures of aortic stenosis and regurgitation severity 
were made according to American Society of Echocardiography guidelines 
[Baumgartner et al 2009, Zoghbi et al 2003]. Quantitative measures of AS severity 
included peak velocity, mean pressure drop and aortic valve area.  Assessment of AR 
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severity included the AR jet:LVOT width ratio, AR pressure half time, peak diastolic 
and end-diastolic flow velocities in the descending thoracic and abdominal aorta. 
 
The severity of MR was assessed by quantitative Doppler with mitral and aortic 
stroke volumes [Enriquez-Sarano et al 1993] and by the PISA method [Enriquez-
Sarano et al 1995]. The stroke volumes obtained from the two methods were 
averaged to give a mean regurgitant volume [Detaint et al 2005]. The mitral valve 
area was obtained using direct planimetry, pressure half time, and continuity methods 
[Hatle et al 1978, Martin et al 1979, Nakatani et al 1988]. The median MVA from 
these three methods was used for analysis. Mean trans-mitral pressure gradients were 
obtained by tracing the continuous wave Doppler signal across the mitral valve 
[Quinones et al 2002]. 
 
3.3.3 ESTIMATION OF PULMONARY ARTERY PRESSURE 
To facilitate estimation of RV systolic pressure, agitated saline was injected to 
enhance the tricuspid regurgitation profile as described in Section 2 [Himelman et al 
1989]. The peak PAP was derived using the simplified Bernouilli equation from the 
peak tricuspid regurgitant jet velocity and added to an estimate of right atrial pressure 
obtained from imaging of the inferior vena cava [Otto 2000].  
 
3.3.4  INDEXING TO BODY SURFACE AREA 
Left atrial area, left ventricular volumes, valve areas and effective regurgitant orifice 
areas were indexed to body surface area [DuBois and DuBois 1916]. 
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3.3.5 EXERCISE STRESS ECHOCARDIOGRAPHY 
All patients underwent symptom-limited exercise testing on a motorized treadmill. A 
standard Bruce protocol was used for patients with MR. However it was noted that 
there was significant clustering of exercise times at the end of each stage and this 
was felt to adversely affect the objectivity of the determination of exercise capacity. 
Consequently for subsequent patients, the protocol was adjusted so that the speed 
and/or incline of the treadmill were increased at 1-min intervals. The maximum 
workload at the end of each 3-min stage remained equivalent to that of the standard 
Bruce protocol. Exercise was stopped for significant dyspnoea, chest discomfort, 
presyncope, fatigue or at patient request. 
 
Immediately after exercise echocardiographic images were obtained in the apical 
four-chamber view, first for LV volumes then for tricuspid regurgitant jet velocity 
with agitated saline enhancement. In all patients, data were obtained within 1 min of 
peak exercise.  
 
3.3.6 OUTCOME MEASURES 
Patients continued with their regular clinical follow up by their usual cardiologist in 
accordance with established guidelines [Bonow et al 2006]. Their clinical 
cardiologist decided the requirement for, and timing of any valve intervention 
blinded to exercise echo data. The only exception to this was if there were major 
abnormalities detected on stress echocardiography in which case the cardiologist was 
informed. Follow up data was collected for two years from the date of enrolment. 
The main outcomes were death, hospitalisation for heart failure and the need for 
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valve replacement surgery. The primary clinical outcome was a composite of death 
and hospitalisation for acute heart failure. The secondary endpoint was a composite 
of death, hospitalisation and valve intervention. 
 
Adverse features on treadmill testing were defined as low exercise capacity (<5 
metabolic equivalents (METs) on treadmill exercise [Fletcher et al 1995, McCully et 
al 2002], an abnormal blood pressure response to exercise (<20 mmHg rise with 
exercise) [Bonow et al 2006], exercise induced pulmonary hypertension (PAP >60 
mmHg post exercise [Bonow et al 2006]) and poor contractile reserve (<4% increase 
in ejection fraction post exercise) [Lee et al 2005, Marechaux et al 2008].  
 
3.3.7 STATISTICAL ANALYSIS 
Two sample student t-tests were used for comparing continuous variables between 
patient groups. Comparison of all valves versus the control group, and valve sub-
groups was performed using the Chi-square or Fisher’s exact tests for categorical 
data where appropriate.  For continuous variables, two independent sample Student’s 
t-test was used for comparing all valves versus controls group.  For comparison 
between subgroup of valves, one-way analysis of variance (ANOVA) was 
performed. Chi squared test was used for categorical variables. Prediction accuracies 
were reported by area under the receiver operating characteristic curve (AUC) and its 
95% confidence interval. Kaplan Meier curves were used to visualize the time to first 
clinical event across different stress echocardiographic parameters.  XLSTAT 
(Version 2014.4.06, Addinsoft 1995-2014) was used for analysis. All tests were two 





All patients who agreed to participate completed all aspects of the study. One 
hundred and fifteen patients with valve disease and 39 control subjects were 
recruited: isolated MR (n=26), AR (n=35), AS (n=28) and MS (n=26) or normal 
valves (n=39) (Table 3.1) 
 
Eighty-one (70%) of VHD patients were assessed as asymptomatic (NYHA class 1). 
The remainder had mild or equivocal symptoms but did not fulfil criteria for surgery 
based on their assessment of valve severity according to Doppler echocardiography 
and clinical assessment performed at rest. Across all VHD patients, 37 (32%) of 
patients had severe valve disease, 69 (60%) of patients had moderate valve disease 
and 9 (8%) of patients had mild disease but had symptoms out of keeping with their 
echocardiographic findings at rest. No patients had evidence of regional wall motion 


























Mitral Regurgitation n (%)  16 (25) 10 (20)  0.49 
Mitral Stenosis n (%)  4 (6) 22 (43)  <0.0001 
Aortic Stenosis n (%)  10 (16) 18 (35)  0.01 
Aortic Regurgitation n (%)  34 (53) 1 (2)  <0.0001 
Age (years) 55±15 48±14 58±15 0.02 <0.0001 
Body Mass Index (kg/m2) 26±4 28±4 29±5 0.01 0.46 
Sex Male (n,%) 23 (59) 50 (78) 23 (45) 0.06 <0.001 
NYHA Class 2 (n, %) 0 (0) 11 (17) 23 (45) 0.07 0.001 
Resting Echocardiography  
Left Atrial Area Index (cm2/m2) 11±2 12±4 16±6 0.01 < 0.0001 
LVEDV (mls/m2) 52±13 77±28 54±19 < 0.0001 < 0.0001 
LVESVI (mls/m2) 19±7 57±30 39±18 < 0.0001 < 0.0001 
Left Ventricular EF (%) 64 (8) 64±6 63±8 0.71 0.38 
Pulmonary Artery Pressure (mmHg) 24±4 29±6 37±13 < 0.0001 < 0.0001 
Exercise Stress Echocardiography  
LVEDVI (mls/m2) 34±13 57±20 40±18 < 0.0001 < 0.0001 
LVESVI (mls/m2) 9±5 17±9 12±7 < 0.0001 0.004 
Left Ventricular EF (%) 78±8 71±8 71±10 < 0.0001 0.87 
Change In Ejection Fraction (%) 13±7 7±8 7±16 0.001 0.79 
Pulmonary Artery Pressure (mmHg) 41±9 46±8 64±20 0.02 < 0.0001 
Metabolic Equivalents (METs) 12.5±3.1 11.1±2.9 7.4±2.9 0.019 < 0.0001 
Systolic BP Rise (mmHg) 46±15 50±18 11±18 0.25 < 0.0001 
% Of Predicted Mets (%) 133±38 106±33 82±41 < 0.0001 0.001 
Peak Heart Rate (bpm) 153±16 143±21 136±25 0.02 0.14 
% Peak Heart Rate (%) 93±13 78±24 84±13 < 0.0001 0.13 
 
LVEDVI: Left Ventricular End-Diastolic Volume Index, LVESVI: Left Ventricular End-Systolic 
Volume Index, EF: Ejection Fraction, BP, Blood Pressure, NYHA: New York Heart Association 
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3.4.1 VHD PATIENTS WITH NORMAL EXERCISE ECHOCARDIOGRAMS 
Sixty-four VHD patients (56%) had normal stress echocardiograms. Most patients 
with AR had normal studies. In contrast only 4 patients (15%) with mitral stenosis 
had a normal stress echocardiogram (Table 3.1). Although patients with VHD and 
normal exercise echocardiograms were younger than controls (48 ±15 vs. 55±15 
years; p=0.02), they had lower exercise capacity (11.1±2.9 vs 12.5±3.1 METS; 
p=0.02). In addition patients with VHD and normal stress echocardiograms had 
larger left atria, larger left ventricles at rest and post exercise and higher PAP at rest 
and post exercise than controls (Table 3.1) 
 
3.4.2 VHD PATIENTS WITH ABNORMAL STRESS ECHOCARDIOGRAMS 
Fifty-one patients (44%) with had abnormal stress echocardiograms and were older 
than those with VHD patients and normal exercise echocardiograms (58±15 vs. 
48±15 years; p<0.0001). However these patients were not older than the control 
group. Patients with abnormal stress echocardiograms had larger left atria, larger 
ventricles and higher PAP compared to patients with VHD and normal stress 
echocardiograms.  
 
3.4.3 SYMPTOMATIC STATUS 
Eighty-one patients were assessed in NYHA class 1. However despite being 
asymptomatic they had worse exercise capacity than control subjects (10.3±3.4 vs. 
12.5±3.1 METS; p=0.001). Patients with NYHA class 2 symptoms had a lower 
exercise capacity than those in NYHA class 1 (7.2±2.3 vs. 10.3±3.4, p<0.0001) 
despite only 2 patients (with equivocal symptoms) having evidence of severe disease 
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at rest (5% vs. 43%, p <0.0001).  Five patients (6%) who were deemed to be 
asymptomatic at baseline had an exercise capacity of less than 5 METS. Twenty-
eight patients (82%) who were deemed to be symptomatic had an exercise capacity 
greater than 5 METS. However when exercise capacity was stratified according to 
age, 30 (37%) asymptomatic patients achieved less than 85% of their age-predicted 
exercise capacity. In contrast 14 (41%) patients who were classed as symptomatic 
achieved more than 85% of their age predicted METS.  Overall the use of objective 
exercise capacity (workload>85% age-predicted METS) resulted in the re-
classification of symptomatic status in 38% of patients. Reclassification of 
symptomatic status was seen most frequently in patients with AR and MS suggesting 
that accurate assessment of symptomatic status is most difficult in these groups of 
patients.  
 
3.4.4 OUTCOME DATA  
There were 3 deaths, 4 hospital admissions for heart failure and 24 patients 
underwent surgery during the 2-year follow up period (Table 3.2). Patients with an 
abnormal exercise test were more likely to die or be hospitalised with heart failure 
during follow up (12% vs. 2%, p=0.03). Exercise induced pulmonary hypertension 
was the only isolated adverse feature on exercise testing that was different in patients 
who died or those who underwent surgery during follow up (Table 3.2).  
 
Patients who were admitted to hospital had lower exercise capacity, higher 
pulmonary artery pressure and a lower blood pressure rise with exercise.  In contrast 
poor contractile reserve (a rise in EF of ≤4 %) did not identify patients with adverse 
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outcome. Exercise capacity was the single best predictor of death or heart failure 
admission.   
 
Patients with an abnormal stress echocardiogram were more likely to meet the 
primary endpoint of death or hospitalisation (Figure 3.1) but not the combined end 
point of death, hospitalisation or need for surgery during follow up (Figure 3. 2). 
 
3.4.5 COMPARISON BETWEEN DIFFERENT VALVE LESIONS. 
Patients with an established indication for surgery were excluded from this study. In 
keeping with the inclusion of some patients with degenerative aortic stenosis, these 
patients were significantly older than the patients in other valve groups (Table 4).  
Patients with stenotic valve lesions had a lower rise in systolic blood pressure than 
those with regurgitant valve lesions (AS 16 ± 23, MS 14 ± 15, AR 59 ± 18, MR 34 ± 
19mmHg; p<0.0001). Patients with MS were the most likely to have exercise 
limitation with 88% of patients failing to achieve >85% of their age-predicted 
exercise capacity.  However symptomatic status at rest did not correspond to exercise 
capacity on exercise stress echocardiography in almost a third of patients regardless 





Table 3.2. Relative proportions of patients with adverse features on stress echocardiography with adverse outcome 
 Death Admission Surgery Death/Admission Any Outcome 
 n (%) p n (%) p n (%) p n (%) p n (%) p 










Normal BP  1  (1) 0 (0) 14 (18) 1 (1) 14 (18) 










METS>5  3 (3) 1 (1) 23 (22) 4 (4) 26 (25) 










PAP<60 mmHg 1 (1) 2 (2) 17 (19) 3 (3) 19 (21) 










Normal ESE  1 (2) 0 (0) 12 (19) 1 (2) 12 (19) 










EF Increase >4% 2 (2) 3 (3) 17 (20) 5 (6) 22 (26) 
*Abnormal ESE is at least one of BP rise<20mmHg, Exercise tolerance <5 Mets or PAP post exercise>60mmHg. 
BP: Blood Pressure, METs: Metabolic equivalents, PAP: pulmonary artery pressure, ESE: exercise stress echocardiogram, EF: Ejection fraction
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Table 3.3  The predictive accuracy of exercise stress echo parameters for clinical outcomes during follow-up. 
 
 Death Admission Death/Admission Operation Any Event 
 AUC p AUC p AUC p AUC p AUC p 
Exercise Capacity 
(METs) 
0.73 (0.57, 0.89) 0.005 0.94 (0.93, 0.96) <0.0001 0.86 (0.76,0.96) <0.0001 0.58 (0.46, 0.69) 0.21 0.65 (0.54, 0.76) 0.007 
BP Rise (mmHg) 0.52 (0, 1.0) 0.92 0.86 (0.78, 0.93) <0.0001 0.72 (0.49,0.95) 0.07 0.51 (0.36, 0.66) 0.90 0.58 (0.45, 0.71) 0.22 
Post Exercise PAP 
(mmHg) 
0.50 (0, 1.0) 1.0 0.73 (0.58, 0.87) 0.002 0.66 (0.36,0.96) 0.30 0.56 (0.40, 0.72) 0.44 0.58 (0.43, 0.73) 0.30 
Change in EF (%) 0.41 (0, 0.83) 0.68 0.31(0, 0.64) 0.25 0.35 (0.10, 0.59) 0.22 0.55 (0.43, 0.67) 0.43 0.46 (0.34, 0.58) 0.48 
 
























P value  






Number of subjects 39 35 28 26 26   
Age (Mean ± SD) 55.4 ± 15.1 43.5 ± 13.5 66.0 ± 9.0 52.7 ± 14.5 50.1 ± 14.8 0.3707 <0.0001 
NYHA Class, n (%) - 3 (9) 11 (39) 10 (38) 10 (38) 0.0001 0.0137 
Exercise Capacity 
Mean ± SD 
12.5 ± 3.1 11.2 ± 3.5 9.6 ± 3.0 9.8 ± 2.3 6.5 ± 2.8 <0.0001 <0.0001 
% peak Heart rate 
Mean ± SD 
93 ±13 77 ± 11 84 ± 12 90 ± 10 87 ± 13 <0.0001 0.0002 
BP rise 
Mean ± SD 
46 ± 15 59 ± 18 16 ± 23 34 ± 19 14 ± 15 0.0002 <0.0001 
METS <5, n (%) 0 (0) 1 (3) 0 (0) 0 (0) 12 (46) 0.0395 <0.0001 
METS <85% predicted, n (%) 4 (10) 12 (34) 5 (18) 10 (38) 23 (88) 0.0002 <0.0001 
Change in NYHA (all), n (%) 
 









NYHA 1 to 2, n (%) 
 









NYHA 2 to 1, n (%) - 2 (6) 7 (25) 5 (19) 0 (0) 0.0215 0.0091 
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Figure 3.1.  Kaplan-Meier curves showing event-free survival (death or 
hospitalisation with heart failure) for patients with a normal stress echocardiogram 





Figure 3.2. Kaplan-Meier curves showing event free survival (death or 
hospitalisation with heart failure, valve surgery) for patients with a normal stress 
echocardiogram (blue line) and an abnormal stress echocardiogram (red line) over 2 

































This study demonstrates that adverse features found on stress echocardiography in 
patients with common forms of valvular heart disease are associated with a worse 
prognosis during a 2-year follow-up period. This is despite these patients not 
fulfilling any criteria for surgical intervention at the time of enrolment. In particular 
patients with exercise induced pulmonary hypertension were more likely to die 
during follow-up. Patients with at least one adverse feature on stress 
echocardiography were more likely to be hospitalised with heart failure or meet the 
combined of endpoint of death and heart failure admission.  
 
3.5.1 PREVIOUS STUDIES OF EXERCISE TESTING IN VHD 
A number of other studies have assessed the role of exercise testing in valvular heart 
disease.  Most evidence is in asymptomatic patients with severe AS and relates 
primarily to exercise electrocardiography (ECG). Previous studies have suggested 
that an abnormal exercise test defined as the development of symptoms, ST 
depression or a failure to augment blood pressure by >20 mmHg predicted the future 
onset of symptoms [Alborino et al 2002, Amato et al 2001] and sudden cardiac death 
during follow up [Amato et al 2001]. More recently a study by Das et al [Das et al 
2005] confirmed the finding that the development of symptoms with exercise was 
superior to clinical history and resting echocardiography in predicting future onset of 
symptoms. However they also found that that the presence of an abnormal BP 
response to exercise was less helpful.  The additional value of exercise stress 
echocardiography over exercise ECG is less clear. Lancellotti et al and Marechaux et 
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al found that an exercise induced increase in mean pressure drop across the aortic 
valve of more than 18 or 20 mmHg respectively was associated with an increased 
risk of symptom onset or death [Lancellotti et al 2005, Marechaux et al 2010]. 
However in patients with reduced LV functional reserve, the ability to generate a 
significant pressure drop across a stenotic valve may be reduced and this finding 
should be interpreted with caution.  The role of exercise echocardiography in aortic 
regurgitation is even less clear. A few studies have looked at the presence of exercise 
induced LV dysfunction in patients with AR. Wahi et al found that a failure to 
augment LV systolic function at peak exercise was predictive of left ventricular 
decompensation [Wahi et al 2000]. In addition we have previously demonstrated that 
even in AR patients who have an appropriate increase in EF with exercise, 
assessment of global longitudinal strain post exercise can detect early LV 
dysfunction [Gabriel et al 2008]. 
 
Similarly in MR a number of studies have demonstrated that mitral regurgitation can 
worsen with exercise and that the absence of contractile reserve is associated with 
reduced event-free survival and can predict early postoperative LV dysfunction 
[Magne et al 2010, Magne et al 2014]. Exercise echocardiography was formally a 
class 1 recommendation in asymptomatic patients with moderate or severe MS and 
symptomatic patients with mild MS [Bonow et al 2006]. However there are no 




3.5.2 CLINICAL ASSESSMENT AND OBJECTIVE EXERCISE CAPACITY 
In this study, patients who were deemed to be asymptomatic by clinical assessment 
alone did indeed have a better objectively measured exercise capacity than those who 
were symptomatic. The asymptomatic group had a much greater proportion of 
patients with severe VHD although, in accordance with current guidelines, 
symptomatic patients with severe valve disease were excluding from undergoing 
stress echocardiography. It was striking that despite thorough clinical assessment by 
an experienced cardiologist, a significant number of apparently asymptomatic 
patients had extremely poor exercise capacity when subjected to exercise stress 
echocardiography and that reclassification of symptomatic status occurred in a third 
of patients across all valve groups. This is in keeping with the findings of other 
studies, which have highlighted the difficulty in the accurate assessment of 
symptomatic status in patients with valve disease.    
 
Previous guidelines [Bonow et al 2006] recommended exercise stress 
echocardiography for asymptomatic patients with severe AS (peak velocity >4 m/s or 
mean gradient >40 mmHg), in asymptomatic moderate or severe MS (MVA <1.5 
cm2) and symptomatic patients with mild MS.  For patients with MS, a rise in PAP of  
>60 mmHg or a pulmonary capillary wedge pressure (PCWP) of >25 mmHg was 
considered an indication for intervention. However the most recent ACC/AHA 
[Nishimura et al 2014] guidelines no longer specifically consider exercise induced 
pulmonary hypertension as a criteria to intervene but instead prompt the clinician to 
reassess the patient’s symptomatic status. Stress echocardiography is now only 
considered a class 1 indication in patients in whom there is a discrepancy between 
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symptom status and clinical assessment and Doppler echocardiographic markers of 
severity at rest [Nishimura et al 2014]. Exercise stress echocardiography is 
recommended in patients with chronic MR where there is a discrepancy between 
symptoms and severity at rest. In addition they suggest that exercise treadmill testing 
can be useful to establish symptoms status and exercise tolerance. No specific 
recommendations are made for stress echocardiography in AR other than it may be 
helpful to define symptom status.   
 
3.5.3 ABNORMAL STRESS ECHOCARDIOGRAMS AND ADVERSE OUTCOME 
Patients with an established indication for surgery were excluded from this study in 
keeping with current guidelines. Consequently given that in some cases intervention 
is now considered at an earlier stage for patients with valve disease, the patients in 
this study consist of a lower risk cohort than in previously published studies. This 
may be reflected in the lower than expected event rate during follow up.  However 
despite this we found a significantly poorer outcome across a range of different 
valvular heart lesions for patients with an abnormal exercise stress echocardiogram. 
Although the best single predictor was an exercise capacity of <5 METS, the 
addition of a poor BP response to exercise and exercise induced pulmonary 
hypertension (PAP >60 mmHg) offered incremental prognostic information and was 
clearly associated with an increased rate of death or admission with heart failure over 
the 2-year follow up period. Conversely the measurement of contractile reserve (CR) 





These findings suggest that stress echocardiography, with the measurement of 
pulmonary pressure post exercise should be considered more frequently in the 
assessment of asymptomatic patients with VHD. It remains unclear whether earlier 
intervention following a positive exercise stress echocardiogram can improve the 
long-term outcome of these patients. Although this needs to be the subject of future 
research, it remains difficult to investigate this as in clinical practice, patients with 
adverse features on exercise stress echocardiography, particularly those with poor 
exercise capacity will have their symptomatic status re-classified and may require 
referral for valve surgery.  
 
3.5.4 CHOICE OF EXERCISE PROTOCOL 
We performed exercise stress echocardiography using a treadmill rather than a semi-
supine ergometer.  The cycle ergometer has a number of advantages in the 
assessment of VHD. In particular it allows images to be obtained during exercise, 
thereby allowing additional measurements such as changes in valve gradients or 
quantitative assessment of MR severity during exercise to be obtained. However 
cycle ergometers are not widely available outside mainland Europe. In addition to 
their widespread availability, treadmill exercise has a number of other advantages. 
Firstly it is more physiological and patients are more readily able to equate 
performance on a treadmill to their exercise capacity in day-to day activities. 
Secondly, patients are often able to achieve higher workloads and higher heart rates 
with treadmill exercise. This was demonstrated by the fact that most patients 
achieved >85% of their maximum heart rate during this study.  However when using 
treadmill exercise with a standard Bruce protocol for the MR cohort, we found 
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significant clustering of patients’ exercise times that coincided with the end of each 
3-min stage of the standard Bruce protocol.  This probably represents a goal-
orientated approach to exercise and perhaps affects the true objective determination 
of exercise capacity. Consequently for other valve groups we adapted the Bruce 
protocol such that the speed and/or incline increased at 1-min intervals. The protocol 
was adapted to ensure that the exercise capacity in METs at the end of each 3-min 
interval remain unchanged when compared to the standard Bruce protocol (Appendix 
1). This resulted in a more even spread of exercise times across VHD patients. This 
suggests that when using treadmill exercise in order to objectively assess exercise 
capacity, the use of a more graduated protocol such as the one used in this study 
should be considered.  
 
3.5.5 STUDY LIMITATIONS 
This study did not specifically assess the role of more detailed PISA based markers 
of severity during exercise in MR or increased valve gradients with exercise in AS 
which have previously been shown to predict outcome [Magne et al 2010, 
Marechaux et al 2010]. In addition we did not assess the role of global longitudinal 
strain post exercise which may identify a higher risk cohort of patients with VHD 
[Magne et al 2014]. Although feasible, these markers are much more difficult to 
assess particularly during exercise and as above requires the use of a semi-supine 
tilting ergonometer to perform reliably. Furthermore it is difficult to compare these 
variables across different types of valve lesions. Instead we chose to focus on easily 
measurable and directly comparable variables such as exercise capacity, BP rise with 
exercise, and PAP. Although we also assessed the presence of CR, defined by a 
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change in EF post exercise, this was not predictive of adverse outcome. 
Measurement of exercise capacity, BP response to exercise and PAP is 
straightforward and hence more readily incorporated into clinical practice. A further 
limitation is that although the total number of patients within the study is reasonable, 
the number of adverse events during follow up was lower than expected. This may 
reflect the overall low-risk cohort of patients recruited within the study. Given the 
low rate of adverse events it was not possible to perform regression analysis to 
determine the effect of other predictors such as age and sex on adverse outcome. 
Although patients with an abnormal stress echocardiogram were older than those 
with a normal stress echocardiogram, the patients within this cohort, most of whom 
had severe VHD, were typically younger than seen in many valve clinics due to the 
high prevalence of rheumatic fever. In addition the number of patients within each 
valve group is relatively small and hence detailed comparison between valve lesions 




The clinical assessment of symptomatic status is unreliable and a significant number 
of patients with VHD who do not meet the criteria for surgery based on clinical 
assessment and resting echocardiography perform badly during exercise stress 
echocardiography. The finding of an abnormal exercise echo is predictive of an 
increased risk of death or hospitalisation with heart failure the next 2 years.  Exercise 
stress echocardiography or if not available exercise ECG should be considered as 





We are very grateful to Dr Gillian Whalley for her assistance with left ventricular 
analysis, to Jenny White for coordinating the study and to Margaret Oldfield for her 
expert echocardiography. The research was supported by grants from the New 
Zealand Heart Foundation, Middlemore Hospital Cardiac Trust (Dr Sharma) and 























Sharma V, Stewart RA, Zeng I et al.  
Comparison of atrial and brain natriuretic peptide for 
 the assessment of mitral stenosis.  




Accurate evaluation of the functional consequences of mitral stenosis (MS) can be 
difficult. The aim of this study was to evaluate the relationship between both atrial 
(ANP) and brain natriuretic peptides (BNP) and symptoms, exercise capacity and 
echocardiographic measures of MS severity. Thirty patients with moderate to severe 
MS and 14 normal controls underwent clinical assessment, exercise stress 
echocardiography, measurement of ANP and BNP and 2 years follow up for clinical 
events. BNP was higher in MS patients than controls (BNP 58 [IQR 34,93] vs. 16 
[14,25], p<0.0001). There was considerable overlap in exercise capacity and 
echocardiographic severity between asymptomatic and symptomatic patients. An 
increase in BNP was associated with a larger left atrial area index (r=0.67,p<0.0001), 
reduced mitral valve area (r = -0.38, p=0.05) and higher resting pulmonary artery 
pressure (r=0.47, p=0.008). Increased BNP predicted lower treadmill exercise 
capacity (AUC =0.82 [95% confidence interval 0.67,0.97], p=0.004), guideline 
criteria for intervention (AUC=0.87 [0.74,0.99], p=0.006) and adverse events during 
follow up  (AUC=0.81 [0.64,0.99], p=0.03). Associations for ANP in general were 
similar but slightly weaker, and ANP did not provide additional predictive 
information to BNP. BNP may improve risk stratification of patients with MS, 




The commonest cause of mitral stenosis (MS) worldwide is rheumatic fever.  
Typically there is an extremely long latent period during which the disease 
progresses slowly. Consequently defining the onset of symptoms can be extremely 
difficult. However patients who are asymptomatic or mildly symptomatic may be at 
risk of adverse haemodynamic consequences including pulmonary hypertension and 
atrial arrhythmias [Olesen 1962, Wood 1954]. The early identification of such 
patients may decrease the risk of stroke, acute decompensation, right ventricular 
failure and identify the need for surgery or percutaneous intervention.  
 
4.2.1 MANAGEMENT OF PATIENTS WITH MS 
Current ACC/AHA guidelines [Bonow et al 2006] recommend percutaneous mitral 
balloon valvotomy (PMBV) in symptomatic patients with moderate or severe MS 
and or asymptomatic patients when pulmonary artery pressure is >50 mmHg at rest 
or >60 mmHg post exercise if the mitral valve morphology is suitable.  Application 
of these guidelines requires regular specialist review with echocardiography during 
follow-up, often for many years. However rheumatic heart disease is most prevalent 
in poor and geographically remote communities that may have limited access to 
regular specialist medical care. Consequently a simple low cost method for 
monitoring patients with known MS in the community, which could identify patients 




4.2.2 NATRIURETIC PEPTIDES IN MS 
It is known that plasma BNP concentrations are elevated in conditions that result in 
increased left ventricular wall stress and it use has been proposed as a test of 
exclusion for left ventricular dysfunction [Levin et al 1998, Richards et al 1998]. 
However in MS the left ventricle is protected from increased left ventricular wall 
stress by the stenotic mitral valve. Consequently the haemodynamic situation in 
patients with significant MS differs to that found in other valve lesions which usually 
result in increased left ventricular wall stress and/or pressure. Despite this however a 
few studies have reported an association between BNP and resting echocardiographic 
measures of severity [Arat-Ozkan et al 2005, Eryol et al 2007, Iltumur et al 2005, 
Selcuk et al 2007]. Atrial natriuretic peptide (ANP) however is released 
predominantly in response to increased atrial wall stress, and might therefore be 
more useful in the monitoring of patients with MS [Ferrari and Agnoletti 1989]. 
Several very small studies have reported associations between ANP and left atrial 
pressure, mitral valve gradient and pulmonary artery pressure in mitral stenosis 
[Ishikura et al 1991, Nishikimi et al 1986, Tsai et al 1990], and one reported that 
ANP but not BNP predicted left atrial pressure in MS [Nakamura et al 1992]. 
 
4.2.3 STUDY AIMS 
This aim of this study is to determine whether the measurement of ANP or BNP 
provides additional information compared to standard assessment of symptomatic 
status and echocardiographic severity in mitral stenosis. In addition we evaluated the 
ability of natriuretic peptides to identify patients with ACC/AHA guideline criteria 
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for balloon mitral valvotomy and to predict adverse clinical outcomes during 2 years 
of follow-up. 
 
4.3  METHODS 
 
4.3.1 STUDY POPULATION 
Patients with mitral stenosis were initially identified from echocardiogram reports 
and outpatient clinics in the Auckland region as described in section 2. Exclusion 
criteria included greater than mild concomitant valvular lesions, previous valve 
replacement surgery, previous myocardial infarction, poor echocardiographic 
images, regional wall motion abnormalities on echocardiography, left ventricular 
impairment (LV ejection fraction<50%), significant renal impairment (creatinine 
>0.16mmol/L), respiratory disease or an inability to walk on a treadmill. Control 
subjects were volunteers from the local community who had no history of cardiac or 
respiratory disease and were age and sex matched. 
 
4.3.2  ECHOCARDIOGRAPHY 
All patients underwent comprehensive echocardiography as outlined in Section 2. 
The mitral valve area (MVA) was obtained using direct planimetry, pressure half 
time, proximal isovelocity area and continuity methods [Hatle et al 1978, Martin et 
al 1979, Nakatani et al 1988]. The median MVA from these four methods was used 
for analysis. Mean trans-mitral pressure gradients were obtained by tracing the 
continuous wave Doppler signal across the mitral valve [Quinones et al 2002]. The 
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left atrial area was measured in the apical four-chamber view [Lester et al 1999]. The 
left ventricular end-diastolic and end-systolic volumes and ejection fraction were 
measured from the apical four-chamber view using the modified Simpson’s single 
plane method. This method was chosen to allow comparison with the post exercise 
volumes. RV area was obtained by measuring the RV end diastolic area in the apical 
four-chamber view. Resting and exercise right ventricular function was assessed 
from the peak systolic tricuspid annular velocity (RV S’) [Lang et al 2005]. Left 
atrial area, left ventricular volumes, and right end diastolic area were indexed to body 
surface area [DuBois and DuBois 1916]. All echocardiographic analysis was 
completed prior to analysis of the blood samples and blind to clinical and outcome 
data. 
 
4.3.3 ESTIMATION OF PULMONARY ARTERY PRESSURE  
To facilitate estimation of RV systolic pressure, agitated saline was injected to 
enhance the tricuspid regurgitation profile as described in section 2 [Himelman et al 
1990]. The peak PAP was derived using the simplified Bernoulli equation from the 
peak tricuspid regurgitant jet and added to an estimate of right atrial pressure 
obtained from imaging of the inferior vena cava [Otto 2000].  
 
 
4.3.4 TREADMILL EXERCISE AND POST-EXERCISE ECHOCARDIOGRAPHY 
Exercise tests were performed using a modified ramped exercise protocol in which 
the speed and gradient of the treadmill increased at one minute intervals [Van Pelt et 
al 2007]. The workload at the end of each 3-min interval was equivalent to the 
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standard Bruce protocol. Continuous 12-lead ECG monitoring was performed with 
blood pressure recordings taken at 2 min and then every 3 min. Exercise was stopped 
for significant dyspnoea, chest discomfort, pre-syncope and fatigue, or at patient 
request.  
 
Immediately after exercise, echocardiographic images were obtained in the apical 
four-chamber view, first for LV volumes, then continuous wave Doppler across the 
mitral valve to obtain mean mitral valve gradient and finally for tricuspid jet velocity 
with agitated saline enhancement. All data was obtained within one minute of peak 
exercise. 
 
4.3.5 MEASUREMENT OF NATRIURETIC PEPTIDES 
Fasting blood samples were obtained from an indwelling intravenous catheter after 
15 min lying supine, immediately prior to the baseline echocardiogram. Blood 
samples were collected in EDTA tubes, centrifuged and plasma stored at –80 ºC. 
BNP and ANP concentrations were measured at study end using established 
radioimmunoassays [Yandle et al 1993]. The upper limit of the normal laboratory 
reference range for BNP is 42 pg/mL and for ANP 83 pg/mL [Yandle et al 1993]. To 
convert natriuretic peptide levels expressed in pg/mL to pmol/L, divide by 3.47 for 
BNP and 3.08 for ANP.  All clinical, echocardiographic, exercise and outcome 




4.3.6 ASSESSMENT OF STUDY OUTCOMES 
Patients underwent regular clinical follow up by their usual cardiologist who also 
decided the requirement for, and timing of mitral valvotomy or valve replacement, 
blinded to peptide levels and exercise echo data. Follow up data was collected for 2 
years from the date of enrolment, except for one patient who moved overseas and 
was lost to follow-up. Outcomes obtained were death, referral for valve intervention 
and heart failure requiring hospitalisation.  The primary clinical outcome was a 
composite of these events. 
 
Low exercise capacity was defined as <5 metabolic equivalents (METS) on treadmill 
exercise [Fletcher et al 1995, McCully et al 2002]. This also represented 
approximately 2 standard deviations below the mean for the age and sex matched 
normal controls.  
 
Consideration of percutaneous mitral balloon valvotomy (PMBV) in patients with 
moderate to severe MS (MVA<1.5 cm2) who are either symptomatic, have low 
exercise capacity, pulmonary hypertension (PAP >50mmHg at rest or >60 mmHg 
after exercise) or raised PCWP (>25 mmHg) is a Class 1 recommendation in the 
current ACC/AHA guidelines [Bonow et al 2006]. With the exception of PCWP 
(which was not measured), peptide levels were assessed against each component of 
the guideline separately and also the combined guideline. The suitability of the mitral 




4.3.7 STATISTICAL ANALYSIS 
Two sample student t-tests or Mann Whitney U test were used for comparing 
continuous variables between patients and controls. Chi square tests or Fisher exact 
tests were used to assess the associations between categorical variables. Pearson or 
Spearman correlation coefficients were used to assess associations between 
continuous variables. Analysis of Variance (ANOVA) was performed to assess the 
differences in the mean echocardiographic and exercise parameters across different 
BNP/ANP range groups. Post hoc Tukey Honest Significant Difference (HSD) tests 
were applied for checking multiple comparisons across groups but did not correct for 
variables-wise multiple testing. Levene's Tests were used to examine group 
homogeneity. Kruskal-Wallis test was used where the homogeneity assumption did 
not hold.  BNP and ANP underwent natural log transformations and non-transformed 
data are reported as median and inter-quartile range.  
 
For descriptive analyses MS patients were divided into three groups according to 
whether BNP was within the normal reference range (<42 pg/mL), above the normal 
range (42 to 84 pg/mL) or more than twice the upper limit of normal (≥84 pg/mL).  
Equivalent cut levels for ANP were 83 and 166 pg/mL.  
 
Logistic regressions were undertaken for natriuretic peptide levels to predict different 
binary endpoints. Prediction accuracies were reported by area under the receiver 
operating characteristic curve (AUC) and its 95% confidence interval. To assess the 
predictive value of the combination of ANP and BNP, the peptide levels were first 
adjusted to provide equal weighting (using results from normal controls) and then 
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summed. Kaplan Meier curves were used to visualize the time to first clinical event 
across different natriuretic peptide range groups.  SAS released 8.0 software (SAS 
Institute Inc., Cary, NL, USA) was used for analysis. All tests were two tailed and a 




In order to determine whether plasma BNP could identify patients with 
haemodynamically significant MS, MS patients were stratified according to whether 
their BNP concentration was within the normal range (42 pg/mL), the intermediate 
range (42–84 pg/mL) or high range (>84 pg/mL). High BNP was defined as >2 times 
the upper limit of normal. The clinical, echocardiographic and treadmill data for 
normal controls and for patients with MS stratified by plasma BNP are presented in 
Table 4.1. 
 
4.4.1 COMPARISON OF PATIENTS VERSUS CONTROLS 
Plasma BNP concentrations were significantly higher in patients with MS compared 
to controls (BNP 58 [34, 93] vs. 16 [14, 25] pg/mL, p < 0.0001). Similarly plasma 
ANP concentrations were also higher in MS patients compared to controls (ANP 111 
[82, 188] vs. 43 [32, 50] pg/mL, p < 0.0001). 
 
Compared to controls, MS patients with BNP concentrations within the normal range 
had a larger left atrial area (11±2 vs. 15±2 cm2/m2, p<0.001), higher PAP at rest 
(23±4 vs. 34±16 mmHg, p = 0.004) and higher PAP post-exercise (40±8 vs. 55±24 
mmHg, p = 0.04). In addition patients with MS in whom plasma BNP remained 
within the normal ranges had a reduction in exercise capacity compared to controls 
(11±3 vs. 8±3 METS, p = 0.006). These observations imply that cardiac remodeling 




Table 4.1.  Baseline characteristics and resting echocardiographic measurements in 
normal controls and mitral stenosis patients with BNP concentrations within, above 
and more than twice the laboratory upper limit of the normal reference range (mean, 


















( ≥ 84 
pg/mL) 
p value 
Number Of Subjects 14 10 11 9 - 
Age (years) 51 (14) 50 (14) 47 (14) 50 (16) 0.90 
Patient Characteristics 
Female n (%) 10 (71%) 10 (100%) 9 (82%) 9 (100%) 0.31 
Body Mass Index (kg/m2) 26.8 (3.9) 27.4 (5.4) 29.7 (5.7) 28.5 (6.7) 0.67 
Atrial Fibrillation 0 1 (10%) 1 (9%) 6 (67%) 0.006 
NYHA Class >1 0 3 (30%) 4 (36%) 7 (78%) 0.09 
Medication 
 Loop Diuretic 0 3(30%) 4(36%) 4(50%) 0.80 
 ACE Inhibitor 0 1 (10%) 2 (18%) 1 (11%) >0.90 
 Beta Blocker 0 1 (10%) 2 (18%) 1 (11%) >0.90 
Echocardiography at rest 
LA Area Index (cm2/m2) 10.7 (1.9) 15.2 (1.7) 18.7 (3.2) 24.5 (7.8) 0.0009 
MV Area (cm2) - 1.4 (0.2) 1.2 (0.3) 1.1 (0.1) 0.02 
MV Area Index (cm2/m2) - 0.8 (0.2) 0.6 (0.1) 0.6 (0.1) 0.05 
Mean MV Gradient (mmHg) - 6 (5) 8 (4) 10 (4) 0.18 
PAP (mmHg) 23 (4) 34 (16) 32 (9) 42 (7) 0.18 
LVEDVI (mL/m2) 45 (8) 45 (7) 49 (9) 34 (12) 0.004 
LVESVI (mL/m2) 15 (6) 17 (5) 19 (6) 13 (5) 0.09 
LVEF (%) 67 (7) 64 (8) 62 (8) 62 (6) 0.85 
RA Area Index (cm2/m2) 9.2 (1.6) 10.5 (1.7) 9.8 (1.9) 14.6 (2.7) <0.0001 
S’ Tricuspid Annulus (cm/s) 12 (2) 11 (2) 11 (2) 11 (2) 0.88 
RVd Area Index (cm2/m2) 11.1 (2.0) 10.6 (1.7) 11.2 (2.0) 10.7 (1.6) 0.69 
 
 
MS: mitral stenosis, BNP: brain type natriuretic peptide, NYHA New York Heart Association; ACE: 
angiotensin converting enzyme; LA: left atrial, MV: mitral valve, PAP: pulmonary artery pressure; 
LVEDVI left ventricular end diastolic volume index, LVESVI: left ventricular end systolic volume 
index, LVEF: left ventricular ejection fraction, RA: right atrial, RVd right ventricular diastolic 
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4.4.2 ASSOCIATION OF PLASMA NATRIURETIC PEPTIDE CONCENTRATIONS 
WITH ECHOCARDIOGRAPHIC AND EXERCISE MARKERS OF SEVERITY IN MS 
PATIENTS  
In MS patients, an increase in BNP was associated with a larger left atrial area index 
(r= 0.67, p<0.0001), lower exercise capacity (r= −0.56, p=0.001) and higher resting 
pulmonary artery pressure (r= 0.47, p=0.008). Associations between BNP and mitral 
valve area (r= −0.38, p=0.05) and systolic blood pressure rise post exercise (r= 
−0.46, p=0.01) were weaker. There was no association between BNP and right 
ventricular size or peak tricuspid systolic annular velocity (S′) at rest or after 
exercise. Associations between BNP and different echocardiographic and exercise 
measurements appeared to be similar for MS patients in sinus rhythm and atrial 
fibrillation (Figure 4.1). 
 
Plasma concentrations of ANP and BNP were strongly correlated (r= 0.76, p < 
0.0001), as illustrated in Figure 4.1. In general associations between ANP and 
echocardiographic measures of disease severity were similar to those observed for 
BNP. However ANP was not clearly associated with exercise capacity (r= −0.19, 







Figure 4.1. Association between the natural log of BNP (lnBNP) and left atrial area 
index (mL/m2), exercise capacity (in metabolic equivalents), mitral valve area index 
(cm2/m2), pulmonary artery pressure (mmHg), systolic blood pressure response to 
exercise (mmHg) and the natural log of atrial natriuretic peptide (lnANP). Normal 
controls (solid circles), MS patients in sinus rhythm (open circles), MS patients in 






Table 4.2. Exercise stress echocardiography data in normal controls and mitral stenosis patients with BNP levels within, above and 
more than twice the laboratory upper limit of the normal reference range 
 
 
Results are mean (standard deviation) or number (%). 
BNP: Brain type natriuretic peptide; MV: mitral valve, PAP: pulmonary artery pressure; LVEDVI left ventricular end diastolic volume index, LVESVI: left 












( ≥ 84 pg/mL) 
P value 
Treadmill Exercise      
 Peak Heart Rate (bpm) 161 (11) 151 (27) 137 (19) 161 (20) 0.07 
 Exercise Capacity (METs) 11.2 (3.2) 8.0 (2.6) 6.0 (2.7) 4.9 (1.7) 0.03 
 Peak Systolic BP (mmHg) 158 (25) 136 (25) 130 (26) 132 (20) 0.84 
 BP Increase (mmHg) 42 (19) 22 (17) 11 (12) 3 (12) 0.02 
Post exercise Echocardiography  
 Mean MV Gradient (mmHg) - 19 (8) 20 (9) 22 (9) 0.84 
 PAP (mmHg) 40 (8) 55 (24) 52 (12) 67 (14) 0.17 
 LVEDVI (mL/m2) 37 (12) 30 (9) 35 (9) 21 (3) 0.002 
 LVESVI (mL/m2) 8 (4) 7 (3) 10 (5) 7 (2) 0.27 
 LVEF (%) 79 (8) 76 (6) 72 (11) 69 (12) 0.27 
 S’ Tricuspid Annulus (cm/s) 21 (4) 19 (6) 16 (3) 16 (5) 0.23 
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4.4.3 COMPARISON BETWEEN ASYMPTOMATIC AND SYMPTOMATIC MS 
PATIENTS  
The comparison of natriuretic peptide levels, echocardiographic and treadmill data 
between asymptomatic and symptomatic patients is shown in Table 4.2. Treadmill 
exercise capacity was similar between symptomatic patients and asymptomatic 
patients (6±2 vs. 7±3 metabolic equivalents, (METS); p=0.19). Echocardiographic 
measures of disease severity did not significantly differ between symptomatic and 
asymptomatic patients, with the exception of resting PAP, which was slightly higher 
in symptomatic patients. BNP was a stronger predictor of decreased exercise 
capacity (AUC=0.82 [95% confidence interval 0.67, 0.97], p=0.004) than mitral 
valve area (AUC=0.62 [0.40, 0.83], p=0.29), resting pulmonary artery pressure 





Table 4.3. Comparison of treadmill exercise outcomes, exercise echocardiography and 
natriuretic peptide levels for asymptomatic and symptomatic patients with mitral stenosis 
 
 
 Asymptomatic Symptomatic p value* 
Number Of Subjects 16 14 - 
Natriuretic Peptides 
 BNP (pg/mL) 52 (31, 73) 82 (49, 118) 0.08 
 ANP  (pg/mL) 89 (71, 142) 129 (108, 286) 0.08 
Rest Echocardiography 
 LA Area Index (mL/m2) 18.2 ± 6. 20.5 ± 5.9 0.16 
 MV Area (cm2) 1.3 ± 0.2 1.1 ± 0.2 0.21 
 PAP (mmHg) 32.1 ± 13.6 39.6 ± 7.7 0.01 
Exercise Echocardiography 
 Exercise Capacity (METs) 7.0 ± 3.0 5.5 ± 2.0 0.19 
 Mean MV Gradient (mmHg) 18.8 ± 8.0 21.7 ± 8.8 0.36 
 PAP (mmHg) 51.5 ± 18.0 64.2 ± 14.8 0.02 
 
 
*Mann Whitney U test. Results are mean ± standard deviation or median (inter-quartile range)  
BNP: Brain type natriuretic peptide; ANP: atrial natriuretic peptide; LA: left atrial, MV: mitral 





4.4.4 PLASMA CONCENTRATIONS OF NATRIURETIC PEPTIDES AS A MARKER 
OF ADVERSE PROGNOSIS 
Seven patients were either referred for valve intervention (n=5) and/or had a hospital 
admission for heart failure (n=4) during follow-up. There  were no deaths during 
follow up. Kaplan–Meier curves for the composite of these outcomes according to 
BNP and ANP concentrations are shown in Figure 4.2. Lower concentrations of BNP 
and ANP were associated with a reduced rate of valve intervention and heart failure 
admission during follow- up (p=0.02 and 0.002 respectively). One patient with a 
BNP and ANP within the normal range met the primary endpoint at 17 months. 
 
The predictive values of both BNP and ANP for ACC/AHA criteria for mitral 
valvotomy and for clinical events during follow-up are presented in Table 4.3. The 
AUCs for ANP and BNP for adverse events during follow-up were similar. However 
BNP was more predictive than ANP for an exercise capacity <5 metabolic 
equivalents, pulmonary hypertension and for guideline criteria for intervention. BNP 
was able to predict any ACC/AHA criteria for intervention with a reasonably high 
sensitivity and specificity (AUC=0.87 (0.74, 0.99), p=0.006). Combining BNP and 






Figure 4.2. Kaplan–Meier plots of time to first clinical event (death, referral for 
valve intervention or hospital admission with heart failure) for patients with and 
without a plasma BNP >84 or ≤84 pg/mL and ANP >166 and ≤166 pg/mL. The cut 
levels are at twice the upper limit of the normal reference range for the laboratory 
[24]. One patient with an adverse event had a BNP at the upper level of normal (40 
pg/mL) and an ANP within the normal range. By log rank test, p=0.02 for 







Table 4.4 The Predictive Accuracy Of BNP And ANP For Different ACC/AHA Guideline Criteria For Balloon Mitral Valvotomy 
And For Clinical Outcomes During Follow-Up 
 
   BNP*  ANP*  ANP and BNP** 
 n AUC p AUC p AUC p 
Symptoms 14 0.70 (0.51,0.89) 0.11 0.70 (0.50,0.89) 0.12 0.69 (0.49,0.89) 0.09 
Low Exercise Capacity (<5 METS) 13 0.82 (0.67,0.97) 0.01 0.58 (0.37,0.80) 0.65 0.69 (0.50,0.90) 0.14 
Pulmonary Hypertension* 10 0.76 (0.56,0.96) 0.05 0.76 (0.56,0.95) 0.07 0.76 (0.56, 0.95) 0.05 
Any ACC/AHA Criteria 18 0.87 (0.74,0.99) 0.006 0.76 (0.57,0.94) 0.07 0.80 (0.64,0.96) 0.01 
Clinical Outcome 7 0.81 (0.64,0.99) 0.03 0.78 (0.54,1.0) 0.04 0.81 (0.59,0.99) 0.03 






In this study, patients with MS and a plasma BNP concentration >84 pg/mL (twice 
the upper limit of the normal reference range) were more likely to have a low 
exercise capacity on treadmill exercise and a higher risk of clinical events during 
follow-up. These patients were also more likely to have a Class I indication for mitral 
balloon valvuloplasty [Bonow et al 2006]. Conversely, although values were higher 
than controls, patients with a BNP concentration within the normal range (<42 
pg/mL) were unlikely to have significant pulmonary hypertension or marked left 
atrial enlargement. In addition these patients had a low rate of valve intervention or 
hospitalisation for heart failure during the next two years. These findings suggest that 
measurement of BNP may assist management decisions for some patients with MS. 
  
In clinical practice symptoms can be difficult to assess because patients gradually 
adapt over time. Our observation that NYHA status was a poor predictor of exercise 
capacity or MS severity highlights this important problem.  Incorrectly classifying a 
patient as symptomatic may result in an inappropriate referral for valve intervention, 
which is associated with significant morbidity and mortality in ~10% of patients 
[Vahanian et al 2007]. An elevated BNP in an apparently asymptomatic patient with 
mitral stenosis may alert the clinician to haemodynamically significant MS, while a 
low BNP is more reassuring.    
  
In the current study, most patients with MS had BNP levels below 100 pg/mL: a 
threshold recommended in the European Society of Cardiology Heart Failure 
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guidelines to exclude cardiac failure as a cause of dyspnoea [Dickstein et al 2008]. 
This implies that clinically relevant thresholds for BNP are lower in MS than in 
patients with LV systolic dysfunction.  
  
4.5.1 BNP AND MARKERS OF LA STRETCH 
The strong correlation between plasma BNP and left atrial area suggests atrial 
secretion of BNP in MS. This hypothesis is supported by evidence for synthesis of 
BNP by atrial myocytes in response to chronic increases in wall stress [Langenickel 
et al 2000] and co-storage of BNP with ANP in atrial granules [Goetze et al 2006]. 
Plasma concentrations of BNP have also been reported to increase with left atrial size 
in patients with moderate or severe mitral regurgitation and normal LV function 
[Kerr et al 2008]. While increased BNP secretion from the right ventricle is also 
possible, there was no association between plasma BNP concentration and right 
ventricular size or systolic function either at rest or post exercise.   
  
4.5.2 COMPARISON OF ANP AND BNP IN MS 
Several previous studies have reported similar associations between plasma ANP, 
BNP and N-terminal pro-BNP and echocardiographic measures of MS severity 
[Arat-Ozkan et al 2005, Eryol et al 2007, Iltumur et al 2005, Selcuk et al 2007]. 
However, these studies did not include stress echocardiography, an objective 
assessment of exercise capacity, or evaluation of outcomes during follow-up. They 
were therefore unable to compare the predictive value of ANP and BNP for several 
clinically relevant markers of disease severity and prognosis. In the current study 
BNP and ANP were closely correlated and had similar associations with 
 
 126 
echocardiographic measures of severity of MS. However ANP was a poorer 
predictor of low exercise capacity and did not provide additional predictive 
information when BNP was known. 
 
4.6 STUDY LIMITATIONS 
Study limitations include the relatively small number of patients evaluated and the 
low number of adverse events during follow-up. Previous studies were also small 
[Arat-Ozkan et al 2005, Eryol et al 2007, Iltumur et al 2005, Ishikura et al 1991, 
Nishikimi et al 1986, Selcuk et al 2007, Tsai et al 1990]. A large multi-centre study 
would provide more accurate estimates of the predictive value of BNP for clinical 
outcomes and more reliably determine the optimal cut-levels for intervention in 
combination with echocardiographic data. Patients with AF tended to have more 
severe MS, but associations between natriuretic peptides and other variables were 
similar for patients in AF and sinus rhythm (Figure 4.1). Valve morphology was 
excluded when evaluating ACC/AHA guideline criteria for PMBV. 
 
Clinical decisions on treatment and timing of referral for mitral valvuloplasty or 
surgery were made by the patient’s usual cardiologist, blinded to clinical, peptide and 
echocardiographic data collected for the study. The study included some 
symptomatic patients who were not referred for intervention on the judgment of their 
usual cardiologist because symptoms were difficult to evaluate or not limiting.  
Inclusion of an exercise test in all patients allowed an objective measure of exercise 
capacity in both symptomatic and asymptomatic patients at low risk.  Subgroup 
analyses have limited statistical power but associations between BNP, exercise 
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capacity and left atrial area were similar for asymptomatic patients and the combined 




BNP provides complementary information to clinical assessment of symptoms and 
echocardiography in MS, and may identify patients with reduced exercise capacity 
related to the valve stenosis.  BNP may be useful for risk stratifying patients with 
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The objective of this study was to determine whether an elevated B-type natriuretic 
peptide (BNP) concentration predicts left ventricular (LV) contractile dysfunction on 
exercise stress echocardiography in patients with severe mitral regurgitation (MR). 
Thirty-three patients with moderate-to-severe or severe MR, LV ejection fraction 
≥60 % and New York Heart Association Class I or II symptoms and 12 controls 
underwent resting and exercise stress echocardiography.  
 
In 20 MR patients, BNP concentration was within the normal range (mean ± standard 
deviation, 26.6±9.3 pg/mL), and in 13 MR patients, BNP was >42 pg/mL (67.8±26.3 
pg/mL). LV end-systolic volume index after exercise was lower in controls than 
patients with MR (p <0.0001), but similar in MR patients with normal and elevated 
BNP, respectively (controls 9±4, MR 20±7 vs. 20± 9 cm2/m2, p<0.05). Pulmonary 
artery systolic pressure (PAP) after exercise was higher in MR patients with elevated 
BNP compared to MR patients with a normal BNP (70±20 vs. 48±11 mmHg, 
p<0.0001) and significantly higher than controls (38±11 mmHg). A two-fold 
increase in plasma BNP concentration was associated with an average increase in 
resting PAP of 7.6 (95% CI 2.9, 12.2) mmHg, an increase in post-exercise PAP of 
14.4 (95% CI 9.0, 19.9) mmHg and increase in left atrial area index of 2.1 (95% CI 
0.5, 3.8) cm2/m2. However, there was no significant association between the plasma 
concentration of BNP and any rest or post-exercise measure of LV systolic function 




These findings suggest that the plasma concentration of BNP may be within the 
normal range in patients with moderate-to-severe or severe MR despite significant 
increases in LV end-systolic volume. Increased plasma BNP concentrations are 
associated with pulmonary hypertension on exercise and left atrial enlargement even 




Severe MR exposes the left atrium to an increase in both pressure and volume of 
blood during cardiac systole. In addition the left ventricle is exposed to an increased 
volume of blood in diastole. Consequently in contrast to MS both the left atrium and 
left ventricle are exposed to varying degrees of pressure and volume overload. In 
very severe MR that has been allowed to persist without mitral valve surgery, 
pulmonary hypertension can develop exposing the right ventricle to increased 
pressure loads. Consequently there are multiple stimuli for natriuretic peptide release 
in patients with significant MR. Previous studies, have demonstrated that in patients 
with MR the plasma concentration of BNP is higher in symptomatic compared with 
asymptomatic patients [Sutton et al 2003]. Other studies have demonstrated that 
patients with MR in whom the plasma BNP concentration is elevated may be more 
likely to have adverse clinical events during follow-up [Detaint et al 2005]. 
 
5.2.1  MANAGEMENT OF PATIENTS WITH MR 
Current guidelines recommend surgery in patients with severe mitral regurgitation 
who are symptomatic [Bonow et al 2006]. They also recommend surgery in 
asymptomatic patients when there are signs of LV dysfunction (EF <60 %) or 
significant LV dilatation (LV end systolic dimension >45 mm). Consequently the 
measurement of BNP in these patients is unlikely to be helpful as the indications for 
surgery are already clear. Potentially of more use would be the ability of natriuretic 
peptides to identify patients with early signs of LV dysfunction or aid in the 
management of patients in whom assessment of symptomatic status is difficult. In 
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addition it can difficult to assess LV function in the setting of severe mitral 
regurgitation as the large volume of blood flowing into the relatively low pressure 
left atrium results in a hyperdynamic LV and early signs of LV dysfunction can be 
missed. Failure to recognize the onset of LV dysfunction may predispose the patient 
to an increased risk of complications and a higher perioperative risk. More recently 
assessment of long axis function with tissue Doppler and the presence of contractile 
reserve on stress echocardiography have been shown to identify subtle LV 
impairment in severe mitral regurgitation [Agricola et al 2004, Haluska et al 2003, 
Leung et al 1996]. 
 
5.2.2  STUDY AIMS 
The aims of this study are to assess the factors influencing the release of natriuretic 
peptides in patients with moderate to severe and severe MR with normal LV ejection 
fraction (LVEF >60%). A secondary aim is to determine whether elevated plasma 
BNP concentrations can identify MR patients who have signs of early LV 
dysfunction on comprehensive echocardiography performed at rest and immediately 




Patients were recruited as outlined in Chapter 2. Specific inclusion and exclusion 
criteria for this sub study are outlined in Table 5.1. Exercise stress echocardiography 
was performed using treadmill exercise according to a standard Bruce protocol.  
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5.3.1 ECHOCARDIOGRAPHIC ASSESSMENT 
Comprehensive Echocardiography was performed by an expert sonographer on 
modern echocardiographic machines according to established protocols both at rest 
and immediately post exercise as described in Chapter 2.   
 
Table 5.1. Inclusion and exclusion criteria for MR patients 
 
Inclusion Criteria Exclusion Criteria 
Moderate –Severe MR  Previous Myocardial Infarction 
Severe MR LV impairment (LVEF <60 %) 
Age >18years Angina 
   
Symptoms of Heart Failure (more than equivocal 
symptoms)  
 Renal Disease (Creatinine >160 µmol/L) 
 Respiratory Disease 
 Other Valve Lesions (>mild) 
 
 
5.3.2 ASSESSMENT OF MR SEVERITY 
Specifically for this study additional assessment was performed to assess the severity 
of mitral regurgitation. Quantitative assessment MR severity was quantified using 
both the volumetric and proximal iso-velocity surface area (PISA) methods.  This 
allowed calculation of both the regurgitant volume and estimation of the effective 
regurgitant orifice area (EROA). The regurgitant volume of both methods was 
averaged to give the mean regurgitant volume. MR severity was also assessed semi-
quantitatively using the vena contracta width and the previously described MR score 
[Thomas et al 1999]. The MR score is calculated from visual assessment of MR jet 
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penetration, mitral continuous-wave Doppler characteristics, left atrial size, 
pulmonary venous flow pattern, tricuspid regurgitation velocity, and PISA radius 
[Enriquez-Sarano et al 1995]. 
 
5.3.3 SPECTRAL DOPPLER AND TISSUE DOPPLER 
Early (E) and late (A) mitral inflow velocities were measured by pulsed-wave 
Doppler ultrasound with the sample volume placed at the mitral leaflet tips. Tissue 
Doppler imaging was performed at the medial mitral annulus from the apical four-
chamber view, and the peak systolic (S’) and diastolic (E’) mitral annular velocities 
and E/E’ measured [Ommen et al 2000].  
 
5.3.4 ASSESSMENT OF RIGHT HEART 
Agitated saline was injected intravenously to enhance the TR jet profile to allow 
assessment of right ventricular systolic pressure (RVSP) using continuous-wave 
Doppler both at rest and immediately post exercise [Himelman et al 1990]. Right 
atrial pressure was estimated as described in Chapter 2 and added to the estimated 
RVSP to allow estimation of pulmonary artery pressure. RV function was assessed 
using the fractional area change method as calculated by (RV end-diastolic area - RV 
end-systolic area)/RV end-diastolic area from the apical 4-chamber view. RV 







33 patients with mitral regurgitation and 12 controls were recruited. Sixteen patients 
with MR were asymptomatic and 17 patients had mild or equivocal symptoms. The 
predominant aetiology of mitral regurgitation was mitral valve prolapse (26 patients) 
with the remainder (7 patients) having rheumatic mitral regurgitation.  
 
5.4.1 COMPARISON OF ALL PATIENTS AND CONTROLS  
The mean age for patients and controls was 53 and 51 years, respectively. There was 
a small but not significant excess of men in the MR group (55% vs. 33%, P=0.21). 
 
5.4.2 COMPARISON OF MR WITH NORMAL BNP VS. CONTROLS 
Baseline characteristics for controls and MR patients stratified by whether BNP 
remained within the normal range (<42 pg/mL) or was elevated (>42 pg/mL) are 
shown in Table 5.2. Although BNP remained within the normal range in 20 patients 
with MR, the actual plasma concentration of BNP was higher than that of age and 
sex matched controls. In addition these patients had significantly larger left 
ventricular volumes at rest than controls indicating that significant LV remodeling 
can occur while plasma BNP concentrations remain within the established normal 
range. In addition, mitral annular tissue velocities during both systole (S’) and 
diastole (E’), and peak mitral E velocity were higher than in normal controls. MR 
patients with a normal BNP had resting pulmonary artery pressures marginally above 
the upper limits of normal but this was significantly higher than normal controls. 
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This difference was more marked with exercise and MR patients with a normal BNP 
had slightly lower exercise capacity. 
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Table 5.2. Comparison of normal controls, and patients with mitral regurgitation 











P value* P value** 
Number Of Subjects (n) 12 20 13 - - 
Age (years) 51 (14) 48 (15) 61 (16) 0.59 0.02 
BNP (pg/mL) 17.6 (4.5) 26.7 (9.4) 68.0 (55.5) 0.004 <0.0001 
ANP 41.6 (19.4) 82.5 (18.5) 162.9 (88) <0.0001 <0.0004 
NYHA Class >1 0 (0%) 9 (45%) 8 (62%) - - 
Resting Echocardiography  
Regurgitant Volume (mL) - 85 (34) 73 (32) - 0.33 
Vena Contracta (mm) - 6.1 (1.0) 6.4 (1.2) - 0.45 
LAAI (mL/m2) 10 (1.7) 17.1 (4.5) 18.1 (4.4) <0.0001 0.46 
PAP (mmHg) 22 (4) 32 (7) 46 (15) 0.01 0.0002 
S’ Tricuspid Annulus (cm/s) 12.3 (2.2) 14.3 (3.0) 13.8 (1.8) 0.03 0.60 
RV Fractional Area Change 0.41 (0.07) 0.32 (0.09) 0.27 (0.07) 0.007 0.11 
LV Function (rest) 
     
LVEDVI (mL/m2) 46 (9) 77 (14) 75 (14) <0.0001 0.7 
LVESVI (mL/m2) 16 (6) 27 (7) 26 (6) <0.0001 0.53 
LVIDs (cm) 3.2 (0.6) 3.3 (0.5) 3.4 (0.6) 0.72 0.64 
LV Ejection Fraction (%) 66 (8) 64 (7) 65 (7) 0.31 0.62 
E Wave (m/s) 0.7 (0.2) 1.1 (0.3) 1.2 (0.4) 0.0001 0.36 
S' Mitral Annulus (cm/s) 8.3 (1.7) 8.7 (1.7) 9.0 (1.7) 0.51 0.61 
E' Mitral Annulus (cm/s) 9.4 (3.5) 10.4 (3.0) 10.0 (2.5) 0.4 0.7 
E/E' Mitral Annulus 7.7 (1.7) 11.7 (4.5) 13.4 (4.6) 0.0002 0.39 
Stress Echocardiography 
PAP (mmHg) 38 (8.2) 48 (11) 70 (20) 0.01 0.0002 
LVEDVI (mL/m2) 38 (9.0) 65 (17) 59 (17) <0.0001 0.25 
LVESVI (mL/m2) 8.5 (3.9) 20 (7) 20 (9) <0.0001 0.91 
LVEF (%) 78 (8.5) 70 (6) 66 (9) 0.005 0.16 
EF (post–pre exercise) 11.6 (4.7) 5.7 (8.2) 0.5 (9.6) 0.05 0.07 
Treadmill Exercise 
Exercise Time (min) 10.7 (2.9) 8.9 (2.0) 5.8 (2.2) 0.04 0.0006 
Peak SBP (mmHg) 159 (24) 158 (28) 130 (28) 0.22 0.04 
Increase In SBP (mmHg) 47 (14) 37 (16) 23 (20) 0.12 0.04 
Peak Heart Rate (bpm) 164 (10) 150 (20) 131 (20) 0.48 0.02 
 
*p value for MR patients normal BNP (≤42pg/mL) vs. controls;  
** p value MR patients normal (≤42pg/mL) vs. elevated BNP(>42pg/mL)
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5.4.3 COMPARISON OF MR PATIENTS WITH ELEVATED VS. NORMAL BNP 
In this cohort, MR patients with an elevated plasma concentration of BNP tended to 
be slightly older and had reduced exercise capacity than those with a normal BNP. In 
addition they had higher pulmonary artery pressure both at rest and with exercise. 
There were no statistically significant differences in any resting markers of LV 
function between patients with an elevated BNP compared to those with a normal 
BNP. There was a trend towards lower augmentation of LVEF with exercise in the 
patients with elevated BNP (increase in EF=5.7% vs. 0.5%, p=0.07), but after 
adjustment for age and beta-blocker status this was not significant (p=0.49). All other 
results were similar after adjusting for age and beta-blocker status.  
 
5.4.4 COMPARISON OF ASYMPTOMATIC VS. SYMPTOMATIC PATIENTS 
For patients with NYHA Class 2 symptoms compared with asymptomatic patients 
with MR, the plasma concentration of BNP was higher (51.9 vs. 33.2 pg/mL, p= 
0.02), rest PAP was greater (42 vs. 32 mmHg, P < 0.0001) and exercise duration was 
less (5.9 vs. 9.6 min, p <0.0001). However, there were no differences in any resting 
or post-exercise measure of LV function between symptomatic and asymptomatic 
patients with MR. 
 
5.4.5 ASSOCIATIONS BETWEEN BNP AND STRESS ECHOCARDIOGRAPHY 
For MR patients, associations between different echocardiographic measures at rest 
and after exercise, with both the plasma concentrations of BNP and exercise capacity 
are presented in Table 5.3. There were strong correlations between the plasma 
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concentration of BNP and PAP both at rest and after exercise (Figure 5.1). There 
were also moderate correlations between the plasma concentration of BNP and septal 
E/E’, left atrial area index, and an inverse correlation with treadmill exercise capacity 
(Figure 5.2). In contrast, there was no correlation between the plasma concentration 
of BNP and any resting or post-exercise measurement of LV function, including 
LVEF, indexed LV volumes or change in EF after exercise (Figure 5.3). There was 
also no association between the plasma concentration of BNP and any 
echocardiographic measures of severity of MR or RV function assessed using 
tricuspid annular tissue velocities and change in RV fractional area at rest 
 
The echocardiographic measures most strongly associated with treadmill exercise 
capacity were resting and post-exercise pulmonary pressure. There was a weak 
association between exercise capacity and post-exercise LV end-diastolic volume 
index but no clear association with other resting or post-exercise measures of LV 
function. 
 
After adjusting for age and sex, the association between natural log scaled BNP and 
both post-exercise pulmonary artery pressure (partial r2=0.49, p<0.0001) and resting 
pulmonary artery pressure (partial r2=0.30, p=0.001) remained strong. There was a 
more modest association between BNP and with exercise capacity (partial r2=0.21, 
p=0.01) and with left atrial area index (partial r2=0.16, p=0.02). The association of 
BNP with resting septal E/E’ (partial r2=0.16, p=0.04) was of borderline statistical 
significance. A two-fold increase in plasma BNP was associated with an average 
increase in resting PAP of 7.6 (95% CI 2.9, 12.2) mmHg, an increase in post-exercise 
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PAP of 14.4 (95% CI 9.0, 19.9) mmHg and 2.1 (95% CI 0.5, 3.8) cm2/ m2 increase in 




Figure 5.1. Association between the natural log of B-type natriuretic peptide 
(LnBNP) and exercise capacity measured in minutes on the Bruce protocol for 
normal controls (open squares) and patients with severe mitral regurgitation (closed 
circles). The non-transformed values of B-type natriuretic peptide in pmol/L are 
shown in brackets. There is an inverse correlation between exercise capacity and 






Table 5.3. Correlations (r) between the plasma level of B type natriuretic peptide and 
exercise capacity with resting and post-exercise echocardiographic measurements for 






Correlation With  
Exercise Capacity 
r p r p 
Rest Echocardiography 
 Regurgitant Volume -0.20 0.27 0.21 0.25 
 Left Atrial Area Index 0.42 0.02 0.03 0.86 
 Pulmonary Artery Pressure 0.53 0.002 -0.42 0.01 
 LVEDVI -0.02 0.28 0.27 0.13 
 LVESVI -0.19 0.31 0.14 0.43 
 LV Ejection Fraction 0.23 0.93 -0.003 0.99 
 S' Septal -0.09 0.63 -0.04 0.85 
 E Wave 0.25 0.15 -0.22 0.22 
 E' Septal -0.24 0.21 0.29 0.13 
 E/E' Septal 0.41 0.03 -0.27 0.17 
Stress Echocardiography 
 Pulmonary Artery Pressure 0.68 <0.0001 -0.50 0.003 
 LVEDVI -0.21 0.23 0.42 0.02 
 LVESVI -0.07 0.70 0.24 0.18 
 LV Ejection Fraction -0.12 0.56 0.12 0.51 
 EF (post-pre exercise) -0.31 0.07 0.21 0.24 
 Exercise Time -0.60 0.0002 - - 
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Figure 5.2. Association between the natural logarithm (Ln) of B-type natriuretic 
peptide and pulmonary pressure (upper panels), and left ventricular end-systolic 
volume index (LVESVI) (lower panels) for normal controls (open symbols) and 
patients with mitral regurgitation (closed symbols). The values of non-transformed 









5.4.6 PREDICTIVE ACCURACY OF BNP IN IDENTIFYING SIGNIFICANT MR 
The sensitivity and specificity of BNP for predicting guideline based abnormal 
resting and post-exercise pulmonary pressures thresholds [Bonow et al 2006], and 
impaired exercise capacity [Thompson et al 2000] are presented in Table 5.4 and 
Figure 5.3. BNP above the upper limit of normal was a good predictor of PAP>60 
mmHg after exercise and PAP >50 mmHg at rest, and a weaker predictor of reduced 
exercise capacity defined as a failure to complete 6 minutes of the Bruce Protocol 
(equivalent to <7METs) 
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Sensitivity %  
(95% CI) 






 Rest (>50 mmHg) 4 100 (40, 100) 69 (49, 85) 0.93 (0.84, 1.0) 
0.03 
 Post Exercise (>60 mmHg) 12 75 (43, 95) 81 (58, 95) 0.87 (0.75, 1.0) 
0.005 
Impaired Exercise Capacity 
  METs Achieved <7 7 86 (42,100) 73 (52, 88) 0.82 (0.64, 1.0) 
0.03 
 
METs: metabolic equivalents; CI: confidence interval; AUC: area under the curve 
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Figure 5.3. Receiver operating characteristics curve for B-type natriuretic peptide for 
pulmonary hypertension after exercise >60 mmHg, and exercise capacity <7 





The sensitivity and specificity of B-type natriuretic peptide >42 pg/mL (upper reference limit 








5.5.1 MAIN FINDINGS 
In this study of asymptomatic or mildly symptomatic patients with moderate to 
severe or severe MR and preserved LVEF at rest, a higher plasma concentration of 
BNP was associated with higher pulmonary pressures, (both at rest and immediately 
post exercise), increased left atrial volume and lower exercise capacity on functional 
testing. However, there were no clear associations between BNP and any measures 
of LV function at rest or after exercise. These results suggest that an increase in the 
plasma BNP concentration does not necessarily indicate the presence of early or 
‘latent’ LV dysfunction in patients with severe MR. 
 
5.5.2 BNP AND MEASURES OF LV FUNCTION 
The lack of a clear association between plasma levels of BNP and measures of LV 
function in the current study contrasts with some previous reports [Detaint et al 
2005, Detaint et al 2006, Yusoff et al 2006]. In a large cohort study including NYHA 
Class 1–4 patients and mild to severe organic MR, Detaint found a weak but 
statistically significant association between the plasma concentration of BNP and LV 
end-systolic volume index (r=0.26). In a separate report that included subjects with 
both organic and functional MR, Detaint et al [Detaint et al 2006] reported that LV 
end-systolic volume index was the major determinant of the plasma concentration of 
BNP. However, in this study, most patients with a LV end-systolic volume ≥60 
mL/m2 and an elevated plasma BNP concentration had primary LV dysfunction. 
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Yusoff et al [Yusoff et al 2006] also reported statistically significant associations 
between the plasma concentration of N-terminal-BNP and several measures of LV 
remodelling including the LV sphericity index and LV end-systolic volume in 38 
patients with severe MR and an EF >55 %. However, unlike our study, the majority 
of patients had NYHA Class 2 or 3 symptoms and some patients had very high 
plasma concentrations of N-terminal-BNP. The variable association between BNP 
and LVESVI observed in these studies probably reflects different inclusion criteria. 
 
In the current study, the plasma concentration of BNP remained within the normal 
range for many MR patients despite significant increases in LV volumes. This 
suggests that compensatory changes in LV volume with MR are not necessarily 
associated with an increase in the plasma concentration of BNP above the normal 
range. Increase in E/E’ is associated with higher LV end-diastolic pressure in patients 
with impaired LV function [Nagueh et al 1997], and there was a modest association 
between E/E’ and BNP in the current study. However in severe MR, MV E increases 
due to the large volume of blood passing through the MV in diastole and in these 
patients the LV end-diastolic pressure may be normal even if MV E is high.  
Consequently the relationship between LV end-diastolic pressure and E/E’ may be 
different in patients with significant MR.  
 
5.5.3 BNP AND MEASURES OF LEFT ATRIAL STRETCH 
Natriuretic peptides are usually produced by ventricular myocytes in response to 
increases in wall stress and by atrial myocytes in response to increased atrial wall 
stress [Goetze et al 2006]. In MR, the predominant pressure load is on the left atrium 
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and, if pulmonary hypertension is present on the RV. In the current study, the plasma 
concentration of BNP was not clearly associated with any measures of early 
dysfunction. These observations are consistent with increased BNP production by the 
left atrium in response to the chronic increase in left atrial wall stress. Limited 
evidence suggests increased synthesis of BNP by atrial myocytes in response to 
chronic increases in wall stress [Langenickel et al 2000] and co-storage of BNP with 
ANP in atrial granules [Goetze et al 2006]. The strong association between the 
plasma concentration of BNP and pulmonary artery pressure also raises the 
possibility of increased BNP secretion from the RV. However, in the current study, 
there was no association between the plasma concentration of BNP and measures of 
resting RV function. 
 
5.5.4 BNP, SYMPTOMS AND EXERCISE CAPACITY 
Previous studies of organic MR have reported an association between the presence 
and severity of symptoms and an increase in plasma concentrations of BNP [Detaint 
et al 2005, Sutton et al 2003, Yusoff et al 2006]. These observations are consistent 
with the strong correlation between BNP and functional capacity in the current study 
(r=0.6, p<0.0001) and with maximum oxygen consumption in a previous study of 
severe organic MR [Messika-Zeitoun et al 2006]. However, resting and exercise 
stress measures of LV function were weak predictors of exercise capacity in this 
study and of maximum oxygen consumption in previous studies of severe MR 
[Messika-Zeitoun et al 2006, Yusoff et al 2006]. Pulmonary artery pressure was the 
strongest echocardiographic predictor of functional capacity in the current study. 
These observations are consistent with severe MR leading to an increase in LA 
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pressure and pulmonary hypertension during exercise even when LV contractility is 
normal or increased. The novel observation from the current study is that these 
effects of severe MR are associated with an increase in the plasma concentration of 
BNP. 
 
5.5.5 CLINICAL IMPLICATIONS 
In patients with a LVEF >60 %, the presence of symptoms attributable to MR, 
pulmonary hypertension at rest and/or after exercise, and decreased exercise capacity 
are ACC/AHA and European Society of Cardiology (ESC) Class I or IIa indications 
for mitral valve surgery [Bonow et al 2006, Vahanian et al 2007]. Measuring the 
plasma concentration of BNP may therefore be useful for evaluating asymptomatic 
patients, and those with equivocal symptoms, even though an increase in BNP does 
not necessarily indicate the onset of LV dysfunction. Further studies are needed to 
reliably assess the value of BNP for this purpose. 
 
5.5.6 STUDY LIMITATIONS 
A limitation of this study is that it does not include follow-up for clinical outcomes 
or reassessment of LV function after mitral surgery. We are therefore unable to 
determine which patients, if any, would develop LV dysfunction. However the 
presence of latent LV dysfunction was assessed using resting and post-exercise 
measures of LV size and performance as previously described [Leung et al 1996]. 
Decrease in the peak systolic mitral annular velocity is also associated with a lower 
LVEF after surgery and with decreased contractile reserve on exercise stress 
echocardiography [Agricola et al 2004]. However, there was no evidence for an 
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association between the plasma concentration of BNP and this measure in the current 
study. The peak systolic mitral annular velocity after exercise may be a more 
sensitive measure of early LV dysfunction [Haluska et al 2003, Van Pelt et al 2007] 
but was not measured in the current study.  
 
This study was limited to a subset of patients with clinically important MR in whom 
indications for surgery were at most equivocal. As discussed previously, we excluded 
patients with Class III or IV symptoms or LV impairment. Prior studies suggest a 
relationship between BNP and LV dilatation and dysfunction when such patients are 
included. The primary focus of this study was to assess the relationship of BNP to 
exercise LV parameters and pulmonary pressures. Because we used treadmill 
exercise there was a limited time window on cessation of exercise to obtain echo data 
and we were therefore unable to assess other variables of interest including exercise 
RV function and change in MR severity with exercise. Although the relationship 
between BNP and both pulmonary pressures and exercise capacity are statistically 
robust, the predictive value of BNP for individual patients requires further study in a 




In this study, many patients with moderate-to-severe or severe MR and a resting EF 
>60 % had significant increases in LV end-systolic volumes, despite plasma BNP 
concentrations within the normal range. Elevated BNP predicted the presence of 
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pulmonary hypertension and left atrial enlargement even when LV systolic function 
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Gabriel RS, Kerr AJ, Sharma V et al.  
B-Type natriuretic peptide and left ventricular dysfunction on exercise 
echocardiography in patients with chronic aortic regurgitation.  




The aim of this study was to determine whether plasma concentrations of B-type 
natriuretic peptide (BNP) predict left ventricular (LV) dysfunction on exercise 
echocardiography in patients with moderate to severe aortic regurgitation (AR). 
 
Thirty-nine asymptomatic or mildly symptomatic patients with chronic moderate to 
severe AR and a normal LV ejection fraction (>50%), and 10 normal controls 
underwent sampling of natriuretic peptides immediately before exercise stress 
echocardiography.  
 
We found that LV end systolic volume index (LVESVI) was increased in AR 
patients with normal BNP (≤42 pg/mL) compared with controls (mean±SD 32±13 vs 
17±7 mL/m2, p=0.002) but was similar for AR patients with normal and elevated 
BNP (38±16, p=0.14). In AR patients there was no association between plasma BNP 
and any measure of LV function on echocardiography at rest (r<0.30, p>0.05 for all). 
However, there was a modest but statistically significant association between the 
plasma concentration of BNP and severity of AR indicated by a greater AR:LV 
outflow tract width ratio (r=0.37, p=0.02) and lower diastolic blood pressure (r=-
0.44, p=0.004). Increased BNP was also associated with a greater LVESVI (r=0.33, 
p=0.04) and lower LV longitudinal strain rate (r = -0.037, p=0.02) on 
echocardiography after exercise.  
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In moderate to severe AR compensatory LV remodelling can occur with no increase 
in plasma BNP. Increased BNP is associated with more severe regurgitation and 






Asymptomatic patients with chronic aortic regurgitation (AR) can remain clinically 
stable for years, but many eventually develop symptoms or LV dysfunction. The 
presence of symptoms, decreased LV function (LVEF <50 %) or severe LV 
dilatation (LV end systolic dimension of 50-55 mm) predicts poorer outcome and 
hence these findings are all an indication for consideration of surgery according to 
current guidelines [Bonow et al 2006, Vahanian et al 2007]. However, up to a 
quarter of asymptomatic patients with chronic AR develop LV dysfunction without 
recognised symptoms [Vahanian et al 2007]. Furthermore the onset of early 
symptoms can be difficult to evaluate clinically. This is important as even mildly 
symptomatic patients (NYHA 2) have a mortality of approximately 6.4% per year if 
untreated [Klodas et al 1997]. In addition many patients can develop significant LV 
dilatation and/or mild LV dysfunction without becoming symptomatic [Vahanian et 
al 2007]. Consequently it would be valuable if other methods can identify 
asymptomatic patients at risk of early decompensation in moderate to severe AR. 
 
6.2.1 PLASMA BNP CONCENTRATIONS IN AORTIC REGURGITATION  
Previous studies have suggested that in patients with AR, BNP concentrations fall 
after aortic valve replacement but continue to rise in those patients treated 
conservatively [Weber et al 2005]. In addition in another study, plasma BNP 
concentrations were higher in patients with AR who were symptomatic [Gerber et al 
2003]. However there was no association between BNP and any marker of increasing 
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LV volume or ejection fraction on echocardiography at rest. In addition although 
several studies have suggested that exercise stress echocardiography can be used to 
identify subtle LV dysfunction in patients with chronic AR [Borer et al 1998, 
Dehmer et al 1981, Johnson et al 1983, Schuler et al 1982, Thompson et al 1985], no 
previous studies have included data from exercise stress echocardiography to 
determine whether plasma natriuretic peptide concentrations can be identify patients 
with early LV dysfunction.  
 
6.2.2  STUDY AIMS 
The aims of this sub-study where to assess the relationship of plasma BNP 
concentrations with markers of disease severity and to determine whether BNP could 
identify patients with early LV dysfunction either at rest or with exercise in patients 




6.3.1 STUDY POPULATION 
The patients were recruited according to the general methodological criteria 
described in Chapter 2. Specifically for this study consecutive patients with 
moderate-to-severe or severe aortic regurgitation attending outpatient clinics in the 
Auckland Region were invited to participate.  This was defined according to the ASE 
criteria (AR jet: Left Ventricular Outflow Tract (LVOT) width ratio was >0.3 and 
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holo-diastolic flow reversal in the descending thoracic aorta) [Zoghbi et al 2003]. 
Key inclusion and exclusion criteria are as defined in Table 6.1.  
 
Table 6.1: Inclusion and exclusion criteria  
Inclusion Criteria Exclusion Criteria 
Moderate –Severe AR* Previous Myocardial Infarction 
Severe AR LV Impairment (LVEF <50 %) 
Age >18years Significant Aortic Dilatation (>5 cm) 
 Atrial Fibrillation 
 Renal Disease (Creatinine >160 µmol/L) 
 Respiratory Disease 
 Other Valve Lesions (>mild) 
 
*AR jet: Left Ventricular Outflow Tract (LVOT) width ratio was >0.3 and holo-
diastolic flow reversal in the descending thoracic aorta 
 
6.3.2 CLINICAL ASSESSMENT 
Subject details were collected from standardised questionnaires by the study 
cardiologist at the time of enrolment. A baseline medical history, medication regime, 
weight, height, pulse and supine blood pressure were obtained. The symptomatic 
status of each patient was graded according to the NYHA classification system. An 
ECG was obtained and baseline blood tests for natriuretic peptide levels were taken. 
 
 158 
6.3.3 MEASUREMENT OF NATRIURETIC PEPTIDES 
Plasma concentrations of BNP were obtained as outlined in Chapter 2 
 
6.3.4 EXERCISE TESTING 
All subjects underwent a symptom-limited exercise test using an adaptation of the 
standard Bruce protocol as defined in Chapter 2. The speed and or incline of the 
treadmill increased at 1-min intervals but the overall workload at the end of each 
stage was the same as for the Bruce protocol. The test was terminated if the patient 
developed marked dyspnoea, fatigue, chest discomfort, >2 mm ST depression, 
significant arrhythmia, or at patient request.  
 
6.3.5 REST AND STRESS ECHOCARDIOGRAPHY 
Two-dimensional echocardiography was performed using a Vivid 7 Dimension 
machine (General Electric, Vingmed Ultrasound, Horten, Norway) before and 
immediately after exercise treadmill testing as outlined in Chapter 2. The acquisition 
protocol is outlined in Appendix 2.  
 
6.3.6 ASSESSMENT OF AR SEVERITY 
LV mass was calculated from linear dimensions using the American Society of 
Echocardiography recommended formula [Lang et al 2005]. AR severity was 
assessed according to standard criteria. This included measurement of the AR jet: 
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LVOT width ratio from the parasternal long axis view and the AR jet: LVOT area.  
The AR pressure half time, peak diastolic and end-diastolic flow velocities in both 
the descending thoracic and abdominal aorta were made. 
 
6.3.7 SPECKLE TRACKING 
In order to detect more subtle abnormalities of LV dysfunction, standard long and 
short axis LV images were acquired at high frame rates to allow measurement of 
strain, strain rate and LV rotation. Endocardial borders were traced in apical and 
short axis views and commercial software automatically tracked myocardial motion 
in six regions of interest. Global LV longitudinal strain and strain rate was generated 
by averaging measurements from all regions of interest in the apical four-chamber 
view [Cho et al 2006]. LV torsion measurements were made using a previously 
described technique [Notomi et al 2005]. 
 
6.3.8 EXERCISE ECHOCARDIOGRAPHY 
Immediately following peak exercise, echocardiographic images were obtained as 
outlined in appendix 2. Apical four-chamber views were obtained at high frame rates 
for LV volume calculations, pulsed wave tissue Doppler imaging and 2D speckle 
tracking based LV longitudinal strain and strain rate measurements. LV torsion 
measurements could not be reliably obtained after exercise. 
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6.3.9 STATISTICAL ANALYSIS 
Correlation coefficients were used to evaluate associations between continuous 
variables. Chi-squared tests were used to investigate whether the proportion of 
NYHA class and AR severity grade differed across groups. Fisher exact tests were 
used where appropriate. Mann–Whitney U tests were applied to test whether the AR 
severity measures and exercise echocardiography differed between groups. Analyses 
of covariance were used to compare across normal control and AR patients with 
normal and elevated BNP adjusting for age; F test and contrasts were derived for 
pairwise comparisons. Post hoc Tukey studentised range significant tests (HSD) were 
also applied in the multi-group comparisons. Peptide concentrations underwent 
natural log transformation due to their right skew distribution in all analyses. Results 
are presented as means and standard deviations unless otherwise stated. A p value 
<0.05 was considered statistically significant. SAS institute released SAS 9.1 was 




Thirty-nine patients with AR and ten age and sex-matched control subjects were 
recruited. The underlying aetiology of aortic regurgitation was rheumatic heart 
disease (18), bicuspid aortic valve (15), connective tissue disease (one), aortic root 
dilatation (two) and uncertain (two). The baseline characteristics are shown in Table 
6.2 The patients had a mean age of 42 years (range 18 to 71).  The majority (32) of 
patients were asymptomatic with 7 patients having equivocal symptoms. Twenty-five 
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(64%) AR patients were on an angiotensin converting enzyme inhibitor, five (13%) a 
calcium channel blocker, and two (5%) a B-blocker. No control patients were taking 
medication.  
 
6.4.1 COMPARISON OF AR PATIENTS WITH CONTROLS  
Compared to controls, AR patients had higher systolic BP and lower diastolic blood 
pressures at rest.  AR patients also had a higher body mass index. Body surface area 
was similar in AR patients and control subjects (1.9±0.3 vs 2.1±0.2 m2, p=0.6). BNP 
concentrations were not significantly higher in AR patients compared to controls (34 
IQR (23/43) vs 33 IQR 29-36 pg/mL; p=0.94) 
 
6.4.2 COMPARISON OF PATIENT WITH NORMAL VS RAISED BNP 
Patients with AR were divided into two groups according to whether they had normal 
(≤42 pg/mL) or elevated BNP (>42 pg/mL) concentrations as determined by the 
normal reference range for the assay used [Yandle et al 1993]. Clinical and 
echocardiographic data are compared for normal controls and patients with AR by 
plasma BNP in Table 6.3. Associations between the plasma concentration of BNP 
and echocardiographic measurements at rest and after exercise are presented in Table 
6.4.
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Age (median, range) 42 (42-63) 42 (18-71)  
Female 4 (40%) 6 (15%)  
NYHA>1 0 7 (18%) - 
Medication    
 ACE Inhibitor 0 25 (64%) - 
 CCB 0 5 (13%) - 
 B-Blocker 0 2 (5%) - 
Systolic BP (mmHg) 112 (9) 129 (6) 0.004 
Diastolic BP (mmHg) 71 (6) 58 (13) 0.01 
BMI (kg/m2) 24 (3) 29 (5) 0.01 
 
NYHA: New York Heart Association; ACE: angiotensin converting enzyme; CCB: 
calcium channel blocker; BP: blood pressure, BMI: body mass index 
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Table 6.3. Exercise stress echo data for patients and controls  
 











P value* P value** 
Age In Years (median, range) 42 (24-63) 41 (18–68) 47 (20–71) 0.95 0.6 
BNP (pg/mL) 33 (27, 36) 28 (21, 36) 64 (59, 133) 0.13 <0.001 
NYHA class >1 0 (0%) 3 (11%) 4 (36%) 0.55 0.06 
Echocardiography 
     
Severe Regurgitation* 
 
4 (14%) 6 (55%) 
 
0.02 
AR Jet to LVOT Width Ratio 
 
0.5 (0.13) 0.62 (0.16) 
 
0.03 
DA Peak Velocity Diastole (m/s) 
 
0.55 (0.15) 0.74 (0.26) 
 
0.02 
DA End-diastolic Velocity (m/s) 
 
0.22 (0.1) 0.3 (0.15) 
 
0.04 
LA Area Index (cm2/m2) 9.8 (2.1) 10.4 (1.7) 11.9 (2.3) 0.35 0.02 
Estimated PAP (mmHg) 25 (4) 27 (6) 32 (6) 0.49 0.03 
LV Function (rest) 
     
LVEDVI (mL/m2) 51.3 (13.5) 88.7 (27.8) 97.6 (30.5) <0.001 0.29 
LVESVI (mL/m2) 17.1 (7.1 32.4 (13.2) 37.6 (16.2) 0.001 0.35 
LV Ejection Fraction (%) 68 (7) 64 (6) 63 (6) 0.43 0.62 
LVIDd (cm) 4.7 (0.5) 5.9 (0.7) 5.9 (0.7) <0.001 0.96 
LVIDs (cm) 3.1 (0.7) 4 (0.5) 4.3 (0.9) 0.001 0.56 
LV Mass Index (g/m2) 89 (21) 175 (43) 201 (38) <0.001 0.08 
S' Mitral Annulus (cm/s) 11.6 (2.3) 8.1 (2.1) 8.1 (1.8) 0.002 0.65 
E' Mitral Annulus (cm/s) 9.7 (1.5) 8.3 (1.2) 8.5 (1.3) 0.001 0.69 
E/E' Mitral Annulus 6.9 (1.7) 9.7 (2.6) 9.4 (2.3) 0.005 0.82 
Treadmill exercise 
     
METS Achieved 14.6 (2.1) 11 (3.3) 10.7 (4) 0.01 0.78 
Peak Systolic BP (mmHg) 159 (11) 187 (24) 191 (25) 0.002 0.66 
Peak HR (beats/min) 173 (10) 159 (17) 148 (18) 0.01 0.11 
LV Function (exercise) 
     
LVEDVI (mL/m2) 37.8 (12.6) 57.8 (18.3) 76.6 (30.5) <0.001 0.05 
% Change In LVEDVI -26 (18) -34 (13) -22 (14) 0.16 0.05 
LVESVI (mL/m2) 7.3 (4.2) 17.4 (8.4) 28.8 (19.6) 0.001 0.09 
% Change In LVESVI -58 (17) -46 (17) -26 (29) 0.08 0.03 
LVEF (%) 82 (7) 71 (8) 66 (11) 0.002 0.25 
Change In EF (%) 14 (6) 6 (7) 2 (11) 0.008 0.18 
S' Mitral Annulus (cm/s) 22 (4) 15 (4) 13 (4) <0.001 0.3 
Change In S' Septum (cm/s) 11 (4) 7 (4) 5 (4) 0.03 0.24 
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Table 6.4.  Correlation (r) between the plasma concentration of (the natural 
logarithm (Ln) of BNP and clinical and echocardiographic measures 
 
 Ln BNP 
 r p 
AR severity   
 Diastolic BP (mmHg) -0.45 0.004 
 AR jet to LVOT width ratio 0.37 0.02 
 AR jet to LVOT area ratio 0.43 0.007 
Echocardiography (rest)   
 LVEDVI (mL/m2) 0.16 0.34 
 LVESVI (mL/m2) 0.19 0.24 
 LV Ejection Fraction (%) -0.11 0.50 
 LV Mass Index (g/m2) 0.28 0.08 
 S’ Mitral Annulus (cm/sec) -0.002 0.99 
 Longitudinal Strain Rate (/s) -0.19 0.25 
 LV Systolic Torsion (°) 0.15 0.38 
 Pulmonary Artery Pressure (mmHg) 0.39 0.02 
 LA Area Index (cm2/m2) 0.53 0.001 
Treadmill exercise   
 METS Achieved -0.11 0.52 
LV Function After Exercise   
 LVEDVI (mL/m2) 0.37 0.02 
 LVESVI (mL/m2) 0.33 0.04 
 S’ Mitral Annulus (m/s) -0.28 0.09 
 Change In S’ (m/s) -0.27 0.10 
 Longitudinal Strain Rate (1/s) 0.33 0.04 
 Change In Longitudinal Strain 
 Rate (1/sec) 
-0.37 0.02 
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6.4.3 BNP AND ECHOCARDIOGRAPHIC VARIABLES AT REST.  
There were significant associations between plasma concentrations of BNP and 
echocardiographic markers of severity of AR including diastolic blood pressure (r=-
0.45, p=0.004), AR jet to LVOT width ratio (r=0.37, p=0.02) and AR jet to LVOT 
area ratio (r=0.43, p=0.007).  However there were no associations between the 
plasma concentration of BNP and any markers of LV size or function at rest (Table 
6.4).  
Similarly when AR patients were stratified according to whether their BNP 
concentration was within the normal range or elevated, AR patients with an elevated 
BNP tended to have more severe aortic regurgitation but no significant difference 
were found in LV size or function (Table 6.3).  
Despite no significant associations being found between BNP and resting markers of 
LV size and function, there were significant associations between the plasma 
concentration of BNP and LA area index (r=0.53; p=0.001) and a modest association 
with pulmonary artery pressure at rest (r=0.39; p=0.02). 
 
6.4.4 BNP AND EXERCISE STRESS ECHO VARIABLES.  
Despite only a small number of patients with mild or equivocal symptoms, AR 
patients had a lower exercise capacity than age and sex matched controls. This was 
the case both for AR patients in whom the plasma concentration of BNP remained 
within the normal range and those AR patients in whom BNP was elevated.  
However there was no significant difference in exercise capacity AR patients with 
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normal and elevated levels of BNP (11.0±3.3 vs. 10.7± 4.0 METs, p=0.78). However 
AR patients with BNP concentration >42 pg/mL had a tendency towards being more 
symptomatic than patients with BNP <42 pg/mL (36% versus 11%, p=0.06). 
 
6.4.5 BNP AND LV FUNCTION ON ECHOCARDIOGRAPHY AFTER EXERCISE 
Although no difference in resting LV size or function was noted, patients with a 
plasma BNP concentration >42 pg/mL tended to have larger left ventricle end 
diastolic (77±31 vs. 58±18 mL/m2; p=0.05), larger end-systolic volumes (29±20 vs. 
17±8 mL/m2; p=0.09) and a smaller percentage  decrease in LVESVI post exercise 
(-26±29 vs. -46±7 %; p=0.03). After adjustment for age this difference was 
statistically stronger with a p value of <0.01 for post-exercise LVESVI, % change in 
LVESVI, post exercise LVEDVI, and % change in LVEDVI. All other results were 
similar with and without adjustment for age. A lower longitudinal global strain rate 




This study demonstrates a number of important findings in relation to the use of BNP 
in the assessment of patients with aortic regurgitation. Firstly many AR patients had 
significant LV remodelling despite a BNP that remained well within the normal 
range.  This supports the findings from a previous study by Gerber et al [Gerber et al 
2003] who investigated the role of BNP in patients with severe AR many of whom 
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had met the echocardiographic criteria for surgery. Again they found no significant 
association between plasma concentrations of BNP and any markers of LV size at 
rest. It is recognized that patients who undergo valve surgery after their left ventricle 
has become severely dilated are at an increased risk of complications and that in 
some cases the ventricles do not return to their normal size after surgery. Our study 
suggests that the finding of a normal plasma concentration of BNP cannot be reliably 
used to exclude the presence of significant LV dilatation in AR.  
The decision to proceed to valve surgery is based on evidence of decompensation, 
either in the form of developing symptoms or by detecting a decrease in LV function 
or severe LV dilatation on echocardiography. There are a number of difficulties with 
approach in clinical practice. Like many valve lesions, chronic aortic regurgitation is 
normally very well tolerated for many years and hence the exact onset of symptoms 
can be extremely difficult to define. In addition echocardiographic assessment of AR 
severity can be challenging and there is often significant inter-observer variation in 
the calculation of LV volumes.  Similarly as above, waiting for an otherwise 
asymptomatic patient to develop significant LV dilatation and or early LV 
dysfunction may put the patient at risk of increased perioperative complications and 
a worse long term outcome.  
 
6.5.1 BNP AND AR SEVERITY 
The measurement of BNP in otherwise asymptomatic patients may therefore be 
useful when symptoms or signs are equivocal. However relatively few prior studies 
have systematically assessed the factors which influence BNP release in patients with 
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AR. Weber et al evaluated the relationship between NT-BNP concentrations and the 
progression of disease in 37 patients with chronic aortic regurgitation and an EF 
>45% undergoing clinical follow up [Weber et al 2005]. They demonstrated a strong 
correlation between AR severity and NT-BNP concentrations, and a significant 
reduction in NT-BNP concentrations after valve surgery. Similarly, Eimer et al 
demonstrated an association between plasma concentrations of BNP and the severity 
of AR [Eimer et al 2004]. However these studies predominantly included patients 
with mild to moderate AR. This study found an association between plasma BNP 
concentrations and several echocardiographic measures of AR severity in a cohort of 
patients with moderate-to-severe or severe AR. Consequently an elevated BNP in the 
absence of an alternative cause in patients with AR should prompt further 
investigation of AR severity if echocardiographic parameters are difficult to assess or 
are indeterminate. 
 
6.5.2 BNP AND LV REMODELING 
Gerber et al [Gerber et al 2003] evaluated 40 patients with chronic AR from 
outpatient clinics and those meeting criteria for valve surgery. In this population of 
patients with markedly dilated ventricles, there was no correlation between BNP 
concentrations and LV dimensions and volumes at rest. Similarly, we demonstrated 
that compensatory LV remodeling may occur in asymptomatic AR patients with 
normal BNP concentrations. Indeed many AR patients had markedly increased and 
LV end-systolic and diastolic volumes and LV mass compared with normal controls. 
Despite this, many of these patients were relatively asymptomatic and had plasma 
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BNP concentrations that remained within the normal range.  This limits the ability of 
BNP to detect patients prior to the development of LV remodeling.  
 
6.5.3 BNP AND EXERCISE CAPACITY 
Although the study by Gerber et al demonstrated higher BNP concentrations in 
symptomatic patients with AR, no study has assessed the relationship between 
concentrations of BNP and exercise treadmill capacity. Previous studies suggest that 
reporting of symptoms does not necessarily correlate with exercise capacity [Das et 
al 2005]. Exercise capacity can be influenced by factors other than cardiac function, 
and there can be considerable individual variation in physical fitness. For this reason 
a direct measure of early LV dysfunction may be preferred. 
 
Prognostic studies have demonstrated worse outcome in AR patients with an 
impaired haemodynamic response to exercise [Borer et al 1998, Wahi et al 2000]. In 
the current study, patients with elevated BNP concentrations had several 
echocardiographic measures suggesting LV dysfunction immediately after exercise. 
AR patients with elevated BNP had higher LV end-systolic and end-diastolic volume 
index and a trend to lower post-exercise ejection fraction than AR patients with 
normal BNP concentrations. However, the predictive value of BNP and for post-
exercise LV dysfunction on echocardiography was modest. Further research will be 
needed to determine whether BNP has prognostic value better than or additional to 
exercise stress echocardiography. 
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Strain rate is a less load-dependent marker of myocardial contractility [Marwick 
2006] which has been associated with subclinical myocardial dysfunction and poorer 
post-operative outcome in patients with organic mitral regurgitation [Lee et al 2004]. 
In the current study, patients with elevated BNP concentrations had lower global 
longitudinal strain rate and change in strain rate after exercise. These observations 
suggest that measurement of BNP may identify early LV dysfunction in patients with 
severe AR, which may not be evident on resting echocardiography alone. 
 
6.5.4 BNP AND TISSUE DOPPLER S’ VELOCITIES 
Two previous studies have investigated the role of long axis contraction (S’) in 
asymptomatic patients with AR [Paraskevaidis et al 2006, Vinereanu et al 2001]. The 
presence of an S’ velocity of the mitral annulus <9 cm/s has been associated with 
poorer exercise tolerance and a higher LV end-diastolic pressure and end-diastolic 
wall stress on cardiac catheterisation. However, there was no significant association 
between S’ velocity at rest or post-exercise and the plasma concentration of BNP in 
this study.  
 
6.5.5 STUDY LIMITATIONS 
The number of patients studied was modest. However, it is unlikely that the 
association between BNP and post-exercise LV dysfunction was due to chance alone 
because there were associations between several post-exercise measures of LV 
dysfunction and BNP. On average patients were younger than in some previous 
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reports. This may reflect the larger proportion of patients with rheumatic heart 
disease who develop AR at an earlier age. Plasma concentrations of natriuretic 
peptides increase with age [Galasko et al 2005, Redfield et al 2002] but after 
adjustment for age, the associations between BNP and post-exercise LV function 
were stronger, and other associations were similar. The study was too small to allow 
meaningful subgroup analyses, for example of patients with no and mild symptoms. 
For asymptomatic patients with normal LV function, the rate of progression to 
symptoms or overt LV dysfunction is on average about 6% per year [Bonow et al 
2006]. A much larger study with long-term follow-up is therefore needed to 




This study suggests that AR patients with elevated BNP concentrations are more 
likely to have early LV dysfunction after exercise, but the clinical significance of 
these changes is currently uncertain. A large prospective study is needed to 
determine whether including serial measurements of BNP or NT-BNP during follow 
up improves the ability to detect early LV dysfunction and thereby allows more 
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Plasma brain natriuretic peptide (BNP) concentrations predict prognosis in patients 
with valvular heart disease (VHD) but it is unclear whether this directly relates to 
disease severity.  We assessed the relationship between BNP and echocardiographic 
measures of disease severity in patients with VHD. Plasma BNP concentrations were 
measured in patients with normal left ventricular (LV) systolic function and isolated 
VHD (mitral regurgitation, MR, n=33; aortic regurgitation, AR, n=39; aortic 
stenosis, AS, n=34; mitral stenosis, MS, n=30), and age- and sex-matched controls 
(n=39) immediately prior to exercise stress echocardiography.  
 
Compared to controls, patients with VHD had elevated plasma BNP concentrations 
[(MR median 35 (IQR 23-52), AR 34 (22-45), AS 31 (22-60), MS 58 (34-90); 
controls 24 (16-33) pg/mL; p<0.01 for all]. LV end diastolic volume index varied by 
valve lesion; [MR (mean 77±14), AR (91±28), AS (50±17), MS (43±11), controls 
(52±13) mL/m2; p<0.0001].  There were no associations between LV volume and 
BNP.  Left atrial (LA) area index varied  [MR (18±4 cm2/m2), AR (12±2), AS (11±3), 
MS (19±6), controls (11±2); p<0.0001], but correlated with plasma BNP 
concentrations: MR (r=0.42, p=0.02), MS (r=0.86, p<0.0001), AR (r=0.53, p=0.001) 
and AS (r=0.52, p=0.002). Higher plasma BNP concentrations were associated with 
increased pulmonary artery pressure and reduced exercise capacity. Despite adverse 




Despite significant LV remodelling, plasma BNP concentrations are often normal in 
patients with VHD. Conversely, mild elevations of BNP occur with LA dilatation in 
the presence of normal LV.  Plasma BNP concentrations should be interpreted with 




Plasma BNP is a powerful prognostic marker in patients with a broad range of 
cardiac diseases including acute [Metra et al 2007] and chronic heart failure 
[McDonagh et al 2001, Rodeheffer 2004] and post myocardial infarction [Richards 
et al 1998]. Plasma concentrations of BNP may also increase in patients with 
valvular heart disease [Arat-Ozkan et al 2005, Detaint et al 2005, Gabriel et al 2008, 
Gerber et al 2003, Gerber et al 2003, Sharma et al 2011, Sutton et al 2003, Weber et 
al 2004], particularly in patients with symptoms and more severe valve lesions. 
Higher concentrations of BNP are associated with a worse outcome in patients with 
mitral regurgitation [Pizarro et al 2009] and aortic stenosis [Lancellotti et al 2010]. 
Patients with valve disease who have significant LV impairment often have very 
high concentrations of BNP [Detaint et al 2006, Nessmith et al 2005] but in these 
patients the indications for surgery are already clear. Measurement of BNP may 
however be useful in patients with heart valve disease and preserved left ventricular 
(LV) systolic function, especially when symptoms and haemodynamic data are 
equivocal.  
 
7.2.1 PREVIOUS STUDIES ASSESSING NATRIURETIC PEPTIDES IN VHD  
Previous studies have evaluated the relationship between plasma BNP concentrations 
and echocardiographic measures of disease severity as well as clinical outcomes for 
specific valve lesions including aortic stenosis, aortic regurgitation, mitral 
regurgitation and mitral stenosis [Gabriel et al 2008, Kerr et al 2008, Sharma et al 
2011, Van Pelt et al 2008]. However, each aortic and mitral valve lesion causes 
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different cardiac pressure and volume loads, and it is unclear whether the mechanism 
of BNP release and clinical implications of elevated plasma BNP concentrations are 
dependent on valve lesion type. These previous studies did not directly compare 
patients with different valve lesions, which result in different volume and pressure 
loads on the heart.  
 
7.2.2  STUDY AIMS 
The aim of this study was to identify both common and valve lesion specific factors 
associated with higher plasma BNP concentrations in patients with preserved LV 
systolic function, who have isolated aortic stenosis (AS), aortic regurgitation (AR), 
mitral regurgitation (MR) or mitral stenosis (MS) and to assess suitability of BNP for 




7.3.1 STUDY POPULATION 
Patients with moderate to severe AS (peak velocity >3.0 m/s), moderate-to-severe 
AR (left ventricular outflow tract (LVOT) width ratio >0.3 and holodiastolic flow 
reversal in descending thoracic aorta), moderate-to-severe MS (mitral valve area 
<1.5 cm2), and moderate-severe or severe MR (effective regurgitant orifice area >0.3 
cm2) were identified from echocardiogram reports and out-patient clinics in the 
Auckland region [Baumgartner et al 2009, Zoghbi et al 2003]. All patients had 
normal left ventricular ejection fraction (AS ≥ 50%, AR >50%, MR ≥ 60%, MS≥ 50) 
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[Bonow et al 2006]. Exclusion criteria included ischaemic heart disease, significant 
renal impairment (creatinine >160 µmol/L on baseline blood tests performed at 
enrolment), respiratory disease, and an inability to walk on a treadmill or a 
contraindication to exercise testing. All patients eligible for inclusion were invited to 
participate.  The patients’ symptomatic status was assessed according to the New 
York Heart Association criteria by a cardiologist blinded to echocardiographic data 
and peptide levels at the time of enrolment. Control subjects were volunteers from 
the local community who were age and sex matched. They were recruited by 
advertisement and had no clinical evidence of cardiovascular or respiratory disease.  
 
7.3.2 EXERCISE TESTING 
All patients underwent symptom-limited exercise testing on a motorized treadmill. A 
standard Bruce protocol was used for patients with mitral regurgitation. However it 
was noted that there was significant clustering of exercise times at the end of each 
stage and this was felt to affect adversely the objectivity of the determination of 
exercise capacity. Consequently for subsequent patients, the protocol was adjusted so 
that the speed and/or incline of the treadmill were increased at 1-min intervals. The 
maximum workload at the end of each 3-min stage remained equivalent to that of the 
standard Bruce protocol. Exercise was stopped for significant dyspnoea, chest 
discomfort, pre-syncope, fatigue or at patient request. 
 
7.3.3 ECHOCARDIOGRAPHY 
All echocardiograms were performed by experienced sonographers on modern 
cardiac ultrasound machines (Vivid 7, General Electric, Vingmed Ultrasound, 
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Norway). All patients underwent comprehensive examination including M-mode, 2-
dimensional, Doppler and tissue Doppler echocardiography modified according to 
their underlying valvular lesions consistent with current guidelines [Baumgartner et 
al 2009, Zoghbi et al 2003]. All analysis was performed offline (Echopac PC version 
4.0.0 GE Medical, Milwaukee, WI) by an experienced cardiologist blinded to the 
results of the patient characteristics and BNP data. All measurements were averaged 
from at least 3, or in cases of atrial fibrillation (AF), 5 cardiac cycles. The left 
ventricular (LV) end-systolic and end-diastolic volumes and ejection fraction (EF) 
were measured from the apical four-chamber view using the modified Simpson’s 
single-plane method [Leung et al 1996]. This method was chosen to allow 
comparison with the post-exercise volumes. The left atrial area was measured in the 
apical four-chamber view [Lester et al 1999].  
 
Assessment Of Valve Severity 
Quantitative and qualitative measures of aortic stenosis and regurgitation severity 
were made according to ASE guidelines [Baumgartner et al 2009, Zoghbi et al 
2003]. Quantitative measures of AS severity included peak velocity, mean pressure 
drop and aortic valve area.  Assessment of AR severity included the AR jet:LVOT 
width ratio, AR pressure half time, peak diastolic and end-diastolic flow velocities in 
the descending thoracic and abdominal aorta. 
The severity of MR was assessed by quantitative Doppler with mitral and aortic 
stroke volumes [Enriquez-Sarano et al 1993] and by the PISA method [Enriquez-
Sarano et al 1995]. The stroke volumes obtained from the two methods were 
averaged to give a mean regurgitant volume [Detaint et al 2005]. The mitral valve 
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area (MVA) was obtained using direct planimetry, pressure half time, and continuity 
methods [Hatle et al 1978, Martin et al 1979, Nakatani et al 1988]. The median 
MVA from these three methods was used for analysis. Mean trans-mitral pressure 
gradients were obtained by tracing the continuous wave Doppler signal across the 
mitral valve [Quinones et al 2002].  
 
Estimation Of Pulmonary Artery Pressure 
Agitated saline was used to facilitate the estimation of pulmonary artery pressure as 
described in Chapter 2.  
 
7.3.4 MEASUREMENT OF NATRIURETIC PEPTIDES.  
Blood samples were obtained from an indwelling intravenous catheter after 15 min 
lying supine, immediately prior to the baseline echocardiogram and immediately post 
exercise. Patients fasted for 2 hours prior to the investigations. Blood samples were 
collected in EDTA tubes and plasma stored at –80 C and for measurement BNP 
concentrations at the study end using established radioimmunoassays [Yandle et al 
1993]. The upper limit of the normal reference range for BNP is 42 pg/mL. To 
convert BNP levels expressed in pg/mL to pmol/L, divide by 3.47 [Van Pelt et al 
2007, Yandle et al 1993]. 
 
7.3.5 STATISTICAL ANALYSIS.  
Previous studies have demonstrated a mean plasma BNP concentration of 22±7 
pg/mL in the normal healthy population [Yandle et al 1993]. A minimum sample 
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size of 30 in each valve subgroup was required to detect a 20% increase in plasma 
BNP concentrations compared to controls (power of 80% and alpha=0.01). 
Categorical data were presented as frequency and percentage, and continuous data 
were presented as mean  standard deviation (SD), or median and inter-quartile 
range (IQR).  BNP underwent natural log transformation in analyses due to its right 
skewed distributions unless specified, and was reported as median and inter-quartile 
range.  Comparison of all valves versus the control group, and valve sub-groups was 
performed using the Chi-square or Fisher’s exact tests for categorical data where 
appropriate.  For continuous variables, two independent sample Student’s t-test or 
non-parametric Mann-Whitney U test was used, where appropriate for comparing all 
valves versus controls group.  For comparison between subgroup of valves, one-way 
analysis of variance (ANOVA) was performed followed by the Dunnett’s test, to 
compare each valve subgroup with control subjects. The Kruskal-Wallis test was 
used when the continuous data was not normally distributed. Pearson correlation 
coefficients were reported for linear associations.  All p-values reported were two 
tailed and a p-value <0.05 was considered significant.  Data was analysed using SAS 





7.4.1 BASELINE CHARACTERISTICS  
All patients who agreed to participate completed all aspects of the study. One hundred 
and seventy five subjects with isolated MR (n=33), AR (n=39), AS (n=34) and MS 
(n=30) or normal valves (n=39) were studied. Plasma BNP concentrations and exercise 
treadmill data was available for all patients. Plasma BNP concentrations (median, inter-
quartile range) were elevated in all valve lesions compared to controls [MR (35 pg/mL, 
23-52), AR (34 pg/mL, 22-45), AS (31 pg/mL, 22-60), MS (58 pg/mL, 34-90), Controls 
(24 pg/mL, 16-33); p<0.01 for all]. For each valvular lesion, patients were divided into 
two groups depending on whether the plasma BNP concentration was within the normal 
range or elevated (>42 pg/mL). 
 
Patients with AS were predominantly male whereas patients with MS were 
predominantly female (Table 7.1). In keeping with the higher proportion of 
degenerative valve disease, AS patients were generally older than those with other valve 
lesions. Patients with mitral valve disease had a higher plasma BNP concentration than 
those with aortic valve disease (46 (29-73) vs. 32 (22-49) pg/mL, p=0.012). For each 
given valve lesion, patients with MS had the highest plasma concentration of BNP. This 
remained the case if patients with AF were excluded from the analysis (BNP in MS with 
sinus rhythm 55 (30-73) vs. other valve lesions 34 (22-52) pg/ml; p=0.02. 
 
The relative use of cardiac medication differed between valve groups. Patients with 
aortic regurgitation were the most likely to be taking medication with 64% of patients 
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taking an angiotensin converting enzyme inhibitor. Forty-three percent of MS patients 
were taking a loop diuretic (at a dose of 40mg furosemide or less) and 32% of patients 
with AS were taking a betablocker. Patients with AS who were not taking a betablocker 
had lower plasma BNP concentrations than those that were [26(20,41) vs. 42 (34,63); 
p=0.03]. There was no other statistically significant difference in plasma BNP 
concentrations between patients that were taking medication compared to those that 
were not in any other valve subgroup 
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Table 7.1. Baseline characteristics, baseline echocardiographic and exercise data 
 
1 P-value relates to All Valves patients compared to controls, 2 P-value for comparison between subgroups. 
* Comparison significant at the 0.05 level between each valve group versus controls 
 
LVEDVI:Left ventricular end-diastolic volume index, LVESVI: left ventricular end-systolic volume index, LVEF: Left ventricular ejection fraction ,PA pulmonary Artery, BP: 
blood pressure, BNP :Brain Natriuretic Peptide. Results are Mean±SD except BNP which is median (IQR)
 Controls MR MS AS AR All Valves P-value1 P-value2 
Number of subjects 39 33 30 34 39 136 - - 
Age, (years)  55 ± 15 53 ± 16 49 ± 14 67 ± 9* 42 ± 14* 53 ± 16 0.404 <0.001 
Female, n (%) 16 (41) 15 (45) 28 (93) 4 (12) 6 (15) 53 (39) 0.817 <0.001 
Body mass index (kg/m2)  25.8 ± 3.5 27.7 ± 5.0 28.6 ± 5.8 28.9 ± 4.5* 28.8 ± 4.7* 28.5 ± 4.9 0.001 0.023 
Atrial fibrillation, n (%) 0 (0) 0 (0) 8 (27) 0 (0) 0 (0) 8 (6) 0.202 <0.001 
Symptomatic, n (%) 1 (3) 17 (52) 14 (47) 17 (50) 7 (18) 55 (40) <0.001 <0.001 
Medication, n (%)         
 Loop diuretic 0 (0) 4 (12) 13 (43) 5 (15) 2 (5) 24 (18) 0.003 <0.001 
 ACE Inhibitor 0 (0) 6 (18) 4 (13) 4 (12) 25 (64) 39 (29) <0.001 <0.001 
 Beta Blocker 0 (0) 6 (18) 4 (13) 11 (32) 2 (5) 23 (17) 0.006 <0.001 
BNP (pg/mL)  24 (16-33) 35 (23-52) 58 (34-90) 31 (22-60) 34 (22-45) 36 (24-62) <0.001 <0.001 
Left atrial area index  10.5 ± 1.9 17.5 ± 4.4* 19.3 ± 5.9* 11.5 ± 2.5 10.8 ± 2.0 14.5 ± 5.4 <0.001 <0.001 
LVEDVI (ml/m2)  52.3 ± 12.7 76.6 ± 14.0* 43.4 ± 11.2 49.6 ± 16.5 91.3 ± 28.4* 66.9 ± 27.6 0.003 <0.001 
LVESVI (ml/m2)  19.0 ± 7.1 26.9 ± 6.5* 16.5 ± 5.9 20.8 ± 12.3 33.9 ± 14.1* 25.1 ± 12.4 0.005 <0.001 
LVEF (%)  64.5 ± 7.6 64.6 ± 6.7 62.4 ± 7.3 61.9 ± 7.0 63.7 ± 6.3 63.2 ± 6.8 0.320 0.380 
PA Pressure (mmHg)  24 ± 4 37 ± 13* 36 ± 12* 32 ± 7* 28 ± 7 33 ± 10 <0.001 <0.001 
Peak heart rate (bpm) 153 ± 16 153 ± 21 148 ± 24 129 ± 20* 133 ±19* 140 ± 23 0.0003 <0.001 
Exercise capacity (METS)  12.5 ± 3.1 9.1 ± 2.7* 6.3 ± 2.6* 9.1 ± 3.2 10.9 ± 3.4* 9.0 ± 3.4 <0.001 <0.001 
Peak systolic BP (mmHg)  169 ± 23 163 ± 30 132 ±23* 159 ± 22 188 ±24* 163 ± 32 0.183 <0.001 
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7.4.2 ADVERSE CARDIAC REMODELING. 
Although all subjects had a normal LV ejection fraction, LV end diastolic volume 
index (LVEDVI) varied considerably across patients and by valve lesion: MR 77±14, 
AR 91±28, AS 50±17, MS 43±11, and controls 52±13 mL/m2; p<0.0001). For each 
valvular lesion, patients were divided into two groups depending on whether the 
plasma BNP concentration was within the normal range (≤42 pg/mL) or elevated. 
The relative numbers of patients with elevated BNP in each group are shown in 
Table 7.2. Even when plasma BNP concentration remained within the normal range 
(<42 pg/mL), those with regurgitant valve lesions had significant LV dilatation 
compared to controls: (LVEDVI in MR 78±14, AR 88±27 and controls 52±12 
mL/m2; p= <0.0001). There was no association between any resting measure of LV 
function and plasma BNP concentration (Table 7.3). 
 
LA area index (LAAI) was greater in patients with mitral compared to aortic valve 
disease: [MR 17±4, MS 19±6, AR 11±2, AS 11±2,) and controls (11±2 cm2/m2, 
p<0.0001). Despite no association with markers of LV size, there, there was a 
consistent correlation with LAAI across all valve lesions: MR (r=0.42, p=0.02), MS 
(r=0.86, p<0.0001), AR (r=0.53, p=0.001), AS (r=0.52, p=0.002), all valves (r=0.57, 
p<0.0001). An increase in plasma BNP concentration was also associated with a 
higher pulmonary artery pressure in all valve lesions (Tables 7.2 and 7.3). 
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52 ± 12 
53 ± 16 
0.96 
50 ± 17 
48 ± 17 
0.73 
45 ± 7 
42 ± 13 
0.50 
88 ± 27 
100 ± 31 
0.20 
78 ± 14 
75 ± 14 
0.59 




19 ± 7 
19 ± 6 
0.89 
19 ± 9 
24 ± 19 
0.95 
16 ± 5 
16 ± 6 
0.91 
32 ± 13 
39 ± 17 
0.25 
28 ± 6 
26 ± 7 
0.81 




64 ± 8 
65 ± 9 
0.90 
61 ± 7 
63 ± 6 
0.47 
63 ± 8 
62 ± 7 
0.57 
64 ± 6 
63 ± 6 
0.54 
64 ± 7 
66 ± 7 
0.57 




10 ± 2 
11 ± 3 
0.69 
11 ± 2 
13 ± 3 
0.008 
15 ± 2 
21 ± 6 
0.0005 
10 ± 2 
12 ± 2 
0.07 
17 ± 4 
18 ± 5 
0.47 




24 ± 4 
25 ± 6 
0.77 
31 ± 6 
35 ± 7 
0.16 
34 ± 16 
36 ± 9 
0.14 
27 ± 6 
32 ± 6 
0.06 
32 ± 7 
47 ± 16 
0.008 






0.51 ± 0.13 
0.41 ± 0.09 
0.04 
0.75 ± 0.15 
0.62 ± 0.14 
0.03 
0.10 ± 0.07 
0.16 ± 0.08 
0.02 
0.34 ± 0.16 
0.32 ± 0.16 
0.72 




12 ± 3 
14 ± 3 
0.22 
10 ± 3 
7 ± 2 
0.003 
8 ± 3 
5 ± 2 
0.02 
11 ± 4 
11 ± 3 
0.65 
10 ± 2 
7 ± 2 
0.001 
 
NYHA: New York Heart Association; LV: left ventricle; LA: left atrium; EROA: effective regurgitant orifice area. BNP: brain natriuretic peptide. 
All data is mean ± SD unless otherwise stated. P values relate to comparison of Normal vs raised BNP groups 
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 LV End-Diastolic Volume Index (mL/m2) 0.22, (0.20)) 0.02, (0.93) -0.24, (0.20) 0.16, (0.34) -0.02, (0.28) -0.01, (0.85) 
 LV End-Systolic Volume Index  (mL/m2) 0.13, (0.43) 0.10, (0.59) -0.06, (0.74) 0.19, (0.24) -0.19, (0.31) 0.01, (0.86) 
 Left Atrial Area Index (cm2/m2) 0.10, (0.57) 0.52, (0.002) 0.86 (<0.0001) 0.53, (0.001) 0.42 (0.02) 0.57, (<0.0001) 
 Pulmonary Artery Pressure (mmHg) 0.29, (0.08) 0.40 (0.037) 0.47 (0.008) 0.39, (0.02) 0.53 (0.002) 0.36, (<0.0001) 
 Valve Area/EROA Index (cm2/m2) - -0.28 (0.10) -0.23 (0.21) 0.22 (0.18) -0.05, (0.79) - 
 Exercise Capacity [METS] 0.23, (0.16) -0.44, (0.009) -0.56 (0.001) -0.11, (0.52) -0.53 (0.001) -0.38, (<0.0001) 
  
LV: Left ventricle; EROA: Effective Regurgitant Orifice Area; BNP: Brain Natriuretic Peptide. Pearson’s correlation used for analysis 
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7.4.3 EXERCISE CAPACITY AND FUNCTIONAL STATUS 
Across all valve lesions, 55 (40%) patients were symptomatic and were more likely 
to have a raised plasma BNP concentration than those who remained asymptomatic 
(49 (32-79) vs. 31 (22-44) pg/mL; p<0.001). Patients who were symptomatic had 
higher pulmonary artery pressures (38±12 vs. 29±8 mmHg; p<0.001), larger left 
atrial area index (16±6 vs. 14±5 cm2/m2; p=0.02), and lower exercise capacity 
(7.1±2.4 vs. 10.4±3.4 METS; p<0.001) than asymptomatic subjects. However this 
finding was not consistent across all valve subgroups and in particular although 
asymptomatic patients with MS and AR had slightly higher exercise capacity than 
those with mild symptoms, this was not statistically significant (Table 7.4). Patients 
with an elevated BNP performed less well on the treadmill than those with a normal 
BNP  (10.1±3.1 vs. 7.2±3.1 METS, p<0.0001).  This finding was consistent and 
statistically significant for all valve subgroups except for those with AR (table 2).  
 
However the patients with poor exercise capacity identified by NYHA class and 
those by an elevated plasma BNP concentration were not identical. Of the 81 patients 
in NYHA class 1, twenty patients had an elevated BNP. These patients performed 
less well on the treadmill than asymptomatic patients in whom BNP remained within 
the normal range (10.9±3.1 vs. 8.7±3.8 METS, p=0.01) 
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26.8 ± 13.0 
- 
33.7 ± 19.3 
45.0 ± 24.8 
0.19 
60.2 ± 45.9 
86.1 ± 50.4 
0.08 
40.9 ± 37.7 
74.2 ± 75.9 
0.10 
33.6 ± 19.4 
52.3 ± 29.7 
0.04 






















52.3 ± 12.7 
- 
 
52.8 ± 14.4 
46.6 ± 18.1 
0.28 
46.9 ± 9.6 
39.4 ± 11.8 
0.07 
90.3 ± 28.6 
95.7 ± 29.5 
0.57 
80.5 ± 11.2 
72.9 ± 15.6 
0.12 




19.0 ± 7.1 
- 
 
18.7 ± 7.6 
22.8 ± 15.4 
0.61 
17.9 ± 6.1 
14.9 ± 5.4 
0.18 
33.3 ± 13.7 
36.7 ± 16.8 
0.50 
28.3 ± 6.4 
25.6 ± 6.5 
0.61 




65 ± 8 
- 
63 ± 8 
61 ± 6 
0.32 
62 ± 9 
63 ± 4 
0.86 
64 ± 6.2 
63 ± 7 
0.80 
65 ± 7 
65 ± 6 
0.96 




10.6 ± 1.9 
- 
11.5 ± 2.5 
11.4 ± 2.6 
0.90 
18.2 ± 6.0 
20.5 ± 5.9 
0.16 
10.6 ± 2.0 
11.8 ± 2.0 
0.14 
17.4 ± 3.9 
17.6 ± 5.0 
0.73 




25 ± 4 
- 
30 ± 7 
35 ± 6 
0.06 
32 ± 14 
40 ± 8 
0.01 
28 ± 6 
31 ± 9 
0.19 
32 ± 6 
42 ± 16 
0.03 






0.51 ± 0.09 
0.45 ± 0.14 
0.15 
0.71 ± 0.15 
0.62 ± 0.16 
0.13 
0.11 ± 0.07 
0.16 ± 0.07 
0.06 
0.38 ± 0.16 
0.29 ± 0.15 
0.10 




12.6 ± 3.1 
- 
10.9 ± 2.8 
7.4 ± 2.5 
0.003 
7.0 ± 3.0 
5.5 ± 2.0 
0.19 
11.3 ± 3.6 
9.4 ± 1.9 
0.26 
11.1 ± 1.6 
7.2 ± 2.1 
<0.0001 
 
NYHA: New York Heart Association; LV: left ventricle; LA: left atrium; EROA: effective regurgitant orifice area. BNP: brain natriuretic peptide. 
All data is mean ± SD unless otherwise stated. P values relate to comparison of NYHA 1 vs. NYHA 2 groups.  
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7.4.4 PLASMA BNP CONCENTRATIONS POST EXERCISE 
Plasma BNP concentrations taken immediately post exercise were higher across the 
whole cohort of patients with VHD (43 (28,75) vs. 33 (22,55) pg/mL, p=0.003). 
However in the individual valve lesions groups, only patients with MR had a higher 
concentration of BNP (Table 7.5). In addition a small rise in plasma BNP 
concentrations was seen in the control group.  
 
There was a strong association between plasma BNP concentrations taken at rest and 
post exercise (r=0.92, p=<0.0001). Across all valves the correlation with plasma 
BNP and left atrial area index, pulmonary artery pressure and exercise capacity 
observed at rest were also seen with plasma BNP taken post exercise (Table 7.6). 
The measurement of plasma BNP concentrations post exercise did not offer any 


















24 (16,33) 33 (21, 43) 0.03 
Mitral Regurgitation 
(n=33) 
35 (23,52) 54 (35, 94) 0.03 
Mitral Stenosis  
(n=30) 
58 (34,90) 71 (43,108) 0.36 
Aortic Stenosis 
 (n=34) 
31 (22,60) 40 (26,75) 0.10 
Aortic Regurgitation 
(n=39) 
34 (22,45) 43 (27,63) 0.16 
All Valves  
(n=136) 
36 (24,62) 43  (28,75) 0.003 
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 LV end-diastolic volume index 
(mL/m2) 
0.24, (0.15) 0.07, (0.72) -0.34, (0.07) 0.17, (0.29) 0.04, (0.81) -0.06, (0.48) 
 LV end-systolic volume index  
(mL/m2) 
0.10, (0.58) 0.18, (0.30) -0.16, (0.42) 0.20, (0.29) -0.08, (0.67) -0.01, (0.92) 
 Left atrial area index (cm2/m2) 0.31, (0.07) 0.47, (0.006) 0.66, (<0.0001) 0.52, (0.001) 0.43, (0.01) 0.52,  <0.0001) 
 Pulmonary Artery Pressure 
(mmHg) 
0.32, (0.05) 0.33, (0.09) 0.23, (0.24) 0.40, (0.01) 0.42, (0.02) 0.36, (<0.0001) 
 Valve area/EROA index (cm2/m2) - -0.22, (0.21) -0.33, (0.08) 0.20, (0.22) 0.13, (0.51) - 








This study evaluated associations between the plasma BNP concentrations and 
echocardiographic measures of LV and LA remodelling in patients with moderate to 
severe aortic and mitral valve disease.  Patients with impaired LVEF were excluded 
so that the impact of factors other than LV systolic function could be evaluated.  
There were several clinically relevant observations.  First, whilst there was a wide 
range of LV remodelling across different valve lesions, there was no correlation 
between the plasma BNP concentration and LV end systolic or end diastolic volumes 
for any valve lesion.   This implies that in VHD patients with normal ejection 
fraction, compensatory LV remodelling is not associated with an increase in plasma 
BNP concentration.  Second, the plasma BNP concentration correlated with LA size 
in all valve lesions. Third, plasma BNP concentrations were higher in subjects with 
mitral compared to aortic valve disease, and highest in patients with mitral stenosis, 
in which setting there is no increase in LV wall stretch or pressure load.  BNP also 
increased with higher pulmonary artery pressures. In these patients, the elevation in 
pulmonary artery pressure was likely to be secondary to an increase in LA filling 
pressure.  These observations are consistent with BNP release from the LA in 
response to an increase in volume and wall stretch. This hypothesis is supported by 
evidence for synthesis of BNP by atrial myocytes in response to chronic increases in 
wall stress [Langenickel et al 2000] and co-storage of BNP with ANP in atrial 




In aortic valve disease, plasma BNP concentrations increased with relatively small 
increases in LA volume.  It is possible that LA dilatation in aortic valve disease 
reflects subtle LV systolic or diastolic dysfunction. However assessment of diastolic 
function, particularly in patients with mitral valve disease is not well validated and 
comparison across valve lesions is not possible.  In subjects with mitral valve 
disease, small increases in LA volume were often not associated with higher plasma 
BNP concentrations, but more marked LA enlargement usually was.  Some patients 
with mitral stenosis were in atrial fibrillation, which is known to be associated with 
higher plasma BNP concentrations [Dussaule et al 1988, Engelmann et al 2005].  
The number of patients with atrial fibrillation in this study was too small to allow a 
reliable analysis of the relationship between atrial fibrillation and BNP. 
 
Higher plasma BNP concentration was associated with pulmonary hypertension in all 
valve subgroups. In addition higher BNP was associated with reduced exercise 
capacity for all valve lesions except for AR.  Symptomatic patients with any valve 
lesion were more likely to have an elevated pulmonary artery pressure or a decreased 
exercise capacity. As this elevated pulmonary pressure and decreased exercise 
capacity are the objective correlates of symptomatic status, this is not surprising. 
However there was considerable overlap in the objective parameters between 
symptomatic and asymptomatic patients consistent with the known difficulties in 
assessing cardiac symptoms particularly in the early stages of decompensation 
[Messika-Zeitoun et al 2006]. Furthermore although both symptomatic patients and 
those with elevated plasma BNP concentrations tended to have objective evidence of 
exercise limitation or echocardiographic features of more advanced valve disease, the 
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patients identified were not identical. This suggests that plasma BNP concentrations 
may offer additional information in assessing the haemodynamic consequences of 
valve lesions in patients with AS, MS, and MR. We did not find similar associations 
between BNP and exercise capacity in patients with aortic regurgitation. The reason 
for the lack of a statistically significant association in the AR cohort is uncertain.  
 
7.5.1 CLINICAL IMPLICATIONS 
In this study, most patients with severe valve disease had a plasma BNP 
concentration of <100 pg/mL: a value below which cardiac failure is considered 
unlikely in patients presenting with dyspnoea [Dickstein 2008].  Patients with valve 
disease and a preserved LV ejection fraction may therefore have clinically important 
symptoms and pulmonary hypertension with a relatively modest increase in BNP.  
Conversely, in patients with other reasons for an elevated BNP, measuring plasma 
BNP concentration to assess valve status may not be helpful.  In this study, patients 
with other known causes of an elevated BNP were excluded.  
 
Previous studies which evaluate outcomes in patients with mitral regurgitation 
[Pizarro et al 2009] and aortic stenosis [Lancellotti et al 2010] suggest that an 
elevated BNP may identify patients who have a higher risk of adverse events.  There 
is known difficulty in evaluating symptoms in some patients [Messika-Zeitoun et al 
2006] and a significant number of asymptomatic patients in this study had an 
elevated plasma BNP concentration.  These patients had a lower exercise capacity 
than those in whom the BNP remained within the normal range. Consequently 
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elevated plasma BNP concentrations in apparently asymptomatic patients should lead 
to a more careful assessment regardless of the type of valve lesion.   
 
7.5.2 STUDY LIMITATIONS 
 The proportion of asymptomatic and symptomatic patients in each valve group 
differed but with the exception of the AR subgroup, at least half of the patients in 
each valve type had mild or equivocal symptoms. The small number of symptomatic 
patients in the AR subgroup may partly explain the lack of associations between 
BNP and exercise capacity in this group. In the AS subgroup only asymptomatic and 
patients with equivocal symptoms underwent exercise testing and in the other 
subgroups patients had at most mild symptoms as those with contraindications to 
exercise testing were excluded from the study. In particular patients with severe AS 
with symptoms of angina were excluded from the study. This selection of 
predominantly asymptomatic and mildly symptomatic patients may be responsible 
for the relatively modest rise in plasma BNP concentration in this cohort. However in 
clinical practice, patients with significant valve disease who have clear symptoms 
usually have a class 1 indication for surgery or valve intervention according to 
current guidelines [Bonow et al 2006, Vahanian et al 2007]. Consequently the 
measurement of BNP in these patients is unlikely to be helpful. A further limitation 
is that although the overall number of patients within this study is modest, the 
number of patients within each valve group is relatively small. This limits the power 
of further subgroup analysis or comparison against other markers of valve severity 
within each subgroup. Furthermore although valve severity was graded according to 
the ASE/EAE guidelines [Baumgartner et al 2009], the grading of severity, 
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particularly between regurgitant and stenotic lesions differs considerably and hence 




In patients with isolated heart valve disease and a preserved ejection fraction, 
significant cardiac remodelling can occur whilst BNP remains within the normal 
range.  However BNP increases with greater left atrial size and pulmonary artery 
pressure in all valve lesions. Consequently plasma BNP concentrations cannot 
reliably identify patients with significant valve disease and therefore should be 
interpreted with caution in these patients. However elevated BNP levels were 
associated with poor exercise capacity and therefore a raised BNP in an apparently 
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CHAPTER  EIGHT 
 
CONCLUSIONS AND FUTURE DIRECTIONS  
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8.1  ASSESSMENT OF SYMPTOMS 
 
This research demonstrates that the accurate assessment of symptomatic status in 
valvular heart disease can be extremely challenging. Regardless of the underlying 
type of valve lesion a significant number of patients who were deemed to be 
asymptomatic by an experienced cardiologist had significantly lower exercise 
capacity than aged matched controls on objective exercise testing. Of greater concern 
was the finding that a small but significant number had extremely poor exercise 
capacity and a number of adverse features on exercise stress echocardiography. This 
confirms our belief that we need additional methods to the current approach of 
assessing symptom status and resting echocardiographic parameters of severity.  
 
8.2 EXERCISE ECHOCARDIOGRAPHY IN VHD 
 
When performed in VHD patients without an indication for surgery based on 
symptomatic assessment and echocardiography performed at rest, exercise 
echocardiography identifies a high-risk cohort of patients who have an increased risk 
of death or hospitalisation of heart failure within 2 years. This is in keeping with 
other studies that have assessed the role of exercise electrocardiography in aortic 
stenosis [Alborino et al 2002, Amato et al 2001]. However although a few other 
studies have demonstrated that worsening of MR severity [Magne et al 2010] may be 
associated with an increased adverse events, there is little other published data 
linking the presence of adverse features on exercise stress echocardiography with 
reduced event free survival in other valve lesions. In this research the event rate was 
 
 200 
too small to assess the role of exercise echocardiography in determining prognosis in 
individual valve lesions. However the findings suggest that exercise 
echocardiography can predict adverse outcome regardless of the underlying valve 
lesion and that there may be a role for routine exercise echocardiography in 
asymptomatic patients with valvular heart disease.  
 
8.3  NATRIURETIC PEPTIDES IN VHD 
  
8.3.1 NATRIURETIC PEPTIDES IN MITRAL STENOSIS 
In contrast to other valve lesions, in MS the LV is not subject to increased wall 
stress. Consequently BNP, which was thought to be released predominantly from the 
left ventricle, was hypothesised to be unhelpful in the assessment of MS severity. 
ANP, which is predominantly released from the atria, appeared to have theoretical 
advantages in the assessment of MS. However we found that plasma BNP 
concentrations were significantly elevated in MS compared to controls and increased 
with MS severity. Indeed there was a fairly strong association with BNP and left 
atrial size and a weaker association with pulmonary artery pressure. In contrast there 
were no associations with any marker of left or right ventricular size or function. 
This suggests that atrial release of BNP may be an important factor in MS. 
 
In addition BNP was found to be able to identify patients fulfilling the ACC/AHA 
[Bonow et al 2006] criteria for intervention with a cut off of twice the upper limit of 
normal have a reasonable sensitivity and specificity for identifying patients who may 
benefit from valve intervention. In addition a BNP level of greater than twice the 
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upper limit of normal was associated with a significantly increased risk of death, 
hospitalisation with heart failure or valve intervention.  
 
A plasma ANP concentration of twice the upper limit of normal was also predictive 
of adverse outcome and again had reasonable sensitivity and specificity in 
identifying patients who fulfilled the ACC/AHA criteria for valve intervention. 
However plasma ANP concentrations performed marginally less well in this regard 
than BNP and did not provide significant additional information. Given that assays 
for BNP are more readily available there was little to favour using ANP in the 
assessment of MS.  
 
8.3.2 NATRIURETIC PEPTIDES IN MITRAL REGURGITATION 
In a cohort of MR patients with normal LV function who were either asymptomatic 
or had equivocal symptoms we found that a significant number of patients had 
plasma BNP levels that remained within the normal range. Despite this there was 
evidence of significant adverse cardiac remodelling with dilated left ventricles and 
enlarged atria. In addition the plasma BNP level was significantly associated with 
left atrial size and higher pulmonary artery pressures both at rest and immediately 
post exercise.  
 
However plasma BNP concentrations were not associated with any marker of LV 
size or systolic function. This is in contrast to previous studies that have suggested 
that LV remodelling is the primary determinant of elevated plasma BNP 
concentrations in MR [Detaint et al 2006, Yusoff et al 2006]. In contrast to this 
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research, previous studies included patients with either LV dysfunction [Detaint et al 
2006], significant symptoms or used a cut-off EF of >55% [Yusoff et al 2006]  
which in the context of severe MR represents mild LV dysfunction. In these patients 
the indication for valve surgery is already clear and the measurement of natriuretic 
peptides is unlikely to offer additional benefit.  
 
One of the most striking findings in this study was the clear relationship between 
BNP and exercise capacity on treadmill testing. This is despite this being a relatively 
asymptomatic cohort of patients. Indeed in MR patients, plasma BNP concentrations 
above the normal range had a reasonable sensitivity and specificity for predicting 
pulmonary hypertension post exercise or impaired exercise capacity. Consequently 
although a normal plasma BNP cannot exclude severe MR with signs of adverse 
cardiac remodelling, even mild elevations of plasma BNP in an asymptomatic patient 
with MR should prompt further reassessment of the patient to ensure that the severity 
or the haemodynamic consequences are not being underestimated.  
 
8.3.3  NATRIURETIC PEPTIDES IN AORTIC REGURGITATION 
In a cohort of patients with moderate-severe or severe AR with normal LV function 
who were asymptomatic or had equivocal symptoms, plasma BNP concentrations 
often remained within the normal range despite the presence of significant LV 
dilatation. Given that severe LV dilatation in asymptomatic patients with AR is an 
indication for valve replacement this finding significantly limits the ability of normal 
plasma BNP concentrations to provide reassurance that surgery is not indicated in 
patients with AR. This finding is in keeping with previous studies which found that 
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although plasma BNP concentrations increase with AR severity, patients with severe 
AR and ventricular dilatation have wide range (1.2pg/mL to 200pg/mL) of plasma 
BNP concentrations with a median BNP concentration of 13.1 pg/mL [Ozkan et al 
2005]. Although we also found an association with BNP and markers of AR severity 
we did not find an association between plasma BNP concentrations and any marker 
of LV size or function at rest. In contrast there was a modest association between 
plasma BNP concentrations and LA size.  
 
However higher plasma concentrations of BNP were associated with signs of early 
LV dysfunction immediately post-exercise assessed using speckle tracking derived 
strain. In particular global longitudinal strain and the change in global longitudinal 
strain post-exercise was lower in AR patients who had elevated BNP concentrations 
than those with normal BNP. Despite this there was no statistically significant 
difference in exercise capacity between AR patients with a normal BNP compared to 
those with an elevated BNP.  
 
8.3.4  NATRIURETIC PEPTIDES IN DIFFERENT VALVE LESIONS 
Unsurprisingly given the differing haemodynamic effects between valve lesions there 
was a wide range of LV volumes between groups with many patients having 
evidence of adverse cardiac remodelling. Despite this there was no association 
between markers of LV size and function for any individual valve lesion. In contrast 
however, there was an association between plasma BNP and LA size in all valve 
lesions. Whilst there was also an association with elevated pulmonary artery 
pressures, the higher pulmonary artery pressure is probably a reflection of the 
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increased LA pressure. Although BNP release from the RV is also a possibility there 
were no associations with BNP and markers of RV size or function.  This suggests 
that LA wall stretch may be an important factor in BNP release in VHD. This 
hypothesis is supported by evidence of synthesis of BNP by atrial myocytes 
[Langenickel et al 2000] and co-storage of BNP with ANP in atrial granules [Goetze 
et al 2006]. 
 
There were only a small number of mildly symptomatic patients within this study 
and of those patients with symptoms few had evidence of severe valve disease at rest. 
Although the presence of symptoms based on clinical assessment was associated 
with poorer exercise capacity on exercise testing, there was considerable overlap in 
keeping with the difficulties in accurately assessing symptom status. In addition 
although patients with elevated BNP also had objective evidence of exercise 
limitation, these were not necessarily the ones that were deemed to be symptomatic 
at rest. This suggests that BNP does offer complementary information to the standard 
assessment of patients with VHD and that the finding of elevated plasma BNP 
concentrations in an otherwise asymptomatic patient should prompt further 
investigation.  
 
8.4 CLINICAL IMPLICATIONS 
 
The findings of this study suggest that the current assessment of patients with VHD 
remains imperfect. A number of patients that are classified as asymptomatic and 
remain under routine follow up based on standard assessment criteria have 
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significantly abnormal findings on exercise echocardiography and/or elevations of 
BNP. These patients appear to be an increased risk of complication and may benefit 
from early surgery.  
 
Consequently routine measurement of plasma BNP concentrations and performing 
regular exercise echocardiography may help identify patients at increased risk. This 
research suggests that measurement of BNP and exercise echocardiography should 
form part of the routine assessment of patients with VHD and perhaps be given 
greater emphasis in clinical guidelines. However further research is required to 
further define the role of both measurement of plasma BNP concentrations and 
exercise echocardiography in the assessment of valvular heart disease.  
 
8.5 FUTURE DIRECTIONS 
 
The finding of this study suggest that both BNP and exercise echocardiography have 
a potential role in the assessment of valvular heart disease. The major limitations of 
this study are the relatively small number of patients within each valve group and the 
lack of repeated BNP measurement. Further investigation in this field is on-going. 
 
8.5.1  NATRIURETIC PEPTIDES IN MITRAL REGURGITATION 
In addition to our work, other investigators have been assessing the role of natriuretic 
peptides in VHD. Pizarro et al studied a large cohort of asymptomatic patients with 
severe organic mitral regurgitation [Pizarro et al 2009]. The assessment of MR 
severity was performed in a similar manner to our study. They followed patients for 
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up to 4 years with an end point of death, symptoms of heart failure of LV 
dysfunction. In the initial derivation cohort they identified a value of 105 pg/mL as 
having the highest sensitivity and specificity for identifying patients with adverse 
outcome. This finding was then confirmed in the remaining patients who served as a 
validation cohort.   
 
Pizarro’s findings in a larger cohort of MR patients suggest that there may be a 
stronger role for BNP in valvular heart disease than our findings. However the cut off 
level of 105 pg/mL is much higher than we observed in our patients with MR. In 
addition they deemed patients who were referred for surgery as not meeting the 
endpoint unless there was evidence of LV dysfunction or heart failure. Crucially 
however Pizarro et al did repeat BNP levels 1 year later and a significant finding was 
that patients whose plasma BNP concentration became elevated during follow-up 
were at increased risk of meeting the clinical end point.  
 
8.5.2  REPEATED SAMPLING OF NATRIURETIC PEPTIDES  
In our study we were only able to sample BNP at a single time point. Although we 
found considerable variation in BNP concentrations between patients with seemingly 
similar severity of VHD, what happens to an individual patients plasma BNP 
concentration over time is perhaps more important than how it compares to a 
population of VHD patients. Indeed it is known that in congestive cardiac failure 
BNP levels fall with treatment and a failure for this to do so is a marker of adverse 
prognosis. Consequently one area for future investigation would be to take serial 
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measurements of BNP as part of routine follow up and compare this to repeated 
objective measures of exercise capacity and clinical outcome.  
 
8.5.3 ASSESSMENT OF VALVE LESION SEVERITY DURING EXERCISE  
As discussed previously the worsening of mitral regurgitation with exercise [Magne 
et al 2010] and the increase in Doppler gradients in AS [Marechaux et al 2010] have 
been associated with adverse outcome and provided increased predictive value 
compared to standard exercise criteria alone. In order to be reliable these studies 
need to be performed on a semi-supine cycle ergonometer. This remains an 
uncommon stress modality outside mainland Europe with relatively few centres in 
the United Kingdom, New Zealand or United States of America using this routinely. 
However this is changing and any future studies should seek to include this 
information in the adverse markers of prognosis identified in this study. In addition 
the ability to acquire images during exercise will facilitate the acquisition of images 
for strain analysis.  
 
8.5.4  TIMING OF SURGERY 
In this study the patients’ plasma BNP concentration was not available to the 
cardiologist caring for the patient. In addition although on ethical grounds any 
significant adverse findings on treadmill exercise were communicated to the 
cardiologist, the information from the exercise stress echocardiogram was not 
routinely used to guide decision-making in the time to referral for valve surgery. The 
next stage of work would be to determine if the routine incorporation of BNP and 
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exercise stress echocardiography can guide clinicians in deciding when to consider 
surgery and improve outcome. 
 
8.5.5 FURTHER PLANNED RESEARCH 
Based on our findings we are planning to further investigate the role of both exercise 
echocardiography and measurement of plasma BNP concentrations. We propose to 
incorporate exercise stress echocardiography and measurement of plasma BNP 
concentrations in patients undergoing follow-up in dedicated valve clinics in the 
Liverpool region.  Plasma BNP concentrations will be measured 6 monthly and 
exercise echocardiography will be performed 12 monthly unless the clinical status of 
the patient requires this to be done more frequently. Exercise echocardiography will 
be performed on a semi-supine cycle ergometer with images acquired for the 
estimation of global longitudinal strain and worsening of valve severity with exercise 
in addition to the standard echocardiographic markers of severity and adverse 
features defined by this study. In addition exercise echocardiography and 
measurement of BNP will be obtained 6 months following valve surgery. Their 





This research has highlighted the known difficulties in managing patients with severe 
valvular heart disease. Although the presence of symptoms are a vital component in 
contemporary guidelines for the management of VHD, this research has 
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demonstrated that assessment of symptomatic status can be unreliable. In particular 
many patients deemed to be asymptomatic had extremely poor exercise capacity on 
objective exercise echocardiography. In addition the presence of adverse features 
markers such as reduced exercise capacity (<METS), pulmonary hypertension post 
exercise (PAP>60 mmHg) and a failure to augment systolic blood pressure (BP 
rise<20 mmHg) are associated with poor prognosis. These markers are relatively 
easy to obtain and this research suggests that exercise echocardiography should be 
used much more frequently in the assessment of VHD and perhaps even incorporated 
into routine clinical practice.  
 
The role of measuring plasma natriuretic peptide concentrations in VHD remains 
more uncertain. Although elevated plasma BNP concentrations are associated with 
some markers of increased severity such as increased pulmonary artery pressure, 
increased left atrial size and reduced exercise capacity, the association is not robust 
enough to use natriuretic peptides to exclude haemodynamically significant VHD.  
However there may remain a role for the use of natriuretic peptides on an individual 
patient basis rather than across a study population. In particular unexplained high 
plasma BNP concentrations or a BNP that is rising during follow-up could suggest 
the need to reassess valve severity. Further work in this area is required and is a 
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      Exercise Natriuretic Peptides & Mitral Stenosis: Exercise Test CRF 
MS Biomarker #  MS . __ __ 
ENP#  ENP . __ __ __ 
Initials: __ __ __ 
Site:
Date   __ __/__ __/__ __ __ __ 
 
 Patient details 
   
D.O.B __ __ /__ __/__ __ __ __ ,   Sex      M               F 
 




1.  Baseline sample      time __ __ : __ __     #  ENP__ __ __A 
 
2.  Exercise sample       time __ __ : __ __     #  ENP__ __ __B 
 time __ __ : __ __     #  ENP__ __ __C 
 time __ __ : __ __     #  ENP__ __ __D 




Protocol:   Bruce std         ,  Bruce mod  _________________________ 
 
Duration of exercise  __ __ min __ __ sec        METS  __ __ . __   
 
Start time __ __.__ __.__ __ , End time __ __.__ __.__ __ 
 
Max pred HR  __ __ __ bpm,  Max HR achieved  __ __ __ bpm,    % __ __ . __ 
  
Stage/time Base/00:00 2min   : 5min   : 8min   : 11min   : 14min   : 17min   :  
HR L       S       
BP L       S       
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Appendix 6 Exercise protocol for use in valvular heart disease. peak exercise capacity at the end of each 3 minute stage is similar to that of 
the BRUCE protocol. 
 
VALVE PROTOCOL BRUCE PROTOCOL Total Time  
 
Time in Stage Speed (Km/h) Grade(%) 
 
Time in Stage Speed (Km/h) Grade (%) (mins) 
Stage 1 01:00 1.8 3 
    
01:00 
Stage 2 01:00 2.1 6 
    
02:00 
Stage 3 01:00 2.7 10 Stage 1 03:00 2.7 10 03:00 
Stage 4 01:00 3.1 11 
    
04:00 
Stage 5 01:00 3.5 12 
    
05:00 
Stage 6 01:00 4 13 Stage 2 03:00 4 12 06:00 
Stage 7 01:00 4.3 14 
    
07:00 
Stage 8 01:00 5 14 
    
08:00 
Stage 9 01:00 5.3 15 Stage 3 03:00 5.4 14 09:00 
Stage 10 01:00 5.8 16 
    
10:00 
Stage 11 01:00 6.4 16 
    
11:00 
Stage 12 01:00 6.8 17 Stage 4 03:00 6.7 16 12:00 
 
